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Summary 
The underlying basis of vertebrate mesodermal patterning by which  the mesodermal 
cells become sequentially determined to more precisely defined cell fates during embryonic 
development remains largely unknown and  is one of the classical problems in 
developmental biology. This demands an in-depth analysis of the endogenous signaling 
cascades and transcription factor networks. Till date, this fascinating puzzle is not yet solved 
since isolation of pure early stage mesodermal cells was not feasible due to practical 
difficulties and hence the functional genomics of the mesodermal cells has not yet been 
successful.  
 
Recently, embryonic stem (ES) cells have been proven to be a promising tool to 
study the early embryonic development in a more physiological context in vitro because of 
their versatility over the other conventional systems. Furthermore, ES cells may revolutionize 
medicine by providing an unlimited renewable source of cells capable of replacing or 
repairing tissues that have been damaged in all degenerative diseases. Using ES cell model 
in vitro, for the first time pure populations of T Brachyury and BMP-2 expressing mesodermal 
lineages and mesodermal derived pure and functional cardiomyocytes have been isolated 
and their entire transcriptomes were profiled using microarrays. To isolate the pure lineage 
specific cells, stable transgenic ES clones transfected with a targeting vector construct in 
which the promoter of lineage specific marker (T, BMP-2 or αMHC) drives the expression of 
both puromycin resistance and enhanced green fluorescence bicistronically with the help of 
an IRES element were generated. The EBs made from these clones were treated at the 
onset of the particular transcript expression with puromycin to enrich the respective lineages.  
 
Furthermore, analysis of the gene signatures specific to mesodermal cells and 
cardiomyocytes that defines their unique cellular and genetic identities contributing a major 
molecular insight into mesodermal patterning has been performed. In addition, a significant 
number of novel putative transcripts whose functions are unknown but expressed in specific 
lineages are enlisted. Few of these transcripts were functionally evaluated for their role in 
germ layer development and patterning. In addition, the purified populations of T Brachyury 
and BMP-2 mesodermal cells are capable of priming themselves to give rise to 
cardiomyocytes along with other mesodermal lineages. Interestingly, the BMP-2 positive 
cells contained predominantly neural crest stem cells (NCSCs) and their lineages namely 
smooth muscle cells, epithelial cells, melanocytes, and astrocytes along with 
cardiomyocytes. The transcriptome characterization of ES cell-derived αMHC 
cardiomyocytes clearly proves that these cells are exhibiting the properties more like the 
cardiomyocytes developed in in vivo conditions from the point of biological processes and 
hence are promising candidates for the future cardiac cell replacement therapy.  
 
In overall, the part of the work presented here will better contribute substantially to the 
lineage specific transcriptomic atlas which will shed light in understanding the complex 
embryonic developmental process. 
 
 
 
 
  
 
Zusammenfassung 
 
Die grundlegenden Mechanismen des sogenannten “mesodermalen Patternings 
(Musters)”, durch welches sich mesodermale Zellen während der Embryonalentwicklung  von 
Wirbeltieren nacheinander zu genau definierten Zelltypen entwickeln, sind weitgehend 
unerforscht. Für ein genaues Verständnis des “mesodermalen Musters” ist eine eingehende 
funktionelle Genomanalyse der endogenen Signalkaskaden und der beteiligten 
Transkriptionsfaktoren erforderlich. Bisher wurde das faszinierende Zusammenspiel dieser 
Faktoren nicht eingehend untersucht, da eine Isolierung von frühen mesodermalen Zellen 
aus experimentell-praktischen Gründen schwer durchführbar ist. Bisher existieren folglich 
diesbezüglich keine erfolgreichen Untersuchungen an mesodermalen Zellen.  
 
Aufgrund ihrer in-vitro-Differenzierbarkeit können embryonale Stammzellen (ES-
Zellen) als vielversprechendes Modell dienen, um frühe embryonale Entwicklungsprozesse 
in einem physiologischen Kontext zu studieren. Aufgrund dessen ist das ES-Zell-Modell 
herkömmlichen entwicklungsbiologischen in vivo-Modellen überlegen. Darüber hinaus 
können ES-Zellen die Medizin revolutionieren, indem sie als eine unbegrenzte Quelle 
erneuerbarer Zellen zur Verfügung stehen, die zur Reparatur oder als Ersatz für 
geschädigtes Gewebe eingesetzt werden können. Solche beschädigten Gewebe kommen in 
den meisten degenerativen Krankheiten vor.  
 
Im Rahmen der vorliegenden Dissertation konnten aus ES-Zellen zum ersten Mal 
weltweit reine mesodermale T (Brachyury)- und BMP-2-positive Zellpopulationen sowie von 
mesodermalen Zellen abstammende, funktionelle Kardiomyozyten gewonnen und deren 
Transkriptom mittels DNA-Microarrays detailliert analysiert werden. Um diese reinen 
Zellpopulationen zu gewinnen, wurden ES-Zellen mit IRES-Vektoren stabil transfiziert, die 
gleichzeitig eine Puromycin-Resistenz-Kassette und eine Reporter-Kassette (grün 
fluoreszierendes Protein) unter der Kontrolle zellspezifischer Promotoren (T, BMP-2, αMHC) 
exprimieren. Diese transgenen Zelllinien wurden in vitro zu “Embryoid Bodies” (EBs) 
differenziert, aus denen nach Puromycinbehandlung die jeweiligen Zelltypen (T-, BMP-2-, 
und αMHC-positive Zellen) in reiner Form isoliert werden konnten 
 
Die Analyse der Microarray-Expressionsdaten führte zur einer Identifikation 
zellspezifischer Genexpressionssignaturen für mesodermale Zellen sowie für 
Kardiomyozyten und somit zur Charakterisierung ihrer spezifischen zellulären und 
genetischen Identität. Diese Untersuchungen gewähren weiterhin einen Einblick in 
das“mesodermale Musters”. Darüber hinaus wurde eine große Anzahl von Transkripten 
ermittelt, deren Funktion bisher unbekannt ist. Einige dieser Transkripte wurden funktional 
bezüglich ihrer Rolle bei der Entwicklung von Keimblättern charakterisiert. Weiterhin konnte 
gezeigt werden, dass reine T Brachyury- und BMP-2-Zellen in der Lage sind, sich zu 
Kardiomyozyten und anderen gewebsspezifischen Zelltypen mesodermalen Ursprungs zu 
differenzieren. Interessanterweise wurden neben Kardiomyozyten zusätzlich Neuralleisten-
Stammzellen, glatte Gefäßmuskelzellen, Epithelzellen, Melanozyten und Astrozyten 
nachgewiesen. Die Transkriptomanalyse der aus ES-Zellen abgeleiteten Kardiomyozyten 
zeigt, dass diese biologische Eigenschaften von in vivo Kardiomyozyten aufweisen und 
infolgedessen zukünftig für eine zelluläre Ersatztherapie von degenerativen 
Herzerkrankungen eingesetzt werden könnten.   
 
Die vorliegende Arbeit wird  zur Erstellung eines zellspezifischen Transkriptom-Atlas 
führen, der zu einem besseren Verständnis komplexer entwicklungsbiologischer Prozesse 
beitragen wird. 
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Introduction 
 
The vertebrate early stage embryo consists of three primary germ layers-the ectoderm, 
mesoderm and endoderm, from which all tissues of the adult are derived later. The 
mesodermal germ layer plays a fundamental role in organizing the vertebrate axes, and give 
rise to, among other structures, the skeletal, muscular, and circulatory systems. Mesoderm is 
an inducible fate, that is, the mesoderm is formed by a mechanism called induction1. 
Induction refers to a process in which extracellular signals bring about a change from one 
cell fate to another in a particular group of cells. The inducing factors and signaling cascades 
that regulate the differentiation and patterning of the mesodermal germ layer have been the 
focus for intensive study for the last decades.  
 
1.1 Early embryonic development in mice 
Much of the earlier investigation about the germ layer formation and patterning came 
from the in vivo experiments involving early embryos. Hence it is worthwhile to start with the 
actual developmental processes in early embryonic development in mice to better 
understand the process of mesodermal patterning.  
 
1.1.1 Pre-implantation embryo  
 
Prior to fertilization, the egg (oocyte) enlarges, divides by meiosis, and matures in its 
ovarian follicle until it reaches metaphase II, a stage of meiotic division. At this point, the 
follicle releases the haploid oocyte into the oviduct, one of two tube-like structures that lead 
from the ovaries to the uterus. The union of the oocyte and sperm and subsequent 
fertilization take place in the ampulla of the oviduct. The fertilized egg (zygote) divides and 
develops as it travels along the oviduct to the uterus (Figure 1). In mice, this process takes 
about 4-5 days. The egg has a protective membrane, the zona pellucida, which stops it from 
implanting in the oviduct wall.  
 
By the time it reaches the uterus, the egg has undergone many cell divisions to form a 
blastocyst, which hatches from the zona pellucida to implant into the uterine wall. In all 
mammals studied, the pre-implantation stages are characterized by a relatively synchronous 
doubling of cell numbers until the 8-cell stage followed by asynchronous cell divisions after 
compaction2. During compaction, the blastomeres become polarized and develop tight 
junctions with the other blastomeres. At the 8-16 cell stage the embryo enters the uterine 
environment, developing into a blastocyst, in which the first events of cellular differentiation 
are observed (Figure 1). 
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Figure 1. Development of the Preimplantation Blastocyst in Mice from Embryonic   Day 0 
(E0) Through Day 5 (E5.0). This picture was adopted from National Institutes of Health. Stem 
Cells: Scientific Progress and Future Research Directions. Stem Cell Information [online], 
http://stemcells.nih.gov/info/scireport (2001)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A schematic view of mouse pre-implantation development. (A) Pluripotent 
stem cells (green) are imaged in a morula as the inner cells, which (B) then form the inner 
cell mass (ICM) of the blastocyst. (C) After giving rise to the primitive endoderm on the 
surface of the ICM, pluripotent stem cells then form the epiblast and start to proliferate 
rapidly after implantation. (D) They then form the primitive ectoderm, a monolayer epithelium 
that has restricted pluripotency, which goes on to give rise to the germ cell lineage and to the 
somatic lineages of the embryo. Certain key transcription factors (blue) are required for the 
differentiation of the various embryonic lineages. Adopted from Niwa, H. Development 2007; 
134:635-646. 
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1.1.2 Post Implantation embryo 
 
Around the time of implantation, the mouse embryo is composed of three distinct cell 
types- the trophectoderm, the primitive endoderm, and the inner cell mass (ICM) (Figure 2, 
3A and 3B)3 . At approximately 4.5 to 5.0 dpc, implantation of the blastocyst into the uterus 
begins. Shortly after implantation, the ICM undergoes rapid proliferation and differentiates to 
form a pluripotent population known as primitive ectoderm. As the primitive ectoderm 
population expands, the innermost group of cells undergoes apoptosis, generating a cavity 
known as the proamniotic cavity. The remaining cells surrounding this cavity differentiate 
further to form a pseudostratified columnar epithelium, which results in the formation of a 
cup-like structure known as the epiblast4. Primitive ectoderm and epiblast cells differ from 
ICM cells in that they have upregulated Fgf5 expression, downregulated Rex expression and 
have lost their ability to generate chimeras following blastocyst injection5-8. Coinciding with 
development of the epiblast, primitive endoderm undergoes differentiation, giving rise to both 
visceral and parietal endoderm. Visceral endoderm forms a tissue that surrounds the 
epiblast, whereas parietal endoderm surrounds the extraembryonic tissues9 (Figure 2 and 
Figure 3). 
 
Gastrulation is the major milestone in early post implantation development. During 
gastrulation, pluripotent epiblast cells are allocated to the three primary germ layers of the 
embryo (ectoderm, mesoderm and definitive endoderm) and the extraembryonic mesoderm 
of the yolk sac and amnion. The primary germ layers are the progenitors of all tissue 
lineages. The specification of tissue lineage is accompanied by the restriction of the 
developmental potency and the activation of lineage specific gene expression. This process 
is strongly influenced by cellular interactions and signaling10,11. 
 
Although much remains unknown about how the embryonic axis is laid down in the 
mouse, it is now clear that reciprocal interactions between the extraembryonic and 
embryonic lineages establish and reinforce patterning of the embryo. At early post-
implantation stages, the extraembryonic ectoderm appears to impart proximal–posterior 
identity to the adjacent proximal epiblast, whereas the distal visceral endoderm signals to the 
underlying epiblast to restrict posterior identity as it moves anteriorward. At gastrulation, the 
visceral endoderm is necessary for specifying anterior primitive streak derivatives, which, in 
turn, pattern the anterior epiblast. Polarity of these extraembryonic tissues can be traced 
back to the blastocyst stage, where asymmetry has been linked to the point of sperm entry at 
fertilization2. 
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Figure 3. (A) Mouse embryo at peri-implantation (E4.75, Pou5f1 expression in the ICM), 
early-streak (E6.5, Otx2 expression in the epiblast), and early-bud (E7.5, Cer1 expression in 
the anterior definitive endoderm) stages. (B) The differentiation of trophectoderm (grey), ICM 
(blue), and primitive endoderm (brown) of E4.75 embryo to the extraembryonic and 
embryonic tissues of E7.5 embryo (germ layer tissues are color-coded, see key). Taken from 
D.A.F. Loebel et al. / Developmental Biology 264 (2003) 1–14.) 
 
1.2 Lineage specification  
One of the distinguishing features of early mammalian development is the maintenance 
of a population of developmentally plastic, pluripotent stem cells, which give rise to all cells 
that constitute the mature organism. The earliest stage of lineage specification in the mouse 
embryo occurs at approximately 3.5 days post coitum (dpc) with formation of the blastocyst 
12. Around 10-20 cells, which appear to be developmentally equivalent, make up the inner 
cell mass (ICM), located at one end of the 3.5 dpc (days post coitum) blastocyst. Mammalian 
development entails the regulated proliferation of these cells and allocation of descendants 
to specific cell lineages following differentiation13.  
 
Around 4.0 days post coitum (dpc), ICM cells lining the blastocoelic cavity 
differentiate to extraembryonic primitive endoderm. Pluripotency is retained by internal ICM 
cells, referred to as the “epiblast”, now surrounded by extraembryonic endoderm and 
trophectoderm. At about the time embryo implants into the uterine wall these pluripotent cells 
begin to proliferate rapidly such that the 20-25 cells present at 4.5d.p.c expand to give rise to 
about 660 cells by 6.5dpc and 8060 cells by 7.5dpc14. Concurrent with pluripotent cell 
proliferation, primitive endoderm cells migrate along the pluripotent cell surface and 
differentiate into one of two cell types.  Primitive endoderm cells that remain in contact with 
the pluripotent cells differentiate into visceral endoderm while those primitive endoderm cells 
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that migrate onto the blastocoelic surface of trophectoderm differentiate into parietal 
endoderm 9 (Figure 2).  
 
Formation of the proamniotic cavity within the pluripotent cell population is first visible 
at 5.0dpc and is accompanied by reorganization of the cells into a pseudostratified columnar 
epithelial sheet. Concomitant with this process, the pluripotent cells become polarized, and 
undergo changes in gene expression and developmental potential suggesting that this 
morphologically distinct pluripotent cell population, termed primitive ectoderm, is derived from 
the ICM by differentiation. Primitive ectoderm provides the substrate for gastrulation, which is 
initiated at around 6.5 dpc. This process transforms the pluripotent monolayer into a 
multilayered embryo consisting of the 3 primary germ layers, mesoderm, endoderm and 
ectoderm. While coordinated regulation of pluripotent cell proliferation, differentiation and 
morphogenesis underpins development of the mammal, relatively little is known of the 
signaling mechanisms that regulate these processes at a cellular or molecular level. 
Accumulating evidence emerging from close analysis of gene expression and knock out 
phenotypes implicates visceral endoderm as a source of signals controlling primitive 
ectoderm formation, maintenance and differentiation15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cell lineage relationships in the early mouse embryo. Taken from 
Cindy C. Lu et al., Current Opinion in Genetics & Development Volume 11, 
Issue 4 , Pages 384-392. 
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The means by which cells are allocated to either embryonic or extra embryonic 
lineages in the blastocyst is not understood. However, the early establishment of cell fate 
may be regulated in part by the POU transcription factor Pou5f1 (also known as Oct4). 
Pou5f1 is expressed in all blastomeres at the four-cell stage but is downregulated in the 
trophectoderm by the blastocyst stage16. Its expression is maintained in the ICM, with highest 
protein concentrations accumulating in the primitive endoderm. Pou5f1 is required for ICM 
formation, as Pou5f1 mutant blastocysts consist only of trophectoderm17. Consistent with the 
mutant phenotype, recent studies have shown that embryonic stem (ES) cells lacking Pou5f1 
differentiate into trophectoderm, whereas cells expressing a single copy of Pou5f1 maintain 
their pluripotent ES cell state. By contrast, a twofold increase in Pou5f1 expression causes 
ES cells to adopt VE or mesodermal fates18. Thus, tight control of Pou5f1 levels may be 
important for cell fate allocation in the blastocyst. It will be interesting to learn whether the 
initial polarity at fertilization or the timing of cell division in blastomeres is linked to expression 
levels of Pou5f1.Whereas Pou5f1 mutant blastocysts lack an ICM, the novel gene Taube 
nuss (Tbn) seems to be required for survival or maintenance of the ICM19. Tbn-deficient 
embryos appear normal at the early blastocyst stage, but by late blastocyst stage consist 
only of trophoblast cells as a result of increased apoptosis in the ICM. Tetraploid aggregation 
experiments in which trophectoderm cells were wild type but ICM cells were mutant indicated 
that Tbn is required cell-autonomously for ICM survival. Another gene whose role in 
trophoblast development is the T-box gene Eomesodermin (Eomes), which is first expressed 
in the trophectoderm at the blastocyst stage20. Embryos lacking Eomes arrest at the 
blastocyst stage, and mutant trophectoderm dies in culture even in the presence of the 
trophectoderm proliferation factor Fgf4, suggesting that Eomes is required cell-autonomously 
for trophectoderm development. 
Embryonic stem (ES) cells can be derived in vitro from the ICM of the peri-
implantation embryo (Figure 5). Like the ICM and the early epiblast, ES cells are capable of 
differentiating into a wide range of fetal tissues in culture21 or in chimeric embryos and can 
even form the entire fetus22. Trophectodermal stem (TS) cells, with the molecular properties 
of diploid trophoblast cells, may be isolated from the blastocyst or extra embryonic ectoderm 
of peri-implantation embryos. TS cells have a restricted differentiation potential: they can 
form giant cells in vitro 23,24 and have only been observed to contribute to trophectodermal 
cell lineages in vivo. Whereas ES cells can be induced to become TS cells18,  TS cells have 
not been shown to acquire the lineage potential of ES cells. As yet, there are no published 
reports of stem cells-derived from the third cell type, the primitive endoderm of the embryo, 
but this remains an exciting possibility (Figure 5).  
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Figure 5.  Colonies of embryonic and trophectodermal stem cells (white arrows) derived from 
the ICM and extra embryonic ectoderm, respectively. Taken from D.A.F. Loebel et al. / 
Developmental Biology 264 (2003) 1–14. 
 
 
1.3 Mesoderm development 
In mouse embryo, major decisions about lineage allocation and cell fate are made during 
gastrulation, between E6.25 –7.525. Mesoderm is generated from the epiblast or embryonic 
ectoderm through the process of gastrulation that is initiated at approximately day 6.5 of 
gestation10. At the onset of gastrulation, the epiblast cells in the region that defines the 
posterior part of the embryo undergo an epithelial to mesenchymal transition and form a 
transient structure known as the primitive streak from which the mesoderm emerges. The 
newly formed mesoderm migrates away from the primitive streak, moves laterally and 
anteriorly and is patterned into various populations with distinct developmental fates. 
Brachyury is expressed in all nascent mesoderm and downregulated as these cells undergo 
patterning and specification into the derivative tissues including skeletal muscle, cardiac 
muscle and connective tissues in addition to blood and endothelium26,27. The first 
mesodermal cells to develop within the embryo contribute predominantly to the extra-
embryonic tissues, giving rise to the hematopoietic and vascular cells of the yolk sac28,29. 
 
1.2.1 Major Molecular control of mesodermal differentiation 
Wnt signaling  
WNT3A signaling induces cells from the epiblast to adopt a paraxial mesodermal 
rather than a neuroectodermal fate after gastrulation30 (for review3 ) . In Wnt3a-/- embryos, 
epiblast cells ingressing into the PS are diverted to a neuroectodermal fate instead of forming 
mesodermal cells. Consequently, ectopic structures resembling neural tubes are formed in 
place of the somites30. Regulation of genes acting downstream of WNT3A signaling requires 
the transcription factors Lef1 and Tcf1. Mouse mutants lacking both Lef1 and Tcf1 develop 
ectopic neural tubes and are defective in paraxial mesoderm differentiation31. WNT3a 
signaling, via Lef1/Tcf1, maintains expression of the mesodermal transcription factor T in 
presumptive paraxial mesoderm32. Maintenance of T expression can be rescued by a 
constitutively active LEF1-β-catenin fusion protein33. The WNT signaling pathway interacts 
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with the FGF pathway to induce mesoderm differentiation (Figure 6, red area). Fgfr1 is 
required for expression of T and Tbx634,35. In chimeric embryos, ectopic neural tubes form 
entirely from Fgfr1-/-  cells, which fail to fully traverse the PS and take on an ectodermal fate 
30,36. The phenotypes of Fgf8 and Fgfr1 mutant mice suggest a role in the migration of 
nascent mesoderm away from the streak, possibly by repression of E-cadherin,35-38. E-
cadherin prevents the interaction of LEF/TCF proteins with the transcriptional co-activator β-
catenin, disrupting WNT signaling. Sequestering E-cadherin rescues expression of a T-lacZ 
reporter, presumably due to the restoration of the WNT signaling pathway35.  
 
BMP signaling 
BMP signaling is essential for the choice between ectodermal and mesodermal fates 
(for review 3). BMP signaling is required to induce mesoderm formation in vivo (Figure 6, red 
area). Most Bmp4-/-  embryos fail to gastrulate and form no mesoderm39. Loss of Bmpr1 and 
Bmpr2b function also results in reduced epiblast proliferation and no formation of mesoderm 
40,41. The similarities in the phenotypes of Bmp4, Bmpr1, and Bmpr2 mutants suggest that 
BMP4 signals predominantly through heterodimers of these receptors40,41.  BMP signaling 
activates receptor regulated SMADs 1, 5,and 8, which interact with the common partner 
SMAD4 to regulate gene expression42. Smad4 is required for epiblast proliferation, 
gastrulation, and mesoderm formation43,44. For correct patterning and differentiation of the 
embryo, the influence of BMP signaling must be modulated by antagonistic molecules. The 
BMP antagonists Chordin and Noggin are expressed in the mouse organizer and promote 
differentiation of ectodermal lineages (Figure 6, blue area). Chordin and Noggin have 
overlapping functions during embryogenesis and are required for anterior neural 
differentiation in the embryo45. 
 
Nodal signaling 
Nodal, a member of the TGF-β superfamily is expressed throughout the epiblast in 
mice. Embryos mutant for nodal lack a proper primitive streak and show a severe reduction 
in mesoderm formation. Cofactors of Nodal belonging to the EGF-CFC family are essential 
for Nodal signaling and they have been found in Xenopus, fish and mouse. The mouse 
counterpart of these cofactors, Cripto is also expressed throughout the epiblast and null 
mutant mice fail to undergo the movements of the epiblast cell to the primitive streak and that 
of the anterior visceral endoderm to its proper location46. Further more, mutants for the 
Lefty/antivin proteins- a class of TGF-β molecules that antagonize Nodal in the mouse, 
zebrafish and Xenopus –display the opposite mutant phenotype to that of nodal. Mouse 
mutants exhibit an expanded primitive streak and excess mesoderm47. 
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Figure 6.  Specification and differentiation of germ layer derivatives in mouse embryos. 
Ectodermal (blue), mesodermal (red), and definitive endodermal (orange) lineages derived 
from the epiblast (brown) are shown, with the signaling pathways and transcription factors 
indicated in green. The question mark signifies the lack of direct evidence for involvement of 
BMP4 in surface ectoderm differentiation in mouse embryos. Taken from D.A.F. Loebel et al. 
/ Developmental Biology 264 (2003) 1–14. 
 
 
1.4 Cardiac development 
 
The heart is the first organ to form during embryogenesis and its circulatory function is 
critical from early on for the viability of the mammalian embryo. The development of the 
vertebrate heart can be considered an additive process, in which additional layers of 
complexity have been added throughout the evolution of a simple structure (linear heart tube) 
in the form of modular elements (atria, ventricles, septa, and valves)48,49. Each modular 
element confers an added capacity to the vertebrate heart and can be identified as individual 
structures patterned in a precise manner. An understanding of the individual modular steps in 
cardiac morphogenesis is particularly relevant to congenital heart disease, which usually 
involves defects in specific structural components of the developing heart. Hence, the 
developmental mechanisms that orchestrate the formation and morphogenesis of this organ 
have received much attention among classical and molecular embryologists. The initiation of 
cardiac differentiation has been the topic of vigorous investigation. However, no single 
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transcription factor that is responsible for the differentiation of lateral plate mesoderm into 
cardiac cells has been identified50.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Stages of Mouse cardiogenesis at E7.5, E8, and E8.5. Major heart forming field is 
shown in black and the anterior (secondary) heart-forming field (AHF) in gray. AS indicates 
atria, sinus venosa; CT, conotruncus; RV, right ventricle; LV, left ventricle; and A, atria. 
Adopted from Zaffran and Frasch, Circ Res 2002; 91:457-469. 
 
In mouse, the heart arises from cells in the anterior lateral plate mesoderm of the 
early embryo, where they are arranged in bilateral fields on either side of the prechordal plate 
and rostral notochord 51.  These fields include the precursors of both myocardial and 
endocardial cells, although there is apparently no common pool of bipotential precursors for 
these two heart cell lineages52,53. The cells of the cardiogenic mesoderm are brought to these 
positions by gastrulation movements that occur in close association with ingressing cells of 
the rostral endoderm. In mammalians and birds, the bilateral fields of the cardiogenic 
mesoderm merge at their anterior margins to form the so-called "cardiac crescent"54 (Figure 
7). More recent studies have identified a second type of heart field that is located more 
medially in the splanchnic mesoderm, directly adjacent to the cardiac crescent. The cells 
from this bilateral field, termed anterior heart-forming field, are fated to generate anterior 
heart structures of the outflow tracts (see review55  (Fig7and 8B).  . The specification of 
cardiomyocytes occurs just before or during the formation of the cardiac crescent, and 
differentiation markers become expressed shortly thereafter (review 51). The earliest steps of 
assembly of the heart tube are initiated by the convergence and fusion of the bilateral heart 
primordia along the midline. The cells of the anterior heart-forming field, after having migrated 
anteriorly, are added to the anterior end of the linear tube during and after this period. The 
resulting beating tubular heart is composed of an external myocardial and an internal 
endocardial layer and also possesses a polarity along the anteroposterior axis, in which the 
prospective tissues of the aortic sac, outflow tract (conotruncus), right ventricle, left ventricle, 
and atria are present in an anterior to posterior order along the tube (Figure 7). In all 
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vertebrates, the tubular heart undergoes a process known as rightward looping. The 
morphogenetic steps required to achieve looping are guided by molecular asymmetries that 
are established in and   around the heart by the embryonic left/right axial pathway. 
Furthermore, in higher vertebrates, septal division of the chambers and formation of the 
valves, which involves endothelial cells, are essential steps leading to the formation of an 
integrated 4-chambered heart with separate venous (or inflow) and arterial (or outflow) poles. 
During the growth process of the cardiac epithelium another distinct cell lineage, the 
migrating cardiac neural crest cells, populate the heart through the outflow channel and 
contribute to the formation of the great vessels and outflow septum51. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 8.  Early markers for the cardiac crescent (A) and anterior heart-forming field 
(B) in the mouse. Adopted from Zaffran and Frasch, Circ Res 2002; 91:457-469. 
 
Transcription Factors involved during cardiomyogenesis 
 
Heart formation requires the precise integration of cell type–specific gene expression 
and morphological development; both are intertwined in their regulation by transcription 
factors. Although many transcription factors have been described as regulators of cardiac-
specific gene expression, the transcriptional regulation of cardiac morphogenesis is still not 
well explored. The most notable cardiac transcription factors and their roles in heart 
formation are summarized in Figure 9 and the transcriptional network in Figure 10.  
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Figure 9. Summary of mouse heart development. Five major stages of heart development 
are shown: (1) cardiac crescent formation at embryonic day (E) 7.5; (2) formation of the 
linear heart tube at E8; (3) looping and the initiation of chamber morphogenesis at E8.5 to 
E9.5; (4) chamber formation; and (5) chamber maturation and septation and valve formation. 
The transcription factors involved or suspected of involvement in these processes are listed 
below each stage. ao indicates aorta; a, atrium; la, left atrium; lv, left ventricle; ra, right 
atrium; rv, right ventricle; ot, outflow tract; sv, sinus venosa; and pa, pulmonary artery. 
Adopted from Bruneau, B. G. Circ Res 2002;90:509-519. 
 
 
 
Figure 10.Schematic of transcriptional networks involved in mammalian heart development. 
(A) Inductive signals activate a set of upstream regulatory genes, encoding transcription 
factors, in the primary and secondary heart fields. The products of these genes activate the 
genes in the core cardiac network (NK2-MEF2-GATA-Tbx-Hand). Some components of the 
network, such as Nkx2-5, are also activated in the primary heart field in response to inductive 
signals. The core network genes cross- and autoregulate their expression and serve as the 
central regulatory network for the activation of muscle-specific genes and genes that control 
the growth and patterning of derivatives of the primary and secondary heart fields. The 
primary heart field gives rise to the left ventricle (lv) and portions of the atria (a), whereas the 
secondary heart field gives rise to the right ventricle (rv), portions of the atria, and the outflow 
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tract. A scanning electron micrograph of a mouse heart at embryonic day 14.5 is shown at 
the bottom. Derivatives of primary and secondary heart fields are shown in blue and pink, 
respectively. The atria, which are derived from the primary and secondary heart fields, are 
shown in purple. (B) Regulatory interactions among cardiac transcription factors in the 
secondary heart field. Solid lines indicate direct transcriptional connections, and dotted lines 
indicate connections not yet shown to be direct. [Adapted from Eric N. Olson, Science 29 
Vol. 313. no. 5795, pp. 1922 - 1927] 
 
Signaling Pathways During the Induction of Cardiogenic Mesoderm 
 
BMP Signaling 
 
The heart-inducing activity of BMP signaling has been confirmed by studies using inhibitors 
of BMP signaling, including the BMP inhibitor noggin, truncated versions of type I (tALK3) or 
type II (tBMPRII) BMP receptors, and inhibitory SMAD651.  These studies show that BMP 
signal transduction is indeed required within the cardiogenic mesoderm, and not only within 
the anterior endoderm, to promote cardiac differentiation. A second important conclusion 
from these data are that BMP signaling is required for the maintenance of Nkx2-5, T-box 
genes, bHLH-factor encoding Hand genes and Gata genes expression at stages during and 
after the fusion of the bilateral heart primordia, but apparently not for the initial activation of 
these genes in earlier stage embryos56-58. 
 
Fibroblast Growth Factor Signaling 
 
Function of FGF signaling in cardiac induction has been obtained in the zebrafish 
system. Zebrafish FGF8 is expressed in the cardiogenic fields of the lateral plate, as well as 
in specific areas of the neural tube. fgf8 (acerebellar) mutant embryos display strong heart 
defects with a particular loss of ventricular structures59. FGF signals not only act during early 
mesoderm development but are also required more directly for the induction of cardiogenic 
transcription factors during subsequent stages51. 
 
Notch Signaling 
 
The direct target genes of Notch in heart development are not known. At least in certain 
contexts, the Hrt (Hesr/Hey) genes of the Hairy/Enhancer of Split family were proposed as 
candidates although there is presently no evidence that the differential expression of these 
genes along the anteroposterior axis of the heart tube is controlled via Notch signaling60. 
Nevertheless, the observations in Xenopus, the heart defects of hypomorphic Notch2 mouse 
mutant embryos, and the heart abnormalities associated with Jagged1 haploinsufficiencies in 
human Alagille syndrome patients indicate that Notch signaling is likely to be required during 
multiple processes in early vertebrate cardiogenesis61.  
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1.5 Embryonic stem cells 
-A versatile tool to study early embryonic development  
 
The pluripotency and immortality of mouse embryonic stem ((ES) cells have made them 
attractive for basic studies of regenerative medicine, as well as for gaining molecular insight 
into cellular differentiation at early developmental stages, which are much more difficult to 
assess by in vivo approaches.  
 
Due to their remarkable ability to recapitulate early embryonic development on their own, 
embryonic stem (ES) cells are revolutionizing the field of developmental biology as a 
potential tool to investigate the molecular mechanisms occurring during the process of 
differentiation from the early embryonic stage to the adult phenotype. ES cells harvested 
from the inner cell mass (ICM) of the early embryo can proliferate indefinitely in vitro culture 
without senescence in an undifferentiated state in the presence of leukemia inhibitory factor 
(LIF) or on the top of a layer of mitotically inactivated mouse embryonic fibroblasts (MEFs).  
In the absence of LIF, ES cells spontaneously differentiate into multicellular ES cell 
aggregates (ESCAs). These ESCAs, also called as embryoid bodies (EBs) represent a more 
physiological context in which the formation of germ layers-ectoderm, mesoderm and 
endoderm and their subsequent differentiation   into   several   germ layer   specific   
phenotypes   can   be studied more extensively than most other in vitro systems (Figure 11). 
The ES cell system offers several important advantages over the conventional studies in the 
early embryos such as the possibility to isolate large numbers of lineage specific cells in 
sufficient quantities at different developmental stages for molecular, biochemical, or 
functional studies using appropriate induction and selection strategies, access to the earliest 
stages of development to investigate the inducing and patterning properties of different 
soluble factors and relative easiness to genetically manipulate with loss or gain of function 
and to generate reporter cells lines to track the spatial and temporal expression of a 
particular gene of interest12,62. Thus ES cell differentiation system paves the platform for the 
discovery of new genes and serves as an elegant model for developmental biology as well 
as for its future potential in tissue replacement therapies. 
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Figure 11. in vitro differentiation of embryonic stem cells. Culture supplements are shown in 
green, culture conditions in black, and germ layer derivatives and tissue-specific markers in 
blue for ectodermal tissues; red for mesodermal tissues; orange for endoderm. EB, Embryoid 
body. Adopted from Developmental Biology Volume 264, Issue 1,1 December 2003, Pages 
1-14. 
 
  
Objective 20
 
 
2. Objective 
 
During early embryonic development, the mesodermal cells become sequentially 
determined to more precisely defined cell fates and give rise to a diverse array of functionally 
important cell types, including  the muscles, heart, vasculature, blood, kidney, gonads, 
dermis and cartilage. How the prospective mesodermal cells integrate the various signals 
they receive and how they resolve this information to regulate their morphogenetic behaviors 
and cell-fate decisions is largely unknown. This demands an in-depth analysis of the 
endogenous signaling cascades and transcription factor networks. Till date, isolation and 
transcriptome characterization of pure mesodermal cells have not been successful due to the 
practical difficulty in isolating the cells in pure form and in sufficient quantities from early 
stage embryos. This leaves a wider gap in our understanding about the mesodermal 
patterning. The present work is aimed to attempt to decipher the underlying mechanisms of 
mesodermal patterning during the differentiation of mesodermal cells into cardiomyocytes 
using ES cell model as an alternative approach and in particular to identify novel genes 
whose functions have not yet been annotated till date but are differentially expressed in 
mesodermal cells and cardiomyocytes.  
 
The objective of this thesis work is to isolate ES cell-derived pure mesodermal cells 
and their lineages in order to characterize their unique transcriptomes by large scale 
microarray analysis and to functionally evaluate few of the novel transcripts, if any, for their 
role in development by “loss of function” and “gain of function” studies.  
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3. Materials and Methods 
 
3.1 MATERIALS 
 
ES cell line 
 
CGR8 cell line (European Collection of Cell culture (ECACC), catalogue number: 
95011018) was used. The germ-line competent cell line CGR8 was established from the 
inner cell mass of a 3.5-day male pre-implantation mouse embryo (Mus muculus, strain 
129/ola). These cells retain the ability to participate in normal embryonic development. 
Differentiation of CGR8 cells is inhibited by the pleiotrophic cytokine Differentiation inhibiting 
Activity (DIA) which is identical to Leukemia Inhibitory Factor (LIF). Addition of DIA/LIF allows 
culture of CGR8 without the use of feeder layers.  Karyotype: 40XY. 
 
 
Consumables: 
 
S.No  Consumables  Manufacturer 
1 T25- tissue culture flask Becton Dickinson 
2 10 cm petri dishes (bacteriological) Greiner 
3 6 cm petri dishes (bacteriological) Greiner, 
4 6-well cell culture plates ( Becton Dickinson 
5 24-well cell culture plates Becton Dickinson 
6 5 ml pipettes Sarstedt 
7 10 ml pipettes Sarstedt 
8 15 ml tubes Falcon 
9 50 ml tubes (F Falcon 
10 cryotubes Nunc 
11 cell counting chamber Neubauer/ Merck 
12 pasteur pipettes 6127-1722 
1 Multipipette Eppendorf 
14 1000 µL micro molecular-pipette Gilson (Amersham) 
15 blue tips Biolabs 
16 Sterile Gene pulser Cuvette Bio-Rad 
17 Trypan Blue 0.4% Gibco BRL 
18 Neubauer Counting Chamber Merck 
19 Hoechst dye Molecular Probes 
20 ProLong Gold Mounting medium Molecular Probes 
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Primers included in our study. 
 
S.No Gene Forward Primer (5’Æ3’) Reverse Primer (5’Æ3’) 
1 1700108l22rik gagaacatcagcgaggatgag caacaggatacacacgcacac 
2 Activin cctagaaagcgggacctatga tacacgggtgcagggtaaggc 
3 Adipsin tggtatgatgtgcagagtgtagtg ggtaggatgacactcgggtatag 
4 Afp cca gaa cct gcc gag agt tgc gcc ttc agg ttt gac gcc att 
5 Aggrecan agagctatttccacacgctacac gtaggttctcactccagggaact 
6 Alkaline Phosphatase acaccttgactgtggttactgct ggaatgtagttctgctcatggac 
7 ANP cag agt ggg aga ggc aag acc cct ctg aga gac ggc agt g 
8 Ap2 (Fabp4) ctggaagcttgtctccagtga tatgatgctcttcaccttcctgt 
9 Bmp-2  tct tag acg gac tgc ggt ctc  cct gag tgc ctg cgg tac aga
10 Bmpr1a ctagacaccagagccctactcaa cctggtattcaagggtatgtcaa 
11 Cbfa/Runx2 atccatccactccaccacgc aagggtccactctggctttgg 
12 Cd34 tatggaaaagcaccaatctgact tctccgtgtaataagggtcttca 
13 Cdx2 gatacatcaccatcaggaggaaa caaggaggtcacaggactcaag 
14 c-Fms taagcaagatctggacaaagagc gagtcattcatgatgtccctagc 
15 C-Kit aactccatgtggctaaagatgaa ccagaaaggtataagtgcctcct 
16 Collagen Ii/Col2a1 aggggtaccaggttctccatc ctgctcatcgccgcggtccta 
17 Collagen X atgccttgttctcctcttactgga ctttctgctgctaatgttcttgacc 
18 Cyclophilin B gcacaggaggaaagagcatc cccacacagacagctgctta 
19 Cytokeratin 20 cgtatagctgtggaagctgatct ctatctccaggttctggtaggtg 
20 Cytokeratin 7 agatcaagaccctcaacaacaaa caacacaaactcattctcagcag 
21 Cytokeratin 8 gatgcagaacatgagcattcata ttcaatcttcttcacaaccacag 
22 Desmin aatggtacaagtccaaggtttca agaaggtctggataggaaggttg 
23 E-Cad tatgatgaagaaggaggtggaga aacaccaacagagagtcgtaagg 
24 EGFP agctgaccctgaagttcatctg Tgatatagacgttgtggctgttg 
25 Eomesodermin agcttcaacataaacggactcaa gaaggtctgagtcttggaaggtt 
26 F4/80 aatgctaccttcacaatccttga ctgccaagttaatggactcattc 
27 Flk-1 ctgaactcaagatcctcatccac gatacacttccttgatgccaaga 
28 Flt-1 cagactcttgtcctcaactgcac ggctctccacattgttgatctta 
29 Fsp-1 (S100a4),  gtccaccttccacaaatactcag ctcctggaagtcaacttcattgt 
30 Gapdh cagcaaggacactgagcaag gggtgcagcgaactttattg 
31 Gata4 ggtgcctccagcggtaactcc tgattacgcggtgattatgtc-3´ 
32 Gene Model 397 gcaagagcagcctatctctga gacttcaggttggtcttgtgg 
33 GFAP ggatttggagagaaaggttgaat tgcaaacttagaccgataccact 
34 Glut4 tccaactggacctgtaacttcat caagttctgtactgggtttcacc 
35 Goosecoid ggctacaacagctacttctacgg cttaaaccagacctccaccttct 
36 Hand1 atcatcaccatcatcaccactc gcgccctttaatcctcttct 
  
Materials and Methods 23
Primers included in our study (continued) 
 
S.No Gene Forward Primer (5’Æ3’) Reverse Primer (5’Æ3’) 
37 Lpl agcagcaagatgtacctgaagac ttctccctagcacagaagatgac 
38 αActinin cagagcctccttcaaccact gagtcataatgcgggcaaat 
39 Mash2 (Ascl2) agagtacattcggaccctctctc ccaccttactcagcttcttgttg 
40 Cardiac Actin tcgggacctcactgactacc cgccatctcgttctcaaaat 
41 Caridiac Troponin C cagaaagggaagtctgagg cgtaatggtctcacctgtgg 
42 Mef2c agcactgacatggataaggtgtt ggtgagtgcataagaggagtcag 
43 Mesp1 agaacctgaccaagatcgagac tctagaagagccagcatgtcg 
44 Mesp2 ctaggaacaagactggacactgg aaagttcaggacagccactgag 
45 MGC117846 tattcagcagctggtcctgtc ttggttcgagaattgaagagc 
46 MHC-ß ccctcctcacatcttctcca gcggcaataacagcaaaata 
47 Myocardin tcctggctcagaaagtgaca cggttcttactgtcacccaaa 
48 Myo-D ctacccaaggtggagatcctg gtggagatgcgctccactat 
49 Myogenin tgtgtaagaggaagtctgtgtcg agcaaatgatctcctgggttg 
50 Myostatin agctcctaacatcagcaaagatg ggtttgatgagtctcaggatttg 
51 Nanog gtggttgaagactagcaatggtc tggtggagtcacagagtagttca 
52 Nestin gaggaagaagatgctgatgaaga gccactgatatcaaaggtgtctc 
53 NF-M tagagcgcaaagattacctgaag ttgacgttaaggagatcctggta 
54 Nkx.2.5 ccaaagaccctcgggcggata gcgcagctgtagccgggactg 
55 Osteocalcin aggagggcaataaggtagtgaac gataccgtagatgcgtttgtagg 
56 Osteocalcin Primers 2 (Bglap) atgctactggacgctggagggt gcggtcttcaagccatactggtc 
57 Osteopontin (Spp1) atgaatctgacgaatctcaccat cttagactcaccgctcttcatgt 
58 P75NTR attgctttcaagagatggaacag ctactgtagaggttgccatcacc 
59 Pax-7 agaaagaagaagatggcgagaag gtagagtccggcagctggtag 
60 PPAR- agaaccttctaactccctcatgg cggcagttaagatcacacctatc 
61 Pref- 1 (Dlk1) gaaattctgcgaaatagacgttc actcttgttgagctctttcatgg 
62 Runx1 tacctgggatccatcacctc gacggcagagtagggaactg 
63 Shh gga agg tga gga agt cgc tgt ttg gcc atc tct gtg atg aac 
64 ACTA2 ctattcaggctgtgctgtcc ccaagtccagacgatgat  
65 Sox9 cacggaacagactcacatctctc aaggtctcaatgttggagatgac 
66 Tyrp1 tccagaagcaacttcgattctac tgttgtattgcctgttatgtcca 
67 Vimentin cttgaagctgctaactaccagga Gaagtctcattgatcacctgtcc 
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Primers for T Brachyury Subcloning  
 
5' T-bra primer 
 
o GCT GAG TCT TCT CTG TCA TTT AAA TTA GGC TCT GTC 
TCA GTT TGC CAT TCA GAT CTT CAC AGC TTG TCT GTA 
AGC GGA TG(80 bp) 
 
3' T-bra primer 
 
o CCT CCC GCC ACC CTC TCC ACC TTC CAG GAG TCT TGA 
CTC CCT ACC CAA CAA GAT CTG CTC TCC TGA GTA GGA 
CAA ATC (78 bp) 
 
 Bgl II restriction enzyme sites are indicated in blue and forward and reverse primer 
sequences to prime minimal vector are indicated in red and underlined. 
 
 
Cell culture Reagents 
 
S.No Medium Catalogue Number Manufacturer 
1 Glasgows buffered minimal essential 
medium (GMEM) 
21710082 Gibco BRL 
2 Fetal bovine serum (FBS) 10500064 Invitrogen 
3 Phosphate buffered saline (PBS) (w/o 
Ca2+/Mg2+
. 14190-094 Invitrogen 
4  
Phosphate buffered saline* (PBS*) (w 
Ca2+/Mg2+) 
14040-091 Invitrogen 
5 Trypsin/EDTA solution (Ca2+/Mg2+-free) ( 25300-054 Invitrogen, 
6 Leukemia inhibitory factor (LIF ESG1107 Chemicon 
7 ß-2-mercaptoethanol (ß-ME) 31350-010 Invitrogen 
8 Gelatine Type II G-2500  
9 Di-methyl sulfoxide (DMSO) D-8418 Sigma Alldrich 
10 Lipofectamine™ 2000 Reagent 52758 Invitrogen 
11 Puromycin dihydrochloride P8833 Sigma 
12 Neomycin (G418 Sulphate) 11811-031 Invitrogen 
13 Blasticidin R210-01 Invitrogen 
 
 Bacterial clones/Bacterial Artificial clones (BACs) 
 
S.No Bacterial clone Catalogue/ Clone ID Company 
1 RP23-376B1 RPC123.C Invitrogen, Germany 
2 MGC117846 30462068 Geneservice,UK 
3 1700108L22Rik IRAVp968A0470D6 RZPD, Germany. 
4 Gm397 IRAKp961F07111Q2 RZPD, Germany. 
 
Instruments Used 
   Zeiss Axiovert 200 fluorescence microscope 
   FACScan (BD, Pharmingen) 
   Biorad Gene Pulser™ 
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Plasmids used 
 
S.No Plasmid name  Catalogue name Company/from 
1 pIRES2 EGFP 632306 Clontech 
2 pIRES Puro3 631619 Clontech 
3 pCAGGS Kind gift Dr. Miyazaki, Tohoku University 
4 pBMP-2-GL3 Kind gift  Dr. Nandini Ghosh-Choudhury, 
Texas,USA 
5 αMHC Kind gift Dr. J. Robbins Cincinnati, OH) 
6 RedET plasmids BAC Subcloning kit Genebridges,Germany. 
7 pPyCAGIP Kind gift Stem cell Technologies 
8 pPPGKIP Kind gift Stem cell Technologies 
9 PMGD20neo Kind gift Dr. M Gassmann, CA, USA 
 
Antibodies 
 
S.No Antibodies Company 
1 Anti-BMP-2 Santa Cruz 
2 anti-alpha Actinin  Sigma 
3 anti-Connexin43 Sigma, 
4 Anti-mouseIgG1-AlexaFluor555  Molecular Probes. 
5 and anti-rabbit-Ig-AlexaFluor647  Molecular Probes. 
 
 
Molecular Biology Kits/Reagents 
 
S.No Kit Catalogue number Company 
1 QIAquick Gel Extraction Kit 28704 Qiagen 
2 Restriction enzymes  New England Biolabs /MBI 
Fermentas 
3 DNA Ligase   MBI Fermentas 
 QIAquick PCR Purification Kit  28104 QIAGEN 
4 QIAGEN Plasmid Mini Kit  12123 QIAGEN 
5 QIAGEN Plasmid Maxi Kit 12162 QIAGEN 
 
Pre-designed On-TARGETplus SMARTpool siRNA Reagents from Dhramacon 
S.No Target gene Catalogue no 
1 Cycophilin B D-001820-20-05 
2 Non-Target D-001810-01-05 
3 MGC117846 L-073711-00-0010 
4 1700108L22Rik L-053323-00-0010 
5 Gm397 L-064700-00-0010 
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Self prepared media and solutions 
SOC Media 
SOC Media was prepared to be used in DNA transformation by dissolving 20g of 
bacto-tryptone, 5g of bacto-yeast extract, and 0.5g of NaCl in 950mL water, then adding 
10mL of 250mM KCl. The solution was titrated to a pH of 7.0 by using NaOH, then diluted to 
1L using water. The new solution was sterilized by autoclaving and cooled before adding 
20mL of sterile 1M glucose and 5mL of sterile 2M MgCl2. 
 
TB buffer 
Mixed 10 mM HEPES pH 6.7, 15 mM CaCl2, 250 mM KCl and adjusted the pH to 6.7 
with KOH. Then added 55 mM MnCl2 and filter sterilized the mixture using a 0.22-µm filter. 
 
 
SOB++ medium 
Added 20 g bacto-tryptone, 5 g yeast extract, 0.5 g NaCl, 0.186 KCl, and the volume 
made up with distilled water to 1 litre. Sterilized by autoclaving and after cooled, added filer 
sterilized 10 mM MgCl2, 10 mM MgSO4 just before.  
 
LB   broth 
Added 20g bacto-tryptone, 5g yeast extract and 5g NaCl in distilled water and the 
volume made up to 1 liter. The pH was adjusted to 7.2 at 370C. Autoclaved for 30 minutes.  
 
LB Agar plates 
 Just before autoclaving the LB broth, added 15% agar-agar and then autoclaved. 
Once cooled to luke warm, added appropriate antibiotics and poured into plates. Once 
solidified, stored them in dark at 40C 
 
 
Antibiotics  
 
antibiotics Stock solutions Working concentration 
Ampicillin 100 mg/ml in water 100 µg/ml 
Chloramphenicol 30 mg/ml in ethanol. 
 
15 µg/ml for BACs 
50 µg/ml for high-copy plasmids. 
 
Kanamycin 50 mg/ml in water 50 µg/ml 
Tetracycline HCl 10 mg/ml in 75% ethanol. 
 
2 µg/ml for pSC101-BAD-gbaA,  
10 µg/ml for high copy plasmids  
 
 
ES cell culture medium:  
 GMEM supplemented with 10% heat inactivated FBS, 100Units/ml LIF  and 50 µM ß-
2-mercaptoethanol (ß-ME). FCS has to be critically checked for optimal results for every 
batch. 
 
Differentiation medium 
IMDM supplemented with 20% FBS, 100 µM β-mercaptoethanol, and 1x concentrated 
MEM. 
 
Freezing medium  
10% DMSO in 90% FBS: 
  
Wash medium 
GMEM supplemented with 5% FBS. 
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Gelatine solution 
5 g type II gelatine in 500 ml PBS was solubilized by heating in a microwave for 3 –5 
minutes till clear solution was obtained. Autoclaved this 1% gelatine solution 30 min and 
stored at 4°C. 
 
 
3.2 METHODS 
 
3.2.1   ES cell culture 
 
Gelatine coating of dishes 
Added 5 ml of 0.2% gelatine solution (prepare diluting the 1% gelatine solution 1:5) 
per T25 flask and placed it in the sterile incubator for at least 3 hours before use for the best 
coating.  
 
Defreezing cells 
Prepared a 15ml falcon tube with 10ml wash media pre-warmed at 
37°C.Thawed rapidly the vial at 37°C water bath. Once thawed, transferred all the 
contents into the falcon tubes with 10ml wash media. Centrifuged at 1000rpm for 6 
minutes. Resuspended the pellet in 5ml medium with LIF Removed the gelatine 
solution contained in the culture flask. Transferred the cell suspension from the tube 
into the gelatine-coated dishes. Placed it in the incubator.  
 
Passaging 
Passaged the cells when they approach 70-80% confluency. Prepared new 0.2% 
gelatine coated flasks or dishes one day before. Aspirated the medium with a sterile Pasteur 
pipette. Washed cells with 5ml 37°C warm PBS Added 2ml Trypsin/EDTA solution. Incubated 
cells for 2-5min at 37°C until they have lost the contact to the flask. Rocked the flask in 
between. After 5-10 minutes, transferred the cells with trypsin into a 15 ml falcon tube with 10 
ml wash medium. Centrifuged at Room Temperature for 6 min at 1000rpm Removed the 
supernatant with a sterile Pasteur pipette Resuspended the cells in 1ml propagation medium 
with LIF. Dispensed 0.2 to 0.3 ml of this cell suspension into 0.2% gelatine coated dishes 
with 5ml culture medium with LIF.  
 
Counting cells 
Prepared a cell counting chamber as described by the manufacturer. Added the 
appropriate volume of the cell suspension. Counted the cells under a microscope and 
calculate the total cell number in your cell suspension as described below. Prepared a 1 x 
106 cells/ml cell suspension finally. 
• Cell titer (cells/ml) = number of counted cells x chamber factor (Neubauer 
chamber = chamber factor 104) 
• Number of total cells = cell titer x volume of cell suspension 
 
Freezing cells:  
 
When cells were around 70% confluency, frozen them. Aspirated the medium with a 
sterile Pasteur pipette. Washed cells with 5ml 37°C warmed PBS.  Added 2ml 
Trypsin/EDTA solution. Incubated cells for 2-5min at 37°C until they had lost the 
contact to the flask. Rocked the flask in between. After 5-10 minutes, transferred the 
cells with trypsin into a 15 falcon tube with 10 ml wash medium. Taken an aliquot for 
cell counting. Centrifuged at room temperature for 6 min at 1000rpm. During 
centrifugation, counted the cells. Removed the supernatant with a sterile Pasteur 
pipette. Resuspended the cells quickly and carefully in ice cold freezing medium (the 
  
Materials and Methods 28
titer should be 1 x106 cells / ml transfer into vials (put 1.5ml suspension into one vial). 
Placed on ice and stored it for two days at –80°C. Then transferred to Liquid N2. 
Thawed one control vial to check everything ok with the freezing procedure 24 hrs 
after transfer to Liquid N2.  
 
Default differentiation protocol-Hanging drop protocol for Generation of embryoid bodies 
(EBs) 
 
Day 2
Day 0 Lid
PBS
Medium
Day 7
Very few EBs contain slowly contracting  
small areas for the first time
Day 10
Nearly all EBs contain larger and  stronger
contracting areas
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Schematic representation of the hanging drop protocol used for 
making EBs 
 
Used a 70% confluent cell culture. Harvested the cells by trypsinisation and made 
viable cell counting with Trypan Blue dye exclusion method using Neubauer counting 
chamber. Cell suspension of 1X106 cells /ml was made initially. Then diluted 1:40 with EB 
differentiation medium to get the final titer of 2.5x104 cells per ml. Using a multi channel 
pipette, spotted 20µl of the cell suspension onto the inside of the upper lid of a10 cm 
bacteriological dishes with the lower lid containing 5ml PBS (Figure 12). Closed the dish 
carefully by inverting gently and incubated it for two days in the incubator for the cells spotted 
in droplets to form EBs. On day 2, the EBs were collected and transferred into a 
bacteriological dish containing 10ml of EB differentiation medium. Made medium change 
whenever the medium turns little yellow and made sure that the EBS don’t starve of the 
medium. On 7th –8th days, first contractile areas will observed and almost all EBs will be 
contracting.  
  
 
3.2.2   Basic Molecular Biological Methods.  
 
DNA agarose gel electrophoresis  
 
Agarose gel electrophoresis was performed to analyse the length of DNA fragments 
after restriction enzyme digests and polymerase chain reactions (PCR), as well as for the 
purification of PCR products and DNA fragments. DNA fragments of different molecular 
weight show different electrophoretic mobility in an agarose gel matrix. Optimal separation 
results were obtained using 0.5-2% gels in TAE buffer at 10 V/cm. Horizontal gel 
electrophoresis apparatus of different sizes were used. Before loading the gel, the DNA 
sample was mixed with 1/6 volume of the 6x DNA-loading buffer. For visualization of the 
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DNA fragments under UV-light, agarose gels were stained with 0.1µg/ml ethidium bromide. 
In order to define the size of the DNA fragments, DNA molecular standard markers were also 
loaded onto the gel. 
 
BAC DNA isolation 
 
Picked colonies and inoculated in 2 ml of LB culture containing the appropriate 
antibiotics. Incubated at 37°C over night with shaking at 1100 rpm. Next day, spun down the 
2 ml over night cultures for 1 min at 11,000 rpm. Discarded the supernatant and 
resuspended the cell pellet in 200 µl buffer P1 with RNase (from QIAGEN DNA Maxi-
preparation Kit). Added 200 µl of buffer P2 (Qiagen) and mixed by inverting the tube several 
times. Added 200 µl of buffer P3 (Qiagen) and mixed by inverting the tube several times. 
Spun down the white lysate at highest speed for 4 min. Transferred the clear supernatant 
into a new 1.5ml-Eppendorf tube and added 0.50 ml of 2-propanol. Mixed by inverting the 
tube and spin down the DNA at highest speed for 5 min. Discarded the supernatant and add 
1 ml of 70% ethanol to rinse the pellet.10. Dried the pellet under the speed vacuum for 2 min 
or leave the tube open on the bench for 5 to 10 min until the DNA pellet is completely dried. 
The BAC DNA was resuspended in 10mM Tris-HCl, pH 8.0. Stored at 40C. 
 
Plasmid and DNA isolation 
 
QIAprep Spin Miniprep Kit and EndoFree Plasmid Maxi Kit  were used for the 
isolation of plasmid DNA and followed exactly the manufacturers protocol.  
 
Preparation of chemically competent DH5α E.coli  
 
Inoculated 3 ml LB medium with the DH5α E. coli strain and incubated the culture 
overnight at 37°Cin an orbital shaker. The next day, added the overnight culture to 500 ml 
SOB++ medium and incubated the culture at 25-30°C until the absorbance at 600 nm reached 
approx. 0.5 (between 0.4 and 0.6). Chilled the culture for at least 10 min on ice. In the 
following steps, the cell suspension was kept on ice as much as possible. Centrifuged the 
cell suspension for 10 min at 4,500 rpm (Sorvall RCB4 rotor) or 6,000 rpm (Sorvall GSA 
rotor) at 4°C. Gently resuspended the pellet in 100 ml ice-cold TB buffer. Incubated the cell 
suspension on ice for 10 min. Centrifuged for 10 min at rpm (Sorvall SS-34 rotor) at 4°C. 
Gently resuspended the pellet in 18.6 ml ice-cold TB buffer and add 1.4 ml DMSO. Incubated 
the cell suspension on wet ice for at least 10 min. Aliquoted the cell suspension 200 µl per 
1.5ml eppendorf tube. Shock-frozen the cell suspension in liquid nitrogen and stored the 
tubes at -80°. The transformation efficiency of the competent cells was determined using 5 
ng of pure plasmid DNA and 200 µl competent cell suspension (see transformation protocol). 
This gave approx 1 x 108 transformants per µg plasmid DNA with DH5 α. 
 
Transformation of chemically competent cells by heat shock 
 
Transformation of DH5α E.coli with plasmid DNA was performed by incubating 200 µl 
of the competent cell suspension on ice after taken from the  -80° storage followed by heat 
shock at 420C for 45 seconds and the subsequent incubation on in ice for 5 minutes. Then, 
750ul SOC media was added and incubated at 37 in orbital shaker for 45 –60 minutes. Then 
the cells were plated onto the top of the agar plates containing the appropriate antibiotics.   
 
 
3.2.3   Recombineering 
 
Oligo design 
Chosen 50 nucleotides immediately of the left of region to be subcloned from the 
BAC  Ordered an oligonucleotide with this sequence at the 5’ end and  3’ end of this oligo 
included PCR primer sequence for amplification of the ColE1+amp template, given in italics 
  
Materials and Methods 30
5’-(N)50 TCACAGCTTGTCTGTAAGCGGATG -3’. Chosen 50 nucleotides immediately right 
of the site to be subloned  and transferred them into the reverse complement orientation. 
Ordered an oligonucleotide with this sequence at the 5’ end and the 3’ end of this oligo 
included the 3’ PCR primer sequence for the ColE1+amp template, given in italics 5’-(N)50 
GCTCTCCTGAGTAGGACAAATC -3’. Included restriction sites between the 5’ homology 
regions and the 3’ PCR primer sequences. 
 
 
PCR 
The oligonucleotides were suspended in dH2O at a final concentration of 25 pmol/µl. 
PCR reaction was set up in volume of 50 µl with 38.5 µl dH2O, 5.0 µl 10 x PCR reaction 
buffer, 2.0 µl 5 mM dNTP, 1.0 µl upper oligonucleotide, 1.0 µl lower oligonucleotide, 2.0 µl 
ColE1+amp template and 0.5 µl Taq polymerase (5 U/µl). The following thermal conditions 
were used. 950C for 60 sec, 570C for 30 sec and 72° C 2min. 30 cycles. Checked 3 µl PCR 
products on a gel to ensure the PCR was successful. The size of the PCR product is around 
2.7kb . Precipitated using 5 µl 3 M sodium acetate, pH 7.0, and 150 µl 100% ethanol. Mixed 
well and precipitate for 5 min at -80°C or 30 min at -20°C. Spun down the DNA at maximal 
speed for 5 min. Carefully washed the pellet once with 500µl 70% ethanol. Dried the pellet at 
37°C using a heating block for 5 -10 min or vacuum dry for 2 min. Resuspended in 5 µl 
10mM Tris-HCl, pH 8.0 (0.2 -0.5 µg/µl). 
 
Electroporation of the Red/ET Plasmid pSC101- tetR-gbaA into the E.coli strain carrying the 
BAC with the gene of interest 
 
Set up an overnight culture. Picked at least ten colonies carrying the BAC and 
inoculated them together in an Eppendorf tube containing 1.0 ml LB medium with appropriate 
antibiotics to select for your endogenous BAC. Punctured a hole in the lid for air. Incubated 
at 37ºC over night with shaking. Next day, set up an Eppendorf tube containing fresh 1.4 ml 
LB medium conditioned with the same antibiotics and inoculated with 30 µl of fresh overnight 
culture. Cultured for 2-3 hours at 37ºC, shaking at 1000 rpm. Centrifuged for 30 seconds at 
11,000 rpm in a cooled Eppendorf benchtop centrifuge (at 2°C). Discarded the supernatant 
by quickly tipping out the supernatant twice, and place the tube on ice. Resuspended the 
pellet with 1 ml chilled dH2O, pipetting up and down three times to mix the suspension. 
Repeated the centrifugation and resuspended the cells again. Centrifuged and tip out the 
supernatant once more; 20 to 30 µl will be left in the tube with the pellet. Kept the tube on 
ice. Added 50ng the Red/ET recombination protein expression plasmid pSC101-tetR-gbaA 
and mixed gently. Kept the tube on ice. Fitting a larger pipette to the same tip, transferred up 
to 30 µl of cell suspension from the tube to the chilled electroporation cuvette. Electroporated 
at 1350 V, 10µF, 600 Ohms. with an Eppendorf® Electroporator 2510 using a 1 mm 
electroporation cuvette. Resuspended the electroporated cells in 1 ml LB medium without 
antibiotics and returned them to the Eppendorf tube. Incubated at 30ºC for 70 min, shaking at 
1000 rpm. Using a small loop, plated 100 µl cells on LB agar plates containing tetracycline 
(25 µg/ml) plus the appropriate antibiotics for the BAC. Incubated the plates at 30°C 
overnight (or for at least 15 hours).  
 
Subcloning 
 
Once the cultures were incubated at 300C , the cells were induced with arabinose 
incubated for 1 hour with shaking at 1100rpm. Then the PCR product with the homology 
arms were  electroporated as mentioned above. Then the cells were plated on LB agar 
plates prepared with appropriate antibiotics. The next day, the colonies were analyzed with 
restriction digestion for the subcloned construct. 
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3.2.4   Generation of ES cell targeting construct and clone generation 
 
ES cell targeting construct 
pIRES2 EGFP was purchased from Clontech, Germany. Human cytomegalovirus 
(CMV) immediate early promoter and enhancer were removed by a double digestion with 
Nhe I and Ase I and then subsequently blunt end ligated to get pIRES2 EGFP φ CMV. 
Puromycin cDNA flanked on its both ends by BamH1 restriction sites which was PCR 
amplified from pIRESPuro3 by Pfu DNA polymerase (Promega, Germany was inserted at the 
Sma I site of pIRES2 EGFP ϕ CMV construct to get  pPuro IRES2 EGFP 
43
52
bp
MCS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Plasmid map of pPuro IRES2 EGFP. This vector was constructed to derive the 
expression of puromycin N acetyl transferase to confer puromycin resistance and EGFP 
bicistronically with use of an IRES element. The multiple cloning sites just upstream of 
puromycin resistance cassette can be used to clone the promoter of interest to generate a 
reporter construct for a gene of interest. The plasmid encodes for neomycin resistance for 
selecting the transformants after electroporation and is the under the control of a ubiquitous 
promoter (SV40 promoter). 
 
Clone Generation 
30-40 µg plasmid was linearised in 100 µl reaction with appropriate enzyme(s). The 
enzyme is then heat inactivated at 800 C in a PCR machine or phenol chloroform extracted if 
the enzyme is resistant to heat inactivation at  800 C. Then the DNA was added to  107 cells 
in the Gene pulser  electroporation cuvette and incubated on ice for 20 minutes before the 
electroporation. Then, the cells were electroporated with 500µFD and   0.24 Volts to get a 
time constant of around 9.8 for optimal results. The cuvette with the cells was place on ice 
and incubated for the next 10 minutes. The electroprated cells were divided equally to seed 3 
gelatine-coated petriplate (100m diameter) with 10 ml media. At the end of 48 hours, 
antibiotic selection was applied to obtain stable transfectants either with neomycin at 
400ug/ml or puromycin at 3ug/ml. When the negative background was cleared, around 9-11 
days post transfection, the colonies were picked with aid of a microscope and propagated in 
the normal way 
 
Generation of  βactin clone expressing Puromycin resistance and EGFP constitutively 
 
1.7kb βactin promoter excised from pCAGGS (kindly provided by Dr. Miyazaki, 
Tohoku University) with EcoRI and SalI was blunt end ligated to EcoRI digested, klenowed 
and 5’ dephosphorylated pPuro IRES2 EGFP to get pβactinp Puro IRES2 EGFP. This was 
then linearised with SacI and electroporated in CGR8 ES cell line and the neomycin resistant 
clones were picked, propagated and analyzed for the functional integrity of the targeting 
vector.  
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β actin promoter
(1.7 kb)
7 kb
β actinp Puro IRES2 EGFP
 
 
Figure 14. Plasmid map of pβactinpPuro IRES2 EGFP 
 
 
3.2.5   Derivation of T-brachyury lineages 
 
T-brachyury Promoter Cloning by Recombineering 
 
5kb promoter region upstream of the translation initiation site of the    T-brachyury 
gene was subcloned from a BAC into the ES cell targeting construct pPuroIRES2 EGFP by a 
recombineering approach as follows (Figure 15). Sequences of 50 bases flanking on either 
side of the promoter region to be subcloned were verified by sequencing. Each 50b 
sequence was added to the 5’ end of the forward/reverse primers with appropriate restriction 
enzyme recognition sites in between (Figure 16). These primers were then   used    to    
amplify     the linear    minimal   vector   containing   ColE1   origin and Ampicillin resistance 
cassette. The linear amplified product was electroporated into the E.Coli harboring the BAC 
and induced to express Red ET proteins. Due to the homologous recombination events 
mediated by the Red E/T proteins and the 50bp homology regions, the minimal vector 
containing the promoter was positively selected with ampicillin. Then the minimal vector was 
digested with the appropriate restriction enzymes to release the T-brachyury promoter, which 
is then ligated in pPuroIRES2 EGFP to get pT-brap PuroIRES2 EGFP. This was then 
linearised and electroporated in CGR8 ES cell line and the neomycin resistant clones were 
picked, propagated and analyzed for the functional integrity of the targeting vector.  
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BAC (RP23- 376B1) clone
9845bp
T-bra Promoter
pT-brap puromycin IRES2 EGFP
4.5kb4.5k  
5kb
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The overall view of the BAC subcloning by recombineering approach to clone T 
Brachyury promoter in the reporter vector approach. 
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Figure 16. Schematic representation of recombineering process involved in sub cloning the T 
brachyury promoter from BAC.  
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Generation of T brachyruy reporter construct and reporter ES cell clones.  
 
  The 4.5 kb T Brachyury contained in the minimal vector was excised with Bgl II and 
ligated to Bgl II digested and terminal 5’ phosphate removed (by calf intestinal phosphatase) 
pPuro IRES2 EGFP to generate pT Bra+ Puro IRES2 EGFP. The plasmids cloned in the right 
orientation were screened by restriction digestion with other enzymes and one among was 
checked by sequencing before electroporation. . This construct was electroporated in CGR8 
with 500µF and 240V in a Bio-Rad Gene PulserTM. The transfected clones were selected by 
400 µg/ml neomycin and after selection, the clones were maintained with 200µg/ml 
neomycin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9845bp 
T-bra Promoter 
      pT-brap puromycin IRES2 EGFP 
4.5kb
Figure 17. Plasmid map of T Brachyury reporter ES cell targeting construct 
  
3.2.6   Derivation of BMP-2+ lineages 
Generation of BMP-2 reporter cell line 
 
A 2.9 kb  BMP-2 promoter fragment with both proximal and distal transcription start sites, 
excised with Hind III and sac I digestion from pBMP-2-GL3 (kindly provided by Nandini 
Ghosh-Choudhury,USA) were blunt end ligated to EcoRI digested and klenowed  pPuro 
IRES2 EGFP to generate pBMP-2p Puro IRES2 EGFP. This BMP-2 reporter construct drives 
the expression of both puromycin resistance and EGFP under the control of BMP-2 promoter 
by the use of IRES sequence. This construct was electroporated in CGR8 with 500µF and 
240V in a Bio-Rad Gene PulserTM. The transfected clones were selected by 400 µg/ml 
neomycin and after selection, the clones were maintained with 200µg/ml neomycin. During 
the EB generation, the neomycin selection was discontinued.  
 
 
 
 
 
 
 
 
Figure 18. Plasmid map of BMP-2 reporter ES cell targeting construct 
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Isolation of BMP-2+ cells 
To induce differentiation, ES cell suspension of 1.6x104 cells/ml was made in IMDM 
supplemented with 20% FCS, 1% none-essential amino acids  (vol/vol), 2 mM L-glutamine 
and 100 µM β-ME. Each bacteriological dish containing 25 ml of this ES cell suspension was 
placed in a 37o C incubator with 5% CO2 for 2 days. Then the 2-days old EBs were transferred 
into a 0.2% gelatine coated 10 cm tissue culture dish. On day 4, the EBs were treated with 
3µg/ml puromycin for subsequent 3 days with every day medium change with fresh 
puromycin. On day 7, the puromycin resistant BMP-2+ cells were used for the experiments. 
 
3.2.7   Derivation of αMHC lineages 
Generation of αMHC reporter construct and αMHC ES clones. 
The 5.5 kb αMHC promoter construct was a kind gift from Dr. J. Robbins (Cincinnati, 
OH). The promoter was klenowed on one end and the other end digested with SacII was 
inserted with one end EcoRI digested and klenowed and other end digested with SacI 
fragment of pPuro IRES2 EGFP to generate p αMHCp Puro IRES2 EGFP. This αMHCp 
reporter construct drives the expression of both puromycin resistance and EGFP under the 
control of αMHC promoter by the use of IRES sequence. This construct was electroporated 
in CGR8 with 500µF and 240V in a Bio-Rad Gene PulserTM. The transfected clones were 
selected by 400 µg/ml neomycin and after selection, the clones were maintained with 200 
µg/ml neomycin. During EB generation, the neomycin selection was discontinued.  
 
(~5.5kb)
 
 
 
 
10,828 bp
α-MHCp puro IRES2 EGFP
 
 
 
 
Figure 19 Plasmid map ofαMHC reporter ES cell targeting construct 
Isolation of αMHC+ cardiomyocytes 
To induce differentiation, the hanging drop protocol was used.  Briefly, an ES cell 
suspension of 2.5x104 cells per ml titer was prepared in IMDM supplemented with 20 % FCS, 
1 % non-essential amino acids (vol/vol), 2 mM L-glutamine and 100 µM β-ME. 20 µl of this 
ES cell suspension was spotted on the inside of the upper lid of a 10cm bacteriological dish 
and then covered over its bottom dish containing 5 ml PBS. On day 2, the formed 
multicellular aggregates (EBs) were transferred to suspension in a new dish with 20 ml IMDM 
supplemented with 20% FCS, 1% non-essential amino acids  (vol/vol), 2 mM L-glutamine 
and 100 µM β-ME. On day 8, contracting clusters were observed. At this stage, cultures were 
either treated with puromycin (4µg/ml) or left without treatment for 7 days with a medium 
change on every alternative day. On day 15, the beating clusters were trypsinised and used 
for FACS analysis or used for RNA extraction.  
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3.2.8   Patch clamp and sharp electrode electrophysiological studies 
 
AP recordings were performed in single αMHC cardiomyocytes and in multicellular 
αMHC+ cell aggregates at days 11-16. Single cardiomyocytes were obtained by dissociating 
puromycin-purified αMHC+ cell aggregates using a protocol described before and incubated 
in DMEM + 20% FCS at 37°C and 5% CO2 for 24-36 hours prior to the measurements. APs 
of spontaneously beating single αMHC+ cardiomyocytes were measured by means of the 
whole-cell current-clamp technique using an EPC-9 amplifier and the PULSE software 
package (Heka Elektronik, Lambrecht, Germany). Patch clamp electrodes had a resistance 
of 3-4 MΩ when filled with intracellular solution containing (in mM) 50 KCl, 80 KAspartate, 1 
MgCl2, 3 MgATP, 10 EGTA and 10 HEPES, pH 7.4. 
Spontaneous electrical activity of cardiomyocytes within plated MHC+ cell 
aggregates was assessed by conventional microelectrode recordings. The resistance of the 
sharp electrodes, which were filled with 3 M KCl, was 20-50 MΩ. Signals were acquired by a 
SEC-10LX amplifier (npi electronic, Tamm, Germany) connected to the PULSE software via 
the interface of the EPC-9.All experiments were performed at 37°C in standard extracellular 
solution containing (in mM) 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES and 10 
glucose or NaCl 136, KCl 5.4, NaH2PO4 0.33, MgCl2 1, glucose 10, hepes 5, CaCl2 1.8 (pH 
7.4 adjusted with NaOH). All electrophysiological data were analyzed off-line with a custom 
made analysis software (kindly provided by Philipp Sasse). 
 
3.2.9   Immunohistochemistry 
One day prior to the sample processing, 50,000 cells per each well of Lab-Tek 
Permanox slide Chambers (Nalge Nunc International, USA) were seeded and cultured in the 
absence of puromycin. After 24 hours, the samples were fixed with 4% Paraformaldehyde or 
with –20 0C cooled methanol-acetone (1:1) solution, permeabilised with 0.1%Triton X-100, 
and labeled with the appropriate primary antibody in the optimal dilutions followed by labeling 
with the respective secondary antibodies. The specificity of the antibodies has been tested 
using the appropriate tissues and isotype control antibodies. 
  
3.2.10 Sudan Red and Alizarin Red S stainings 
 
  The paraformaldehyde fixed samples were treated with Alizarin Red S for 5 minutes 
and then excess Alizarin Red was washed off by dipping in Aceteone: Xylene (1:1), followed 
by wash in Xylene. Then stained for haemtoxylin for 10 minutes and the excess dye was 
washed off in running water.  
 
 
3.2.11 Semi-quantitative RT-PCR 
 
Design of the RT-PCR primers 
 
For the design of the primers, the online software “Primer3” was used. 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Care is taken to choose the exon 
spanning primers to avoid the genomic DNA amplification. Primers with 23 bases and 
melting temperature around 600 C which give rise to amplicon sizes from 150-400 base pairs 
were preferred.  Most of the Oligos were ordered from Metabion (Martinsried, Germany) and 
the rest from MWG (Ebersberg, Germany).  
 
cDNA synthesis and PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen,Hilden,Germany) with  on-
Column DNase I (Qiagen) digestion according to the manufacturer’s instructions. 5µg total 
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RNA was reverse transcribed using SuperScript II Reverse transcriptase (Invitrogen) with 
random primers according to the manufacturer’s recommended protocol. PCR amplification 
was done with REDTaq ReadyMix (Sigma) with 0.4µM each primer.  GAPDH was used as 
an internal control. The following conditions were used. An initial denaturation at 950C for 2 
minutes, followed by 22-35 cycles of 30 sec denaturation at 950C, 30 sec annealing at 600C 
and 60 seconds of elongation at 720. A final extension at 720C for 5 minutes was included. 
Electrophorectic separation of PCR products was carried out on 2% agarose gels with 
0.001% Ethidium Bromide.  
 
3.2.12 FACS analysis 
 
Single cell suspension was prepared by trypsinisation. Cell clumps were removed by 
passing through cell strainer cap of round bottom tube from Falcon® (BD, Germany). 
Propidium Iodide staining (Sigma) was included to exclude dead cells.  Acquisition of 10,000 
live (PI negative) cells was made with FACScan (BD Biosciences) and the data analysis was 
done with CellQuest software (Becton Dickinson). The respective wild type EBs on the same 
day as the sample EBs were used as the control.  
 
3.2.13 Affymetrix Hybridization 
 
Total RNA was extracted from undifferentiated ES cells and EBs using the RNeasy 
total RNA isolation kit (Qiagen GmBH, Hilden, Germany). The preparation quality was 
assessed by agarose-formaldehyde gel electrophoresis. Three independent total RNA 
preparations, each 15 µg from the enriched specific lineages and the mixed cell population 
and from the undifferentiated ES cells were labeled with Target Labeling and Control 
Reagent package (Affymetrix) as described in the manufacturer’s instructions. Briefly, 
double-stranded cDNA was synthesized using the one-cycle cDNA synthesis module. 
Biotinylated cRNA was synthesized with the IVT labeling kit and cleaned up using the sample 
cleanup module. After fragmenting of the cRNA for target preparation using the standard 
Affymetrix protocol, 15 µg fragmented cRNA was hybridized for 16 h at 45 °C to Mouse 
Genome 430 2.0 arrays which carry probes representing 45101 probe sets. Following 
hybridization arrays were washed and stained with streptavidin-phycoerythrin in the 
Affymetrix Fluidics Station 400 and further scanned using the Hewlett-Packard GeneArray 
Scanner G2500A. The image data were analyzed with GCOS 1.4 using Affymetrix default 
analysis settings and global scaling as normalization method. After RMA normalization 63 
three pair-wise comparisons have been performed using the Student t-test (unpaired, 
assuming unequal variances). A Student t-test p-value < 10-2 and a fold change > 2 were 
used to identify and restrict the number of differentially expressed genes. For differentiation 
of treatment and developmental aspects hierarchical clustering of probe sets differential 
expressed between the three conditions in the F-test comparison (p-value cut off 10-7; n = 
617 probe sets) has been performed. The cluster analysis has been done using cluster 
version 2.11 64 applying mean-centering and normalization of genes and arrays before 
average linkage clustering with uncentered correlation. 
 
3.2.14 Affymetrix Analysis 
 
 DAVID functional annotation tool was used to classify the transcripts according to the 
Gene Ontologies. (http://david.abcc.ncifcrf.gov/summary.jsp). Hierarchical clustering was 
performed with Gene Cluster (Eisen et al. (1998) PNAS 95:14863).  
 
3.2.15  Quantitative Real time PCR 
 
Validation of the Affymetrix data was performed by quantitative real time PCR 
analysis with the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, 
Foster City, CA). 100ng RNA was reverse transcribed with ThermoScript™ Reverse 
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Transcriptase (Invitrogen). Then Real time PCR was perfomed in triplicates for every sample 
using TaqMan Gene Expression Assays from Applied Biosystems (Foster City, CA). The 
Gene Expression Assays included for the validation were Brachyury (T)  (Mm00436877_m1), 
Sox17 (Mm00488363_m1),        αMHC (Mm00440354_m1), BMP-2 (Mm01340178_m1), 
GAPDH(Mm99999915_g1), and  Nanog (Mm02019550_s1). Averaged Ct values of each 
qRT-PCR reaction from the target gene were normalised with the average Ct values of the  
housekeeping gene, GAPDH, that ran in the same reaction plate to get Ct value .  The fold 
change was calculated by using the formula, fold-change= 2-( Ct gene1 - Ct gene2). Ct  of the 
gene in the sample in which it is expressed lowest is taken as Ct gene2 to calculate the fold 
change using the above formula. The resulting fold change is expressed as percentage of 
the maximum.  
 
 
3.2.16 Episomal overexpression 
For episomal overexpression studies, the original pMGD20 (a kind gift from Dr. M 
Gassmann) was linearised with PvuI, klenowed and blunt end ligated to EcoRI digested, 
klenowed pEF-1/Bsd vector (purchase from Invitrogen) to get pMGD20 Blasticidin. This 
plasmid encodes the polyoma large T antigen required for the episomal maintenance of the 
vector pPyCAGIP. T Brachyury clones were transfected with linearised pMGD20 Bsd with 
NotI.  The novel transcripts cDNA clones were purchased from RZPD Deutsches 
Ressourcenzentrum fuer Genomforschung GmbH, Germany and geneservices, UK. The 
cDNAs were cloned in pPyCAGIP and the resulting overexpression plasmid was used to 
transfect the T Brachyury ES cells with lipofectamine 2000 transfection which are already 
transfected with pMGD20 Bsd. Stable clones were generated with puromycin selection and 
used for the experiments and the expression of the Large T antigen was checked by semi-
quantitative PCR as shown in figure 20A.  
 
 
  
3.2.17 siRNA Knock down 
Optimization of siRNA delivery with Lipofectamine  
 
  The optimal amount of lipofectamine and optimal concentration of siRNA was 
determined using the siControl Reagent from Dharmacon. Positive control siRNA labeled 
with Rhodamine and targeted against Cycophilin B was used for the optimization. 
1x105CGR8 cells were plated 24 well dishes one day before transfection and were 
transfected with gradient amounts of Lipofectamine from 0.5µl to 1.5 µl with different 
concentrations of siRNA for determining the optimal conditions. When increased the 
Lipofectamine amounts more than 1.5 µl, toxicity was observed to a greater extent. As shown 
in the figure 20B, 1.0 µl Lipofectamine 2000and 100nm siRNA was found to be optimal, when 
performed in 24 well dishes. When transfected in 6 well plates, the amounts were linearly 
scaled up (4 fold) as recommended by Dharmacon.  
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4.Results and Discussion 
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4.1 EXPERIMENTAL DESIGN 
 
For the isolation of mesodermal lineages and cardiomyocytes, the promoters of the 
following candidate genes were made use of to generate the respective stable ES cell lines 
with reporter (enhanced green fluorescent protein) and selection marker (puromycin 
resistance) under the control of the respective promoters.  
1. T-brachyury  ---Isolation of nascent mesodermal cells 
2. Bmp2   ---Isolation of late mesodermal cells 
3. αMyosin heavy chain  ---Isolation of cardiomyocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
0 1 2 3 4 5 6 7 10
T brachyury
Figure 21 Expression patterns of the T Brachyury, BMP-2 and αMHC transcripts 
used for isolation of nascent mesoderm, late mesoderm and cardiomyocytes 
respectively during the course of differentiation, as obtained from microarray 
analysis.  
 
 
Once the pure populations of mesodermal and cardiac cells were obtained, 
transcriptomic profiling of specific lineage cells were performed using microarrays. In 
addition, phenotypic analysis of the isolated cells was analyzed by immunohistochemistry 
and semi-quantitative PCR. Using bioinformatics approach, all the differentially expressed 
genes were analyzed. In the latter part, functional evaluation of the novel transcripts highly 
expressed in mesodermal cells but whose functions are still not yet annotated was done by 
using loss of function (siRNA mediated knock down) and gain of function (episomal over-
expression) studies.                               
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4.2 Transcriptomic profiling of wild type ES cells and differentiating  EBs 
 
ES cells are pluripotent and can give rise to any type of cells depending on the 
culture conditions. ES cells when maintained in the presence of adequate amount of LIF or 
cultivated on mouse embryonic fibroblasts remain in undifferentiated state and represents 
the inner cell mass of the blastula in the embryonic context.  
 
 When applied hanging drop protocol or placed in suspension in the absence of LIF, 
ES cells differentiate into 3 dimensional multicellular aggregates called Embryoid bodies. The 
mesoderm is established on day 3, the time point at which T Brachyury expression peaks 
high. The first contracting cardiomyocytes are observed on day 7 onwards. For the selective 
lineage of any mesodermal cells, either the formation of more mesodermal cells should be 
favoured at the expense of other germ layers or the differentiation of mesoderm into the 
lineage of choice should be enhanced at the expense of other mesodermal lineages. Till 
date, the mechanisms of mesoderm development and other germ layers development 
remain still elusive.  
 
In order to better understand the molecular mechanism of germ layer development 
and their lineage commitment, a large scale transcriptomic profiling of undifferentiated 
embryonic stem cells and the differentiating EBs at daily intervals over a period of 10days, 
the latest time point at which the onset of cardiomyogenesis is complete, was performed as a 
first step towards characterizing the pure mesodermal and cardiac population. The 
morphologies of the embryonic stem cells and the differentiating EBs are shown in the Figure 
22. We used feeder layer free embryonic stem cell line CGR8 and “Hanging drop protocol” 
as outlined in section (3.2.6) to obtain more reliable and reproducible experimental results. 
The differentiation of embryonic stem cells is stage specific. Establishment of ectoderm 
precedes mesoderm formation and occurs between day 0-3. Establishment of mesoderm 
and definitive endoderm occurs 2 days onward and 3days onwards respectively. Thus the 
germ layer development from ES cells mimics the embryonic development sequentially 
(Figure 23). 
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Figure 22:  Morphologies of the differentiating EBs on daily intervals. Cavitation occurs in the 
same way as in the in vivo embryonic development, starting from day 5 at which time point 
BMP-2 is expressed at its peak and is postulated to be the initiator of cavitation by its 
apoptotic property.  
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Figure 23 Stages of germ layer formation during embryonic stem cell differentiation. Nanog 
and Pou5f1 are the markers for pluripotent stem cells, Fgf5 , marker for primitive ectoderm, 
Neurofilament heavy(Nefh), marker for ectodermal lineages, T Brachyury, a pan-marker for 
nascent mesoderm and Sox17, pan marker for definitive endoderm. The values on Y axis 
represent the relative magnitude of expression.  
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4.2.1 Validation of the Affymetrix data by Real Time PCR Quantitation 
 
The affymetrix data obtained from the ES cells and the differentiating EBs were 
verified by quantitative real time PCR analysis of the pluripotent and germ layer specific 
genes –Nanog, T- Brachyury, Bmp-2, Neurofilament H, Sox 17 and α- myosin heavy chain. 
As seen in the figure 24, the Real time PCR data correlated very well with the affymetrix 
data.  
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Figure 24 Validation of the affymetrix results by qPCR. The fold change was calculated by 
using the formula, fold-change = 2-( Ct gene1 - Ct gene2). Ct of the gene in the sample in which it 
is expressed lowest is taken as Ct gene2 to calculate the fold change using the above 
formula. The pink line represent results from quantitative PCR and the blue line from 
affymetrix data. 
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4.3 CHARACTERIZATION OF T-BRACHYURY+ MESODERMAL POPULATION 
 
In the mouse embryo, mesoderm is generated from the epiblast or embryonic 
ectoderm through the process of gastrulation that is initiated at approximately day 6.5 of 
gestation (for review see 10). At the onset of gastrulation, the epiblast cells in the region that 
defines the posterior part of the embryo undergo an epithelial to mesenchymal transition and 
form a transient structure known as the primitive streak from which the mesoderm emerges. 
The newly formed mesoderm migrates away from the primitive streak, moves laterally and 
anteriorly and is patterned into various populations with distinct developmental fates. 
Brachyury is expressed in all nascent mesoderm and downregulated as these cells undergo 
patterning and specification into the derivative tissues including skeletal muscle, cardiac 
muscle and connective tissues in addition to blood and endothelium27,65. In the ES/EB model 
system, mesoderm, as defined by expression of the T-box gene Brachyury, is induced within 
48 hours of the onset of differentiation and persists until day 4 (Figure 25).  To visualize and 
to isolate these short lived nascent mesodermal cells which are at the very beginning of 
patterning, we generated transgenic ES cell clones transfected with a plasmid construct in 
which T Brachyury promoter (4.5kb) drives the expression of both EGFP and puromycin 
resistance cassettes bicistronically with the help of an IRES element.  
 
4.3.1 Generation and analysis of the T-brachyury ES cell clone 
 
Stable T-Brachyury clones were generated by electroporation with linearised pTbrap 
IRES2 EGFP construct with neomycin selection. Embryoid Bodies, when made from the T-
brachyury ES cell clone by hanging drop protocol and analyzed at regular intervals, showed 
the transient expression of T-brachyury transcripts as shown by RT-PCR in figure 25a. FACS 
analysis of the EBs showed the same pattern of EGFP expression as the transcript 
expression (Figure 25D). The ES cells and EBs from this transgenic clone behaved faithfully 
with the wild type ES and EBs.  The T-brachyury expression is distributed uniformly 
throughout the EBs as evident from the EGFP expression in every EB (Figure 25C).  
 
4.3.2 Isolation and Transcriptomic Profiling T-brachyury+ population 
  
On day 0, EBs were made from T-brachyury ES (CGR8) cell line by hanging drop 
protocol. On second day, the hanging drops EBs were transferred into suspension. On third 
day, the EBs were treated or untreated with puromycin at a concentration of 5ug/ml for 2 
days. On 5th day, the medium was changed and added medium with or without puromycin at 
a concentration of 2µg/ml for 1 day. On day 6th , RNA was isolated from EBs treated or 
untreated with puromycin for affymetrix analysis. Application of puromycin led to the 
enrichment of the T-brachyury cells up to 79% (Figure 26). The puromycin resistant T- 
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brachyury population along with the undifferentiated ES cells from the T-brachyury ES cell 
clone and the control 6day EBs without puromycin treatment were included for transcriptomic 
profiling. 
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Figure 26 A) Schematic outline of the protocol for the enrichment of T Brachyury population  
by puromycin selection. B, C, D and E). The purity of the T-brachyury population obtained by 
the protocol (A) as assessed by FACS analysis.  
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4.3.3 Validation of Affymetrix data by quantitative real time PCR 
The affymetrix data obtained from the ES cells, puromycin treated 6day EBs (T-
brachyury+ cell population and puromycin untreated 6 day EBs) were verified by quantitative 
real time PCR analysis of the pluripotent and germ layer specific genes –Nanog, T- 
Brachyury, BMP-2, Neurofilament H, Sox 17 and α- myosin heavy chain. As seen in the 
figure 27, the Real time PCR data correlated very well with the affymetrix data. 
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Figure 27. Validation of the affymetrix results by qPCR. The  fold  change was calculated  by  
using the  formula, fold-change =  2-( Ct gene1 - Ct gene2). Ct  of the gene in the sample in which 
it is expressed lowest is taken as Ct gene2 to calculate the fold change using the above 
formula. The pink line represent results from quantitative PCR and the blue line from 
affymetrix data. 
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4.3.4 Affymetrix analysis of the transcriptome of T-brachyury+ population 
To rule out the differentially expressed transcripts are specific to T-brachyury cells 
and are not due to the puromycin application, transgenic β actin clones were generated in 
the same way like the T-brachyury clones except that the  βactin promoter in the place of T-
brachyury was used to serve as puromycin treatment controls.  There were 6 unique 
transcripts with student t-test value of p<0.01 differentially expressed between puromycin 
treated 7day β actin EBs and untreated β actin EBs (as discussed for BMP-2 transcriptome 
analysis in the next chapter) and were excluded from the analysis. Thereafter the 
transcriptomic analysis was performed as follows. 
 
4.3.4.1 Major pathways / biological processes differentially regulated in T Brachyury cells 
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Overall, there are 5616 unique transcripts differentially expressed (2 fold up or 2 fold 
down with an ANOVA p value cut off of less than 0.01) compared to either the T Brachyury 
ES cells or 6day old control EBs (i.e., the intersection of all differentially expressed genes in 
T Brachyury population in comparison to at least one of either the ES cells or 6day EBs. 
Among these transcripts, 711 transcripts are participating in pathways and 723 genes are 
implicated in embryonic development as shown in figure 28.  Strikingly 95 transcripts 
participate in MAPK signaling pathway, 54 transcripts in Wnt Signaling and 41 transcripts in 
TGFβ signaling pathways (Figure 28). The differential expression of these transcripts in each 
pathway is summarized in figures 29,30and 31. Most of the rest transcripts take part in 
metabolism and a significant number of them in cell cycle, p53 signaling pathway, focal 
adhesion and axon guidance as shown in annexure 1.   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 28. An overview of the number of transcripts differentially expressed in T brachyury 
population according to different Gene Ontologies(GOs), as obtained from DAVID analysis.
  
 51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Up regulated
No change
Down regulated
Legend
Figure 29. Hierarchical clustering of the transcripts differentially expressed in T-brachyury+ 
cells that participate in TGF β signaling pathway  
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Figure 30. Hierarchical clustering of the transcripts differentially expressed in T brachyury+ 
cells that participate in MAPK signaling pathway  
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Figure 31. Hierarchical clustering of the transcripts differentially expressed in T brachyury+ 
cells that participate in Wnt signaling pathway  
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Figure 32. Hierarchical clustering of the transcripts differentially expressed in T Brachyury 
cells that involve in axon guidance. 
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This shows that the T Brachyury population has several dynamically ongoing functional 
signaling cascades, which are implicated to play a crucial role in early embryonic 
patterning. The transcripts involved in axon guidance are almost down regulated indicating 
the transition of primitive ectoderm into mesoderm  and development of neuronal 
phenotypes in the control but not in T Brachyury population (Figure 32). 
 
4.3.4.2 Classification of differentially expressed transcripts in T Brachyury in comparison to 
ES cells and 6day control EBs  
 
T Brachyury population is a transient one during differentiation under normal conditions 
and needs co-operation from other 2 germ layers for the further lineage commitment. 
When they were kept in isolation from the other germ layers, their interaction with the other 
germ layers is eliminated and hence they slow down in terms of the differentiation and 
remain in differentiation state between the starting ES cell state and the 6d control EBs 
which, are far advanced in terms of differentiation due their intact interaction with the other 
2 germ layers. Hence characterization of differentially expressed transcriptome of T 
Brachyury population needs to be compared with both the T ES cells and 6d Control EBs. 
Thus the analysis will need to be addressed as follows.  
 
1. Upregulated in T Brachyury+ cells than both ES ells and 6day control EBs 
 
i. Uniquely upregulated in T Brachyury cells (Not Differentially 
expressed in ES cells Vs 6day EBs)  
 
ii. Not Uniquely expressed in T Brachyury cells (Differentially 
expressed in ES Vs 6d EBs) 
 
2. Downregulated in T Brachyury+  than both ES ells and 6day control EBs 
i. Uniquely downregulated in T Brachyury cells (Not Differentially 
expressed in ES cells Vs 6day EBs) 
 
ii. Not Uniquely expressed in T Brachyury cells (Differentially 
expressed in ES versus 6d EBs) 
 
3. Upregulated in T Brachyury+  than ES cells but downregulated than 6d control EBs 
 
4. Upregulated in T Brachyury+  than 6d control EBs but downregulated than ES cells 
 
 
 
 
 
 
 
 
 
 
 
Results and Discussion 56
Analysis of upregulated transcripts in T Brachyury+ cells in comparison to both ES cells 
and 6day EBs.  
 
  There are 427 transcripts upregulated in T Brachyury cells in comparison to both 
ES cells and 6day old control EBs. Among them, there are 342 transcripts, which do not 
show any differential expression among ES cells and 6day EBs. The other 85 transcripts 
even though are upregulated compared to both ES cells and 6day EBs, they in turn show 
differential expression among ES cells and EBs. The distribution of the transcripts 
according to Gene Ontology “Biological Process” as analyzed with David functional 
annotation tool is presented in the Figure 33.  The 393 transcripts upregulated uniquely in 
T Brachyury cells but not in ES VS EBs are the bona fide transcriptomic signatures of T 
Brachyury+ mesodermal cells.  There are 42 T Brachyury cell specific transcripts involved 
in development according DAVID analysis and are enlisted in table 1.  The unique T 
Brachyury cell specific transcription factors and the transcripts involved in signaling and 
development are enlisted in tables 2 and table 3. The rest transcripts are represented by 
more than one Gene ontologies and are shown as heat map in annexure 2. Among the 
transcripts upregulated in T Brachyury cells that in turn showed differential expression in 
ES cells Vs EBs, there are 18 transcripts involved in developmental processes and are 
listed in the annexure 3. 
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Figure 33. Transcripts upregulated more than both ES cells and control EBs according to 
the biological processes. A) All transcripts which are upregulated in T Brachyury cells than 
both ES cells and 6 day control EBs. B) The T Brachyury cell specific unique transcriptome 
that does not show differential expression between ES cells Vs 6 day EBs but show up-
regulation in T Brachyury cells than both ES cells and EBs. 
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Table. 1a The development related transcripts specifically upregulated in T Brachyury population. The fold change is expressed relative to the 
lowest value of expression that is normalized to be 1. 
 
Affy_IDs NCBI ID Gene Name ES cells 6d Control EB T Brachyury+ ANOVA p Value 
1416192_at  NM_025898 
N-ethylmaleimide sensitive fusion protein attachment protein 
alpha 1.17 1.00 2.40 1.24E-06
1416953_at NM_010217 connective tissue growth factor 1.36 1.00 4.65 4.32E-07 
1417311_at NM_024223 cysteine rich protein 2 1.00 1.69 4.18 2.22E-08 
1417850_at   NM_009029 retinoblastoma 1 1.00 1.29 3.62 1.93E-06
1418289_at   NM_016701 nestin 1.00 1.15 2.32 6.18E-03
1418357_at NM_008241 forkhead box G1 1.00 1.93 8.03 5.47E-05 
1418901_at NM_009883 CCAAT/enhancer binding protein (C/EBP), beta 1.78 1.00 6.42 1.99E-06 
1419204_at NM_007865 delta-like 1 (Drosophila) 1.61 1.00 6.70 3.22E-06 
1419340_at NM_031260 Moloney leukemia virus 10-like 1 1.51 1.00 3.48 6.07E-05 
1419440_at NM_021447 tripartite motif-containing 54 1.74 1.00 4.16 2.83E-05 
1420696_at NM_013657 
sema domain, immunoglobulin domain (Ig),secreted, 
(semaphorin) 3C 1.05 1.00 3.01 5.71E-06 
1420964_at NM_007930 ectodermal-neural cortex 1 1.63 1.00 3.65 1.74E-05 
1421207_at NM_008501 leukemia inhibitory factor 1.44 1.00 4.45 8.26E-06 
1421273_at NM_080843 suppressor of cytokine signaling 4 1.00 1.04 2.82 1.13E-04 
1421365_at   NM_008046 follistatin 1.52 1.00 3.25 8.25E-07
1421375_a_at NM_011313 S100 calcium binding protein A6 (calcyclin) 1.37 1.00 6.84 5.79E-06 
1422033_a_at NM_053007 ciliary neurotrophic factor 1.00 1.01 4.40 2.08E-06 
1422054_a_at NM_011386 SKI-like 1.00 1.15 3.53 6.12E-05 
1422959_s_at NM_030743 zinc finger protein 313 1.01 1.00 2.26 6.25E-05 
1423315_at NM_133234 Bcl-2 binding component 3 1.00 1.22 3.21 3.75E-06 
1424208_at NM_008965 prostaglandin E receptor 4 (subtype EP4) 1.00 1.06 5.88 2.14E-07 
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Table.1b. The transcripts specifically upregulated in T Brachyury population which play a role in development (continued). The fold change 
is expressed relative to the lowest value of expression that is normalized to be 1. 
 
Affy_IDs NCBI ID Gene Name ES cells 6d Control EBs T Brachyury+ ANOVA p Value 
1426430_at    NM_010588 jagged 2 1.01 1.00 2.93 2.71E-07
1427420_at NM_183248 NK6 transcription factor related, locus 2 (Drosophila) 1.22 1.00 2.69 4.11E-06 
1427735_a_at NM_009606 actin, alpha 1, skeletal muscle 1.00 1.39 8.80 5.81E-07 
1428319_at NM_026131 PDZ and LIM domain 7 1.00 1.54 3.62 1.49E-06 
1429974_at    NM_023814 T-box18 1.63 1.00 3.54 4.54E-03
1431320_a_at NM_010864 myosin Va 1.00 1.59 3.40 3.65E-04 
1432155_at NM_028459 Wiskott-Aldrich syndrome-like (human) 1.00 1.14 2.38 1.44E-03 
1437302_at NM_007420 adrenergic receptor, beta 2 1.00 1.70 3.81 1.63E-03 
1439016 x at NM 011468 small proline-rich protein 2A 1.00 1.04 2.66 9.65E-06
1440085_at NM_175540 ectodysplasin A2 isoform receptor 1.22 1.00 4.46 5.23E-06 
1440626_at NM_008275 Homeo box D13 (Hoxd13), mRNA 1.30 1.00 3.07 2.06E-05 
1444151_at  NM_010487
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 
3  1.25 1.00 2.88 1.80E-03 
1448325_at NM_008654 myeloid differentiation primary response gene 116 1.26 1.00 7.86 3.16E-09 
1449391_at NM_009554 zinc finger protein 37 1.00 1.00 2.02 2.07E-03 
1450722_at    NM_016714 nucleoporin 50 1.00 1.13 2.74 4.16E-08
1450957_a_at NM_011018 sequestosome 1 1.00 1.03 3.24 6.24E-06 
1450971_at NM_008655 growth arrest and DNA-damage-inducible 45 beta 1.00 1.96 8.00 4.74E-07 
1451596_a_at NM_011451 sphingosine kinase 1 1.00 1.06 3.08 6.46E-05 
1452113_a_at NM_008999 RAB23, member RAS oncogene family 1.35 1.00 2.76 1.62E-07 
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Table. 2a The transcription factors that are specifically upregulated in T Brachyury population. The fold change is expressed relative to the 
lowest value of expression that is normalized to be 1. 
 
Affy_IDs NCBI ID Gene Name ES cells 6d Control EBs T Brachyury+ ANOVA p Value 
1416019_at NM_026106 down-regulator of transcription 1 1.66 1.00 3.81 4.15E-05 
1417487_at    NM_010235 fos-like antigen 1 1.01 1.00 2.26 1.04E-04
1417516_at NM_007837 DNA-damage inducible transcript 3 1.00 1.29 8.27 1.08E-08 
1417850_at   NM_009029 retinoblastoma 1 1.00 1.29 3.62 1.93E-06
1418323_at NM_010193 feminization 1 homolog b (C. elegans) 1.04 1.00 3.31 3.58E-08 
1418357_at NM_008241 forkhead box G1 1.00 1.93 8.03 5.47E-05 
1418616_at NM_010757 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K 1.00 1.95 6.20 2.44E-06 
1418901_at NM_009883 CCAAT/enhancer binding protein (C/EBP), beta 1.78 1.00 6.42 1.99E-06 
1419191_at NM_010434 homeodomain interacting protein kinase 3 1.00 1.12 2.37 1.77E-04 
1419558_at NM_008575 transformed mouse 3T3 cell double minute 4 1.10 1.00 2.32 8.35E-04 
1419641_at NM_011221 purine rich element binding protein B 1.00 1.49 4.07 5.94E-06 
1420433_at NM_028958 TATA box binding protein -associated factor 1.94 1.00 4.89 2.93E-05 
1421021_at NM_001005605 AE binding protein 2  1.00 1.08 2.70 1.42E-04
1421867_at NM_008173 nuclear receptor subfamily 3, group C, member 1 1.50 1.00 3.75 2.65E-04 
1422033_a_at NM_053007 ciliary neurotrophic factor  1.00 1.01 4.40 2.08E-06
1422893_at NM_019460 Scm-like with four mbt domains 1 1.65 1.00 3.54 8.31E-06 
1425356_at XM_484882 zinc finger protein 142 1.09 1.00 2.29 3.06E-04 
1426298_at NM_010574 Iroquois related homeobox 2 (Drosophila)  1.00 1.11 3.22 7.26E-06
1427420_at NM_183248 NK6 transcription factor related, locus 2 (Drosophila) 1.22 1.00 2.69 4.11E-06 
1427559_a_at  NM_001025093 activating transcription factor 2 1.16 1.00 2.63 6.40E-06 
1429217_at NM_028298 zinc finger protein 655 1.10 1.00 2.40 5.69E-06 
1429974_at  NM_023814 T-box18 1.63 1.00 3.54 4.54E-03 
1432155_at  NM_028459 Wiskott-Aldrich syndrome-like (human) 1.00 1.14 2.38 1.44E-03 
1433634_at XM_284454 interferon regulatory factor 2 binding protein 2 1.00 1.76 4.29 7.96E-06 
1434419_s_at NM_001003898 TAR DNA binding protein  1.27 1.00 3.16 1.32E-05
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Table. 2b The transcription factors  that are specifically upregulated in T Brachyury population (continued). The fold change is expressed 
relative to the lowest value of expression that is normalized to be 1. 
Affy_IDs NCBI ID Gene Name ES cells 6d Control EBsl T Brachyury+ ANOVA p Value 
1435197_at NM_008900 POU domain, class 3, transcription factor 3 (Pou3f3), mRNA 1.00 1.07 2.84 2.96E-05 
1435307_at NM_175455 RIKEN cDNA 6430502M16 gene 1.35 1.00 26.79 2.92E-07 
1437302_at NM_007420 adrenergic receptor, beta 2 1.00 1.70 3.81 1.63E-03 
1437788_at NM_031183 trans-acting transcription factor 6 1.00 1.28 3.02 1.24E-04 
1438725_at XM_109726 thyroid hormone receptor associated protein 1 1.00 1.56 3.79 6.65E-05 
1440085_at NM_175540 ectodysplasin A2 isoform receptor 1.22 1.00 4.46 5.23E-06 
1440626_at NM_008275 Homeo box D13 (Hoxd13), mRNA 1.30 1.00 3.07 2.06E-05 
1440855_at NM_029705 Machado-Joseph disease homolog (human) 1.34 1.00 2.75 1.68E-05 
1441935_at NM_023472 ankyrin repeat, family A (RFXANK-like), 2 1.00 1.54 3.84 2.68E-04 
1444712_at  XM_282974 
PREDICTED: gene model 739 [Mus musculus], mRNA 
sequence 1.21 1.00 3.42 2.17E-04
1447930_at XM_484142 bromodomain adjacent to zinc finger domain 1A 1.00 1.89 5.28 4.09E-05 
1448022_at    --- --- 1.30 1.00 10.18 2.40E-06
1449152_at NM_007670 cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 1.00 1.34 3.18 9.33E-06 
1449391_at NM_009554 zinc finger protein 37 1.00 1.00 2.02 2.07E-03 
1450481_at NM_008651 myeloblastosis oncogene-like 1 1.00 1.02 5.19 1.51E-05 
1450957_a_at NM_011018 sequestosome 1 1.00 1.03 3.24 6.24E-06 
1451639_at NM_009884 CCAAT/enhancer binding protein (C/EBP), gamma 1.12 1.00 2.36 6.30E-07 
1455925_at NM_029947 PR domain containing 8 1.00 1.16 2.98 6.81E-04 
1457240_at NM_130860 
Cyclin-dependent kinase 9 (CDC2-related kinase) (Cdk9), 
mRNA 1.03 1.00 2.08 2.87E-04 
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Table.3 The transcripts specifically upregulated in T Brachyury population that encode for proteins involved in Signaling. The fold change is 
expressed relative to the lowest value of expression that is normalized to be 1. 
 
Affy_IDs NCBI ID Gene Name ES cells 6d Control EB T Brachyury+ ANOVA p Value 
1416458_at NM_007477 ADP-ribosylation factor 2 1.00 1.21 3.46 2.39E-06 
1417516_at NM_007837 DNA-damage inducible transcript 3 1.00 1.29 8.27 1.08E-08 
1418105_at   NM_019675 stathmin-like 4 1.00 1.14 7.57 1.17E-06 
1418819_at NM_026011 ADP-ribosylation factor-like 10C 1.00 1.39 3.05 6.07E-04 
1418943_at NM_023057 RIKEN cDNA B230120H23 gene 1.00 1.16 2.50 3.93E-05 
1421207_at NM_008501 leukemia inhibitory factor 1.44 1.00 4.45 8.26E-06 
1421273_at NM_080843 suppressor of cytokine signaling 4 1.00 1.04 2.82 1.13E-04 
1421867_at NM_008173 nuclear receptor subfamily 3, group C, member 1 1.50 1.00 3.75 2.65E-04 
1422033_a_at NM_053007 ciliary neurotrophic factor 1.00 1.01 4.40 2.08E-06 
1422638_s_at NM_018750 Ras association (RalGDS/AF-6) domain family 5 1.00 1.45 2.92 9.07E-05 
1423047_at NM_023764 toll interacting protein 1.00 1.50 3.23 2.54E-05 
1424208_at NM_008965 prostaglandin E receptor 4 (subtype EP4) 1.00 1.06 5.88 2.14E-07 
1424332_at NM_139154 Rab40c, member RAS oncogene family 1.08 1.00 2.76 1.72E-04 
1425420_s_at NM_015771 large tumor suppressor 2 1.00 1.35 3.47 1.77E-04 
1427679_at XM_618738 large tumor supressor 1.00 1.18 2.80 2.63E-04 
1429444_at XM_485698 RAS-like, family 11, member A 1.27 1.00 3.93 1.26E-05 
1435014_at NM_175122 RAB39B, member RAS oncogene family 1.00 1.26 2.92 1.95E-04 
1435432_at NM_178119 centaurin, gamma 2 1.00 1.61 3.35 1.09E-06 
1436192_at  1.30XM_130646 ADP-ribosylation factor guanine nucleotide-exchange factor 2 1.00 3.15 2.12E-06 
1437074_at NM_024225 sorting nexin 5 1.83 1.00 4.16 2.58E-03 
1437302_at NM_007420 adrenergic receptor, beta 2 1.00 1.70 3.81 1.63E-03 
1437741_at NM_024454 RAB21, member RAS oncogene family 1.00 1.35 3.30 2.53E-06 
1438097_at NM_011227 RAB20, member RAS oncogene family 1.00 1.08 2.91 2.36E-05 
1440085_at NM_175540 ectodysplasin A2 isoform receptor 1.22 1.00 4.46 5.23E-06 
1450957_a_at    1.00NM_011018 sequestosome 1 1.03 3.24 6.24E-06 
1450971_at NM_008655 growth arrest and DNA-damage-inducible 45 beta 1.00 1.96 8.00 4.74E-07 
1451596_a_at     NM_011451 sphingosine kinase 1 1.00 1.06 3.08 6.46E-05
1452113_a_at NM_008999 RAB23, member RAS oncogene family 1.35 1.00 2.76 1.62E-07 
1455399_at XM_110525 connector enhancer of kinase suppressor of Ras 1 1.00 1.58 3.51 4.66E-07 
1458595_at NM_175515 PDZ domain containing 6 1.00 1.79 3.67 4.04E-05 
  
Results and Discussion 62 
Table.4 Devemopment related transcripts upregulated in T Brachyury cells than both ES cells and EBs but in turn show differential 
expression among ES cells and 6 day control EBs. The fold change is expressed relative to the lowest value of expression that is normalized to 
be 1. 
 
NCBI ID Gene Name ES cells 6d Control EB T Brachyury+ 
NM_010029 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 18.81 1.00 92.42 
NM_011580  thrombospondin 1 1.00 14.95 30.90 
NM_011817 growth arrest and DNA-damage-inducible 45 gamma 1.00 7.53 26.97 
NM_013657 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C 1.00 2.03 24.21 
NM_139298 wingless-type MMTV integration site 9A 1.00 2.96 15.99 
NM_009255 serine (or cysteine) peptidase inhibitor, clade E, member 2 1.00 5.90 14.33 
NM_011526  transgelin 1.00 6.55 14.00 
NM_009964 crystallin, alpha B 1.00 5.74 13.16 
NM_009573 zinc finger protein of the cerebellum 1 1.00 4.78 11.86 
NM_008655 growth arrest and DNA-damage-inducible 45 beta 1.00 2.44 11.38 
NM_013749 tumor necrosis factor receptor superfamily, member 12a 1.00 2.07 11.37 
NM_176930 RIKEN cDNA C130076O07 gene 1.00 4.47 10.74 
NM_008343 insulin-like growth factor binding protein 3 1.00 3.36 9.74 
NM_011674 UDP galactosyltransferase 8A 4.22 1.00 9.39 
NM_010118 early growth response 2 1.00 2.80 7.38 
NM_013562 interferon-related developmental regulator 1 2.60 1.00 7.28 
NM_010516 cysteine rich protein 61 1.00 2.48 5.31 
NM_011536  4.67 T-box 4 1.00 2.03
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3. 
 
 
2. Downregulated in T Brachyury than both ES cells and 6day control EBs 
 
 
 There are 411 unique transcripts downregulated in T Brachyury cells than both ES 
cells and 6day control EBs. Of them, there are 338 transcripts uniquely downregulated in T 
Brachyury cells (these do not show any differential expression among ES cells and 6day 
EBs). Among them, the developmental related transcripts and transcription factors are listed 
in the annexures 4 and 5.  Apart from that, 73 transcripts are downregulated in T Brachyury 
cells compared to both ES cells and 6day  EBs, which in turn show differential expression 
among ES cells and EBs and some of them are  GTPase regulators and 9 others are related 
to development as listed in annexure 6A and B. 
Upregulated in T Brachyury+ cells than ES cells but downregulated than 6day 
old control EBs 
  256 unique transcripts were found to be upregulated in T Brachyury cells 
compared to ES cells but down regulated in comparison to 6day control EBs. Among them, 
5 transcripts are involved in TGF β signaling pathway and they are - MAD homolog 3, 
Paired-like homeodomain transcription factor 2, Transforming growth factorβ2, BMP-2 and 
inhibitor of DNA binding 3. Interestingly the Id protein and Pitx2 are upregulated to direct 
mesoderm specification. There are 6 transcripts which play a role in Wnt signaling pathway 
are MAD homolog 3, Prickle like 1 (DROSOPHILA), SRY-BOX containing gene 17 
(Sox17), Frizzled homolog 1, Cyclin D2 and Frizzled homolog 2. Sox17 is early marker for 
endoderm. Apparently, the transcript is present in the T-brachyury population indicating the 
existence of mesendoderm as already reported by several groups. Kubo and his 
colleagues used brachyury (T) as a marker for primitive streak mesoderm and showed that 
T-GFP-expressing cells in ES cell cultures could give rise to cells expressing endodermal 
markers66. Among the 256 transcripts, 45 transcripts are developmentally important genes 
as shown in the annexure 7.  
 
4. The transcripts upregulated in T Brachyury cells than 6d control EBs but 
downregulated than ES cells. 
There are 225 unique transcripts, which are upregulated in T Brachyury+ cells 
compared to 6day EBs but downregulated in comparison to ES cells. The development 
related transcripts and transcription factors are shown in annexures 8 and 9. It is 
interesting to note that the transcripts Oct4 and Fgf4 are upregulated in T Brachyury cells 
compared to the control EBs.  
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4.4 CHARACTERIZATION OF BMP-2+ MESODERMAL POPULATION 
BMP-2, the late mesodermal marker and a member of TGF-beta superfamily, plays 
a crucial role in early embryonic patterning as evidenced from gene-ablation studies67,68. 
Its expression immediately follows the transient expression of T-Brachyury in the nascent 
mesoderm.  It is expressed normally in lateral plate mesoderm and extra embryonic 
mesoderm67,69. BMP-2+ mesodermal cells at this stage denote a subset of mesoderm, 
important being the lateral plate cardiogenic mesoderm25. Administration of soluble BMP-2 
to chick embryo explant cultures induces full cardiac differentiation in stage 5 to 7 anterior 
medial mesoderm, a tissue that is normally not cardiogenic70.  
Since BMP-2 is a cardiogenic factor as well as expressed in the cardiogenic mesoderm, it 
is highly imperative to investigate the molecular nature and phenotype of the mesodermal 
cells expressing BMP-2 during the early stages of development in the context of 
cardiomyogenesis. Also, It has been well documented that BMP-2 is a potent apoptotic 
inducer and a potent neurotrophic factor depending upon the target cells in a concentration 
gradient dependant manner, mostly by its paracrine mode of action71-73. Thus, BMP-2 
plays a pivotal role not only during cardiomyogenesis but also during other early embryonic 
patterning and lineage specification. Till date, the molecular nature and phenotype of the 
mesodermal cells expressing BMP-2 during the early stages of development have not yet 
been characterized leaving a black box in understanding their molecular interactions with 
the target cells in the vicinity to conclude their role during early embryonic patterning and 
lineage determination. This is partly due to the pleiotrophic effects of BMP-2 and mainly 
due to the practical difficulty in isolating pure early stage BMP-2 expressing cells in 
sufficient quantities during early embryonic development in vivo. 
Extensive investigation of the in vitro ES cells-based developmental model in the 
last 2 decades has proven it to be an invaluable tool to unravel the molecular enigma 
during the embryonic development in particular to better understand the mechanisms by 
which lineage decisions are made during early embryogenesis12. Recapitulation of early 
embryonic development, access to the early embryonic development, fine control over the 
process of differentiation, relative easiness to harvest the experimental material in 
sufficient quantity and quality in a very short time and to investigate molecular 
developmental events applying reporter gene manipulations make the in vitro ES-based 
model superior over the in vivo animal models12,62. 
To address the molecular nature and behavior of the BMP-2+ mesodermal cells 
during their differentiation into their lineage specific somatic cells, we first established an 
ES cell-derived transgenic Bone morphogenetic protein-2 (BMP-2)-expressing lineage for 
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developmental studies in vitro. In order to identify all the possible signal transduction 
pathways and biological processes characteristic of the BMP-2+ cells, we performed large-
scale expression studies using Affymetrix expression microarrays. Our study on the 
phenotypic identification of the ES cell-derived BMP-2 lineage specific cells shows that the 
early BMP-2 population contained a heterogeneous population of predominantly neural 
crest stem cells and their lineages-smooth muscle cells (SMC), epithelial like cells, 
astrocytes and melanocytes. When early BMP-2+ population was further cultured under 
certain conditions contained cardiomyocytes, macrophages and osteoblasts. Interestingly, 
these are the cell phenotypes which need BMP-2 for their phenotypic induction and 
demonstrates the presence of a multi-lineage progenitor phenotype resembling neural 
crest stem cells. More over, identification of the key signal transduction pathways induced 
or repressed in BMP-2+ cells explains the observed potential of BMP-2 in modulating early 
embryonic development, in particular the mesodermal patterning.  
 
 
 
4.4.1.Generation and analysis of the BMP-2+ ES cell clone  
 The transgenic BMP-2+ ES cell line was generated with the linearised pBMP-2-
Puro IRES2 EGFP construct by stable transfection. The transfected clones are neomycin 
resistant. The ES cells do not express BMP-2 in the undifferentiated state but express 
BMP-2 during the course of differentiation at a later stage as shown in the RT-PCR data in 
figure 34A, when the ES cells were induced to undergo differentiation by the hanging drop 
protocol. Normally, the BMP-2 transcript expression starts to show up on day 2, gradually 
increases in expression level until its peak expression on day 5 after which the transcript 
expression is at the basal level even after 10days of differentiation. The ES cells and EBs 
from the BMP-2 clone faithfully behaved as the wild type ES cells and EBs (figure 34A and 
B). During the course of differentiation (by hanging drop protocol), the EGFP fluorescence 
increases significantly after 2 days and initially the EGFP expressing cells found to be 
scattered within the 2-days to 4-days old EBs (Figure 34C). As the differentiation 
continues, the EGFP fluorescence peaks on day 5 and the EGFP expressing cells are 
localized to a particular region in every EBs as shown in figure 34C.  
4.4.2. Isolation and transcriptomic Profiling of BMP-2+ cell population  
Isolation and further characterization of the BMP-2+, puromycin-resistant cells have 
been optimized according to the protocol described in Figure 35A. Briefly, single cell 
suspension of BMP-2+ ES cells was seeded in bacteriological dishes for two days to form 
2-day old EBs. Then, the 2-day old EBs were transferred into gelatine coated tissue culture 
dishes and cultured for further 2 days. Thereafter, plated EBs were treated with 3µg/ml 
puromycin for the subsequent 3 days. After trypsinisation of puromycin-resistant 7-day old  
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 34 A., Analysis of the BMP-2 transcript expression by RT-PCR from EBs derived 
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BMP-2+ cells, FACS analysis has been performed. As demonstrated in Figures 35.B and 
35.C, after 3 days of puromycin treatment, EGFP fluorescing and puromycin resistant 
BMP-2+ cells (hereafter called BMP-2+ cells) accounted for 93% of the cells whereas the 
control EBs without puromycin treatment (hereafter called control EBs (=7-day old EBs)) 
contained only 11% of BMP-2+ cells. This resulted in an enrichment of nearly 8.5 fold of 
the BMP-2+ cells. 
 
 
 
As demonstrated in figure 36A, plating of the BMP-2+ cells in gelatine coated tissue 
culture dishes for the subsequent 3 days in the presence of puromycin results in a bright 
EGFP-positive BMP-2+ cell population. Furthermore, the BMP-2 protein has been detected 
by immunostaining using BMP-2-specific antibodies (Figure 36B and 36C). The 
undifferentiated BMP-2 ES cells were included as negative control (Figure 36D). As 
demonstrated, BMP-2 is only detected in the cytosol and specifically in vesicles of the 
BMP-2+ cells. Plating and culture of the BMP-2+ cells in the presence of puromycin for 8 
more days resulted in a heterogeneous population/colonies of cells with different 
morphologies as shown in Figure 37. 
 
A 
50µm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B C D
Figure 36 A, BMP-2+, 3 days after plating in gelatine coated tissue culture dishes in the 
presence of 3µg/ml puromycin. Scale bar represents 50µm. B, C, D, Detection of BMP-2 in 
BMP-2+ cells by immunohistochemistry staining. Stainings were done after the BMP-2+ 
cells were trypsinized and plated on microscopic slides for 24 hours. D, ES cells were used 
as negative control. Scale bar represents 20µm.  
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Figure 37 Morphology of the cells-derived from BMP-2+ cells after culturing for 8 days in 
the presence of 3µg/ml puromycin 
 
 
 
 
 
 
4.4.3 Phenotypic charecterisation of BMP-2+ cell lineages  
Expression of genes in the BMP-2+ cells associated with plasticity, mesodermal 
and neural crest stem cell phenotypes  
 
The early BMP-2 lineage cells are still in the state of plasticity 
BMP-2+ cells significantly upregulate Oct4 and Nanog transcripts expression 
compared to the 7-days old control EBs in which several somatic cell types are developed 
(Figure 38A) but at a level lower than ES cells. This implicates that there are some 
population of BMP-2+ cells with multi-lineage progenitor phenotypes, which are still in the 
state of certain plasticity and which can be induced to give rise to different cell fates 
depending upon the stimuli they receive. This is further confirmed due to the upregulated 
expression of Leukemia Inhibitory Factor (LIF) in BMP-2+ population compared to the 7-
days old control EBs. Interestingly, the transcripts of Activin, Nodal and Cripto are also 
upregulated in BMP-2+ population compared to the 7-days old control EBs. Recently, it has 
been demonstrated that TGF-β/Activin/Nodal signaling pathway is necessary for the 
maintenance of pluripotency in embryonic stem cells74. Therefore, the increased level of 
the pluripotency associated gene markers-Oct4 and Nanog might be partly explained by 
the increased expression of LIF, Activin and Nodal observed in the BMP-2+ cells (figure. 
38). 
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The BMP-2+ cells exhibit mesodermal characteristics 
 
 
The expression levels of the mesodermal markers in BMP-2+ cells show increased levels 
of expression of nodal, activin, eomesodermin, cripto, and Mesp2 whereas the expression 
of T-bra and Mesp1 was lower in the BMP-2+ cells compared to the control 7-days old EBs 
(Figure 38).  In this context, it has been shown that Activin and Nodal which are members 
of transforming growth factor beta (TGF-β) superfamily play a pivotal role in inducing and 
patterning mesoderm and endoderm, and in regulating neurogenesis and left-right axis 
asymmetry (for review see75). Nodal genes have been identified in numerous vertebrate 
species and are expressed in specific cell types and tissues during embryonic 
development75. Moreover, Nodal null mouse mutants lack mesoderm and overexpression 
of Nodal in mouse ES cells leads to up-regulation of mesodermal and endodermal cell 
markers emphasizing the key role of Nodal for mesoderm formation76. Also, it is repeatedly 
shown that Activin is involved in the mesodermal pattering during  Xenopus embryo 
development77. Cripto is the founder member of the EGF-CFC family initially related to the 
epidermal growth factor (EGF). Cripto is expressed  in tumor tissues and studies in the 
mouse have established an essential role of cripto in the formation  of  precardiac 
mesoderm and differentiation to fucnctional cardiomyocytes78 
The T-box gene Eomesodermin (Eomes) is required for mesoderm formation and 
the morphogenetic movements of gastrulation. It has been shown in the mouse that lack of 
Eomes abrogates the formation of embryonic and extraembryonic mesoderm20. In this 
context, it has been shown that Eomes is specifically required for the directed movement 
of cells from the epiblast into the streak in response to mesoderm induction20. Interestingly, 
we found a dramatically low level of T-Brachyury expression in BMP-2+ cells compared to 
the 7-days old control EBs, indicating that the either BMP-2+ cells represent a subset of 
mesodermal population, the mesoderm formation is nearly complete at the time of BMP-2 
expression whereby T-Brachyury expression is downregulated or the necessary signals 
from the non-BMP-2 population to induce stronger T-brachyury expression are eliminated 
due to puromycin selection. T-Brachyury is an essential gene for the mesoderm formation 
as demonstrated in the mouse65. Mesp1 and Mesp2 are basic helix-loop-helix (bHLH) 
transcription factors that are co-expressed in the anterior presomitic mesoderm (PSM) just 
prior to somite formation79 in the mouse embryo. Furthermore, it has been shown that 
Mesp1 has a significant role in the epithelialization of somitic mesoderm and it has been 
assumed that Mesp2 is responsible for the rostro-caudal patterning process itself in the 
anterior PSM79. Recently, it has been shown that Mesp1 is expressed in almost all of the 
precursors of the cardiovascular system in the mouse, including the endothelium, 
endocardium, myocardium, and epicardium80. Thus, the in vitro derived BMP-2 lineage 
cells exhibit more mesodermal characteristics. This conclusion is further supported by the 
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derivation of most of the mesodermal tissues and complete absence of endodermal 
phenotypes from these BMP-2 cells in the later stages as described below.  
 
 
 
 
BMP-2+  cells lack endodermal phenotypes  
Interestingly, transcripts of α-feto protein (AFP) and Sonic Hedgehog (Shh) were not 
detectable in BMP-2+ cells (figure 38A). AFP represents a marker for the endoderm-
derived hepatocytes.  The expression pattern of Sonic Hedgehog studied in several 
species indicates that Shh is essential for the endoderm-derived organ development such 
as foregut development, gut development, gastrointestinal duodenal and pancreas 
deveolpment81. These results show a dramatically reduced or more likely the complete 
absence of the endodermal lineage specific cells.    
The BMP-2+ cell lineage contains neural crest stem cells and their derivatives 
The BMP-2+cells contained enriched expression of ectodermal markers-
Neurofilament H (NF-H,) and M (NF-M). But it is evident that the BMP-2 cells shared more 
mesodermal characteristics as described in the previous sections. Further investigation of 
this contrary situation led to the conclusion that these may be more likely due to neural 
crest stem cells, as reported in several observations where these cells share a more 
ectodermal and a less mesodermal characteristics82-85. Expression of the neural crest stem 
cells  (NCSCs) specific p75NTR86 and Nestin transcripts at higher levels compared to the 
7-days old control EBs (Figure 39A)  confirmed the presence of  enriched NCSCs in BMP-
2+ cells. In addition, expression of smooth muscle α actin (SMA), astrocytes specific Glial 
fibrillary acidic protein (GFAP) and melanocytes specific Tyrosine phosphates 1 (Tyrp1) in 
BMP-2+ cells as shown in figure 39A confirmed the presence of NCSC lineages as well in 
the BMP-2+ lineage. Expression of p75NTR in BMP-2+ cells was further confirmed by 
immunohistochemical staining with an antibody against p75NTR on BMP-2+ cells, one day 
after plating in the absence of puromycin. In addition, presence of glial cells has been 
confirmed by immunohistochemical staining with an antibody against Glial fibrillary acidic 
protein (GFAP), on BMP-2+ cells, one day after plating in the absence of puromycin 
(Figure 39C.b). Notably, it has been reported that the differentiation of NCSCs into their 
lineage fates is mainly dependant on the presence of BMP-2 in the required threshold level 
and also the availability of the other factors in combination83. In this context, it is well 
demonstrated that exogenous addition of recombinant BMP-2 to cultured NCSCs isolated 
from chicken explants of cranial and trunk dorsal neural folds from stage 8/9 embryos 
resulted in the differentiation of NCSC into glial, melanocytes and smooth muscle cells83. It 
is surprising to note that the BMP-2 local concentration increased by BMP-2+cells 
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themselves are able to induce the differentiation of NCSCs into their lineages without the 
exogenous the addition of BMP-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Expression of pluripotent, trophectodermal, mesodermal, and endodermal gene 
markers in BMP-2+ cells. A, RT-PCR analysis for the representative genes, B-D, Relative 
fluorescence signal units as obtained from Affymetrix profiling for the genes presented in A 
and also other representative genes. 
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Figure 39. A-, RT-PCR analysis for the representative genes associated with neural crest 
stem cells, B. Relative fluorescence signal units as obtained from Affymetrix profiling for 
the genes presented in A. C, Detection of p75 (B) and GFAP in BMP-2+ cells labeled by 
immunohistochemistry. Immunuostainings with anti-p75 (Ca) and anti–GFAP (Cb) to show 
the presence of neural crest stem cells and the astrocytes, respectively, in BMP-2+ cells 
one day after plating (7+1 days in total). 
 
During vertebrate embryonic development, as the notochord induces the 
transformation of surface ectoderm to neuroectoderm, a multipotential middle cell layer 
develops with characteristics of both cell types. These cells called, the neural crest cells 
migrate dorsolaterlally to form the neural crest, a flattened irregular mass between the 
surface ectoderm and neuroectoderm. This layer of cells separates into right and left 
portions and then migrate to various locations within the embryo to give rise to most 
structures of the peripheral nervous system (PNS) such as Schwann and glia cells of the 
autonomic and enteric nervous systems, endocrine cells such as the adrenal medulla and 
C-cells of the thyroid) as well as non-neural tissues such as pigmented pigment cells of the 
skin and internal organs, smooth muscle musculature of the cardiac outflow tract and great 
vessels,  pericytes,  craniofacial bones, cartilage and connective tissues87,88. Wnt1 and c-
kit are well known mediators for melanocytes differentiation of NSCS89,90and are found to 
be expressed  in the BMP-2+ population.  The tyrosine kinase, c-kit, has been found in the 
cell membranes of hematopoietic stem cells, primordial germ cells and presumptive 
subepidermal melanocytes91 Intriguingly, wnt-1 and BMP-2 act synergistically to suppress 
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differentiation and to maintain NCSC marker expression and multipotency by combinatorial 
Wnt1/BMP-2 signalling92 
 
 
 
The presence of Wnt1 transcripts present in BMP-2+ population may be interpreted 
in 2 ways. 1) The Wnt1 may be involved in the maintenance of neural crest stem cells in 
their pluripotency state in combination with BMP-2. 2) Wnt1 may be involved in driving the 
differentiation of NCSCs into melanocytes.  Both possible roles by wnt1 cannot be ruled 
out in BMP-2 population since there are proliferating NCSC on one side (as evident from 
increase in cell number when subjected to immunohistochemistry), and the occurrence of 
melanocytes in the same culture on the other hand. The local BMP-2 and/or Wnt1 gradient 
may drive the neural crest stem cells to produce either smooth muscle cells, pericytes or to 
melanocytes or to remaining their  pluripotent state, respectively. 
This is the first study that enables getting ES cells-derived neural crest stem cells 
and their derivatives all at the same time selectively via BMP-2 promoter based lineage 
selection approach. The co-expression of Wnt1 and BMP-2 in the same culture indicates 
the existence of both an environment to keep the neural crest stem cells in stemness and 
also the stage of ongoing differentiation of NSCS to form melanocytes. Thus, the study on 
these BMP-2 expressing cells during early differentiation of ES cells will pave the way for 
the better understanding of the neural crest stem cells and their differentiation into their 
lineages. The BMP-2+ cells-derived from the ES cells may serve as an ideal model for the 
neural crest stem biology in the future since the neural crest stem cells and their 
derivatives can be selectively enriched by the BMP-2 promoter driven lineage selection 
approach. In addition, it provides a valuable system where the enriched neural crest stem 
cells prime themselves to differentiate into their cell specific lineages, since the enriched 
NSCS secrete BMP-2 and causes a BMP-2 gradient negating the supply of exogenous 
BMP-2 addition. Noggin, an inhibitor of BMP-2 can be used to keep the neural crest stem 
cells in their plasticity. Once the fine-tuning of BMP-2 derived neural crest stem cells to 
keep in their plasticity is made, then they will be the potential candidates for the cell 
replacement therapy, since they can mould into any tissue depending upon the local 
environment prevailing within the tissue in which they are injected. 
 
BMP-2 cell contain predominantly smooth muscle cells  
Figure 40A shows that culturing of the BMP-2+ cells for 8 days in the presence of 
puromycin resulted in the development of a heterogeneous cell population of cells with 
different morphologies. Figure 37B indicates cells with smooth muscle-like morphology. 
The immunohistochemical staining of smooth muscle cells has been performed with an 
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antibody against smooth muscle α actin, 1 day after plating the BMP-2+ cells (7+1 days in 
total), 8 days after plating with puromycin (7+8 days in total), 18 days after plating with 
puromycin (7+18 days in total) and 18 days after plating without puromycin (7+18 days in 
total) (Figure 40Ca-d). Detection of Smooth muscle cells even 18 days after puromycin 
treatment indicates that SMC express BMP-2 and therefore they survive the puromycin 
treatment 93.  
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Figure 40. Detection of smooth muscle cells after differentiation of the BMP-2+ cells.  A, 
Expression of SMA in the BMP-2+ detected by semi-quantitative RT-PCR method. B, 
Diagram indicates the microarray expression levels of various smooth muscle specific 
genes in BMP-2+ cells.    C(a-d), detection of smooth muscle cells, 1 day after plating the 
BMP-2+ cells (7+1 days in total) (Ca), 8 days after plating with puromycin (7+8 days in 
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total) (Cb), 18 days after plating with puromycin (7+18 days in total) (Cc) and 18 days after 
plating without puromycin (7+18 days in total) (Cd).  
 
 
Preparation of hanging drops EBs applying the differentiation protocol (Figure 41B) 
as previously described94 from a mixture of BMP-2+ cells with wild type ES cells in a ratio 
1:1, 1:2, 1:4, 10:1, 50:1, 1:10 and 1:50, respectively, did not augment/delay the onset of 
contractile activity in comparison to the control observed on day 12. Also, there were not 
any significant differences in terms of magnitude of the intensity of the contractility (data 
not shown). This corresponds to the observation where recombinant BMP-2 added during 
the differentiation of ES cells, no enhancement of cardiomyogenesis has been observed95. 
In order to investigate the capacity of the BMP-2+ cells to differentiate in cardiac beating 
cells, secondary EBs were made from these BMP-2+ cells by hanging drop protocol and 
the differentiation process was observed in comparison to the control EBs. The secondary 
EBs when made from the BMP-2+ population were contracting on 11th day like the 
secondary control EBs made from the CGR8 wild type EBs without puromycin and 
secondary EBs made from the β−actin CGR8 clone transfected with   β-actin promoter 
driven puromycin resistance and EGFP expression cassettes treated in the same way as 
the secondary BMP-2+ EBs with puromycin. Notably, the intensity of the contracting areas 
in the BMP-2+ EBs was significantly stronger, compared to the both controls. The whole 
EB was contracting in a jellyfish like fashion where as in the controls (Fig. 41C). The 
contracting areas persisted for a longer time when compared to the controls for more than 
a week. In order to demonstrate that an increased beating activity of the cardiomyocytes 
generated from the BMP-2+-cells correlates with an increased expression of cardiomyocyte 
gene markers, we investigated the expression of α-cardiac actin and αMHC in EBs at day 
11 secondary EBs. As clearly indicated, an increased expressed level of both cardiac 
specific genes was observed in the EBs generated from BMP-2+ cells (Figure 41D) 
compared to both the control secondary EBs.  
BMP-2+ cells give rise to cardiomyocytes after downregulation 
The expression level of the cardiac marker genes NKx2.5 (early), MLC-2a, α-
cardiac actin and Mef2c is reduced in the BMP-2+ cells compared to the control 7-days old 
EBs (Figure 41A) suggesting that cardiomyogenesis is repressed in the BMP-2+ cells. 
Accordingly, also Mesp1 was found to be repressed (Figure 38A). Culturing of the BMP-2+ 
cells even for further 28 days (35 days in total) in the presence or absence of puromycin 
did not result in cardiac cell beating clusters (data not shown).  
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Figure 41. Differentiation of the BMP2+ cells to cardiac cells. A, RT-PCR analysis of the cardiac markers in BMP2+ cells and other controls. B. 
Schematic outline of the protocol used to derive cardiomyocytes from BMP2+ cells. C, the morphology of the contracting EBs. The red arrows indicate 
the contracile area(s) in that EB and D, RT-PCR analysis of the representative cardiac markers in 12 day secondary EBs derived by hanging drop 
protocol from single cell suspension obtained from 7 day old primary EBs generated by the hanging drop protocol from CGR8 wild type EBs without  
puromycin treatment, β-actin puro EGFP EBs and BMP2 EBs with puromycin treatment.  
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Thus, BMP-2+ cells have the capacity to develop into cardiomyocytes. Interestingly, the 
cardiomyogenic potential apparently seems to be regulated by the BMP-2+ lineage cells 
only. These findings suggest that the BMP-2+ cells are primed to become cardiomyocytes 
independently of the other BMP-2+ negative lineage cells. But the secondary EBs 
maintained with puromycin and the contractile secondary EBs when treated with 
puromycin did not contain cardiomyocytes. So, it is imperative to note that the 
cardiomyocytes don’t express BMP-2 but descend from the BMP-2+ mesodermal cells. At 
the same time, the cardiomyocytes developed from the BMP-2+ cells are dependant on 
paracrine action of BMP-2 secreted by the neighboring cells of BMP-2 lineage cells96.  
 
Vascular and haematopoietic cell gene markers from BMP-2 population 
Expression of E-cadherin, Flk1, Flt1, Pecam1 and Runx1 shows the presence of 
vascular endothelial progenitors in the BMP-2+ population (Figure 42A). As demonstrated 
in figure 42B, BMP-2+ cells are able to differentiate into cells with an epithelial/endothelial 
morphology after culturing for 8 days in the presence of puromycin. Detection of epithelial-
like cells has been confirmed by immunohistochemistry. As indicated in figure 42Ca-d 
epithelial-like cells were detected even after 11 days after culturing in the presence of 
puromycin. 
Expression of c-kit and CD34 and Runx1 indicates the presence of hematopoietic 
stem cells in BMP-2 population (Figure 42A).  Ihh that is implicated in haematopoiesis and 
vasculogenesis97 also is expressed in the BMP-2+ cells but the expression level is lower 
than that of the control cells. Flt-1 also known as vascular endothelial growth factor 
receptor 1 (VEGFR-1) is a high-affinity tyrosine kinase receptor for VEGF and is normally 
expressed only in vascular endothelial cells. However, Flt-1 transcript was recently found 
to be expressed in human peripheral blood monocytes98. Monocytes  are known to 
differentiate into a variety of cell types such as osteoclasts in bone, Kupffer cells in liver, 
dendritic cells in the immune system, and mature macrophages in a number of tissues98 . 
Expression of Flt-1 and c-fms in BMP-2 population indicates the possible monocyte-
macrophage lineage existence in the BMP-2+ cell population.  
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 Figure 42 Analysis of the vascular and haematopoietic cell gene markers in BMP-2+ cell 
population. A, RT-PCR analysis of the BMP-2+ cells. B, Relative fluorescence signal units 
as obtained from Affymetrix profiling for the genes presented in A. C, Immunuostainings 
with anti-pan cytokeratin over the period of time to show the presence of epithelial like 
cells.  Ca, one day after plating the BMP-2+ cells (7+1 days in total). Cb, 8 days after 
plating with puromycin (7+8 days in total). Cc, 18 days after plating with puromycin (7+18 
days in total).  Cd, 11 days after plating without puromycin (7+11 days in total). 
 
 
 
 
 
 
 
 
 
  
Results and Discussion  79 
BMP-2+ cells give rise to osteoblasts and express gene markers for satellite cells     
and fibroblasts  
 
 
Expression of osteopontin, Cbfa, osteocalcin and alkaline phosphatase in BMP-2+ cells 
showed the possible occurrence of osteoblasts (Figure 43A). When BMP-2+ cells plated 
and maintained with the differentiation medium and puromycin showed Alizarin red positive 
clusters after 18days (Figure 43B) indicating the first appearance of osteoblasts. After 35 
days of culturing in the presence of puromycin, brightly stained with Alizarin red were 
observed confirming the occurrence of osteoblasts in culture (Figure 43C). These results 
show that the puromycin resistant BMP-2+ cells per se are cable of differentiating into 
osteoblasts. It may be also possible that the osteoblasts might be developed from the 
BMP-2+ derived NCSC cells in the presence of an increased BMP-2 concentration for 
longer periods of time99. 
Expression of the transcription factor Sox9, the proteoglycan aggrecan, collagen II (with 2 
alternate splicing forms) was detected in the BMP-2+ population indicating the existence of 
chondrocytes100(Figure 43A) . Sox9 is a key transcriptional factor for chondrocytic 
differentiation of mesenchymal cells via chondrocytes-specific enhancer of the pro alpha1 
(II) collagen101.  Expression of Pax-7 and myoD shows the presence of satellite cells102,103.  
Satellite cells represent a distinct lineage of myogenic progenitors responsible for 
maintenance of skeletal muscle104.  MyoD is only expressed when satellite cells are 
activated to proliferate and differentiate into primary myoblasts, which will in turn 
differentiate into cells of the myofibres of skeletal muscles103. An elevated level of MyoD in 
the BMP-2+ population indicates either the proliferation or the differentiation of satellite 
cells into primary myoblasts in BMP-2 culture. But the expression of myogenin and 
myostatin was not detected in the BMP-2+ cell population suggesting the absence of 
skeletal muscle cells by RT-PCR even after 40 cycles. Interestingly, it has been reported 
that the satellite cells can spontaneously differentiate into adipocytes in an alternative 
mesenchymal pathway105. Expression of FSP-1 shows fibroblast phenotype occurring in 
the BMP-2+ cell population. FSP-1 has been implicated in the epithelial-mesenchymal 
transition and is a representative marker for mesenchymal cells106 . 
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Figure 43. analysis of osteoblast, chondrocyte and myocyte specific markers in BMP-2+ cells.
A, RT-PCR analysis in BMP-2+ cells. B, C, Alizarin stanings on 18th day after plating the
BMP-2+ cells (7+18 days in total) and on 28 days after plating (7+28, 35 days in total). D,
Relative fluorescence signal units as obtained from Affymetrix profiling for the genes
presented in A. 
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BMP-2 cell lineage contains monocytes but not mature adipocytes  
The RT-PCR analysis of the BMP-2+ population showed the expression of the pre-
adipocyte gene marker pref-1107, the pan-adipocyte markers PPARγ108 aP2, Glut4109 and 
LPL as well as the pan- macrophage marker c-fms107,108,110(Figure 44A and D). Although, 
the markers PPARγ, aP2 and Glut4 are unique to adipocytes, expression of these genes is 
also found to be expressed in macrophages. Similarly, trophoblast lineage also expresses 
c-fms107. Notably, the cells-derived from the BMP-2+ cell population after 11 days of 
cultivation in the presence of puromycin were not found to be positive for either Oil Red O 
or anti F4/80 stainings eliminating the occurrence of mature adipocytes and macrophages 
in the later stages (data not shown). Also, no expression of   adipsin111, a marker for 
mature adipocytes, could be detected demonstrating the absence of the mature adipocytes  
in the BMP-2+ cells. Thus, the BMP-2+ cell population contains only the pre-adipocytes 
expressing PPARγ, aP2, Glut4 and Pref-1 but not adipsin. Apparently, other factors 
secreted by BMP-2 negative cells are required for maturation of preadipocytes to 
adipocytes. 
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Figure 44. A, RT-PCR analysis of adipocyte specific markers. B, Relative fluorescence 
signal units as obtained from Affymetrix profiling for the genes presented in A. C, Sudan 
red staining on 11 days old puromycin untreated culture after plating the BMP-2+ cells 
(7+11, 18 days in total). D, F4/80 Immunuostaining on 18 days old puromycin untreated 
culture after plating BMP-2+ cells (7+18, 25 days in total).  
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Notably, after 11-days of BMP-2+ cells culturing in the absence of puromycin, there were 
cells stained with Sudan Red and F4/80, a marker for macrophages as shown in figure 
43B and 43C. These findings suggest that macrophages are derived from differentiated 
BMP-2+ cells in which BMP-2 expression is downregulated at a later time. 
4.4.4 Selective enrichment of different BMP-2+cell phenotypes with puromycin  
 When the different day EBs were treated with puromycin for 3 days and when the 
subsequent puromycin treatment was either discontinued, or maintained all the time or 
maintained in 3 days alternating intervals as shown schematically in figure 45A, different 
BMP-2 lineages are enriched depending on the starting day of puromycin treatment and 
the subsequent puromycin selections. Cardiomyocytes were enriched when the 6day EBs 
were treated with puromycin for 3 days and discontinued the treatment after that. On 19th, 
when analyzed with semi-quantitative PCR, the cardiomyocytes are enriched when 
compared to the other BMP-2 lineage phenotypes. When the wild type CGR8 EBs were 
treated in the same manner, there were no viable cells even after 19 days, implying that 
the 3 days of puromycin at 3µg/ml concentration is very effective in selecting BMP-2 
lineage cells with highest purity.  The enrichment of the particular BMP-2 lineage at the 
respective conditions is color coded with a blue box in figure 46. It is worthwhile to note 
that in the all the conditions, the enrichment of a particular lineage was found but in 
addition to other phenotypes. This approach did not select only one phenotype at the 
whole expense of the others. 
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Figure 45.  Schematic overview of puromycin treatment on different stage EBs and 
subsequent puromycin treatment conditions. All the time the first puromycin treatment was 
3ug/ml for 3 days and later either the puromycin at a concentration of 2ug/ml was added to 
the culture or discontinued completely or added in regular 3 days intervals. Finally on day 
19, the RNA was isolated from every sample and analyzed for the enrichment of the BMP-
2 lineage cells. 
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Figure 46.   RT-PCR analysis of the BMP-2 mesodermal lineage marker genes on 19th 
day after the different day EBs were treated with puromycin for 3 days and then either 
discontinued or continued all the time or in alternative intervals of 3 days.  
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4.4.5 Validation of Affymetrix data by quantitative real time PCR 
 
The affymetrix data obtained from the ES cells from the BMP-2 clone, puromycin treated 
7day EBs (BMP-2+ population and puromycin untreated 7 day EBs) were verified by 
quantitative real time PCR analysis of the pluripotent and germ layer specific genes –
Nanog, T- Brachyury, Bmp-2, Neurofilament H, Sox 17 and a- myosin heavy chain. As 
seen in the figure 47, the Real time PCR data correlated very well with the affymetrix data.  
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Figure 47. Validation of the Affymetrix data by Quantitative real-time PCR analysis of 5 
representative genes. The fold change was calculated by using the formula, fold-change = 
2-( Ct gene1 - Ct gene2). Ct  of the gene in the sample in which it is expressed lowest is taken 
as Ct gene2 to calculate the fold change using the above formula. The pink line represent 
results from quantitative PCR and the blue line from affymetrix data. 
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4.4.6 Transcriptomic  analysis of the BMP-2+ cell population  
  To rule out the differentially expressed transcripts are specific to BMP-2+ 
cell and are not due to the puromycin application, transgenic β actin clones were 
generated in the same way like the BMP-2 clones except that the  β actin promoter instead 
of the BMP-2 promoter was used to serve as puromycin treatment controls.  Under the 
same experimental conditions as for the derivation of BMP-2+ cells, on day 4 the EBs were 
either treated with puromycin or untreated for the subsequent 3 days. On day 7, the RNA 
samples were prepared from the βactin ES cells, 7 day old puromycin treated  β-actin EBs 
and untreated control β-actin EBs. The samples were affymetrix profiled in the same way 
as for the BMP-2 samples.  
 
As the first step, the differentially expressed genes due to puromycin application 
were analyzed. There were 6 unique transcripts with student t-test value of p<0.01 
differentially expressed between puromycin treated 7day β actin EBs and untreated β-actin 
EBs and were excluded from the BMP-2 transcriptome analysis.  
4.4.6 Major pathways / biological processes differentially regulated in BMP-2+ 
cells 
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Figure 48.  An overview of the number of transcripts differentially expressed in BMP-2+ 
population according to different Gene Ontologies (GOs), as analyzed with DAVID 
functional annotation tool. 
Overall, there are 1682 unique transcripts differentially expressed (2 fold up or 2 
fold down with an ANOVA p value cut off of less than 0.01) compared to either the BMP-2 
ES cells or 7day old control EBs.  Among them, 28 transcripts participate in MAPK 
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signaling pathway, 19 transcripts in Wnt Signaling and 13 transcripts in TGFβ signaling 
pathways. 19 transcripts take part in cell cycle.  This shows that the BMP-2 population also 
has several dynamically ongoing functional signaling cascades, which are implicated to 
play a crucial role in early embryonic patterning. Overall, among the 1682 transcripts 
differentially expressed in BMP-2+ cells in comparison to BMP-2 ES cells and 7 day control 
EBs, 206 genes are implicated in embryonic development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49.  An overview of the number of transcripts differentially expressed in BMP-2+ 
cell population involved in pathways, as obtained from DAVID analysis.
 
 
 
4.4.7 Classification of differentially expressed transcripts in BMP-2+ cell in 
comparison to ES cells and 6day control EBs.  
 
BMP-2+ cell population represents a subset of mesoderm unlike the pan mesodermal 
marker, T Brachyury. Like the T Brachyury cells, BMP-2 cells also needs co-operation from 
other 2 germ layers for the further lineage commitment during differentiation under normal 
conditions. When they were kept in isolation, their interaction with the other germ layers is 
eliminated and hence they slow down in terms of the differentiation and remain in 
differentiation state between the starting ES cell state and the 6day control EBs which, are 
far advanced in terms of differentiation due their intact interaction with the other 2 germ 
layers. Hence characterization of differentially expressed transcriptome of BMP-2 
population needs to be compared with both the BMP-2 ES cells and 6day Control EBs in 
the same way as performed for the T Brachyury transcriptome analysis. Thus the analysis 
will need to be addressed as follows  
 
19
12
6
19
6
13
28
0
5
10
15
20
25
30
W
nt
 S
ig
na
lin
g 
A
po
pt
os
is
N
itr
og
en
M
et
ab
ol
is
m
C
el
l C
yc
le
N
eu
ro
de
ge
ne
ra
tiv
e
D
is
or
de
rs
TG
F-
B
et
a
S
ig
na
lin
g 
M
A
P
K
 S
ig
na
lin
g 
  
Results and Discussion  87 
 
 
1. 
 
i. Uniquely upregulated in BMP-2+ cells  (Not differentially expressed 
among ES cells and 7day old control EBs) 
 
ii. 
 
2. 
 
i. 
 
ii. 
 
3. 
 
4. 
 
 
Transcripts upregulated in BMP-2+ cells than both ES ells and 7day control EBs 
Not Uniquely expressed in BMP-2+ cells (Differentially expressed 
among ES cells and 7day old control EBs) 
 
Transcripts downregulated in BMP-2+ cells than both ES ells and 7day control EBs 
Uniquely downregulated in BMP-2+ cells (Not differentially 
expressed among ES cells and 7day old control EBs) 
Not Uniquely expressed in BMP-2+ cells (Differentially expressed 
among ES cells and 7day old control EBs) 
 
Transcripts upregulated in BMP-2+ cells than ES cells but downregulated than 7day 
control EBs 
Transcripts upregulated in BMP-2+ cells than 7 day control EBs but downregulated 
than ES cells 
 
 
Analysis of upregulated transcripts in BMP-2+ cells in comparison to both ES cells 
and 7day EBs.  
  There are 271 transcripts upregulated in BMP-2+ cells than both ES cells and 7day 
control EBs. Among them, there are 209 transcripts, which do not show any differential 
expression among ES cells and 7day EBs. The other 62 transcripts even though are 
upregulated than both ES cells and 7day EBs, they in turn show differential expression 
among ES cells and EBs. The 209 transcripts upregulated uniquely in BMP-2 cells but not 
differentially expressed among ES cells and EBs are the bona-fide transcriptomic 
signatures of BMP-2+ mesodermal cells and these transcripts over-represent transcription 
factors and apoptosis, when analyzed with DAVID gene functional tool.   The unique BMP-
2 cell specific transcription factors are enlisted in table 5 and transcripts involved in 
apoptosis in table 6. . The transcripts upregulated in BMP-2 cells which in turn shows 
differential expression among ES cells and EBs did not over-represent any biological 
processes other than the normal physiological processes.  
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Gene Name 
Table.5 List of transcription factors upregulated specifically in BMP-2+ cells. The fold 
change is expressed relative to the lowest value of expression that is normalized to be 1. 
 
 
 
 
 
 
 
 
 
 
Unigene ID ES cells 
7day 
Control 
EBs BMP-2+
Mm.303534 Down-regulator of transcription 1 1.00 1.08 2.26
Mm.100273 Junction-mediating and regulatory protein 1.00 1.81 8.35
Mm.130752 ash1 (absent, small, or homeotic)-like (Drosophila) 1.07 1.00 2.44
Mm.27663 
transcription elongation factor B (SIII), polypeptide 
3 1.10 1.00 2.31
Mm.2444 Myelocytomatosis oncogene 1.32 1.00 2.67
Mm.196325 RIKEN cDNA A730098D12 gene 1.00 1.00 2.05
Mm.254233 ELK4, member of ETS oncogene family 1.02 1.00 2.79
Mm.209903 Activating transcription factor 2 1.00 1.32 3.30
Mm.156727 Vcell division cycle 73 1.00 1.17 2.89
--- Cleavage and polyadenylation specific factor 6 1.00 1.48 3.22
Mm.194486 PHD finger protein 3 1.41 1.00 3.14
Mm.206555 zinc finger protein 655 1.00 1.00 2.52
Mm.28646 RIKEN cDNA 6430596G11 gene 1.00 1.33 3.44
Mm.130883 Metadherin 1.04 1.00 3.57
Mm.132238 Adult male aorta and vein cDNA 1.31 1.00 2.72
Mm.267116 RAR-related orphan receptor alpha 1.00 1.65 5.07
Mm.218423 RIO kinase 2 (yeast) 1.25 1.00 2.66
Mm.379292 zinc finger, ZZ domain containing 3 1.00 1.33 3.54
Mm.128165 AT hook containing transciption factor 1 1.48 1.00 3.93
Mm.189270 Ectodysplasin A2 isoform receptor 1.00 1.02 3.15
Mm.271914 Machado-Joseph disease homolog (human) 1.00 1.38 3.21
Mm.325827 G1 to S phase transition 1 1.00 1.01 2.44
Mm.40828 Sequestosome 1 1.46 1.00 3.86
Mm.273090 
CCAAT/enhancer binding protein (C/EBP), 
gamma 1.06 1.00 2.47
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Table 6.List of transcription factors upregulated specifically in BMP-2 cells playing 
their role in apoptosis. The fold change is expressed relative to the lowest value of 
expression that is normalized to be 1. 
 
Unigene ID Gene Name 
ES 
cells 
7d Control 
EBs BMP-2+
Mm.271878 phorbol-12-myristate-13-acetate-induced protein 1 1.00 1.39 3.62
Mm.100273 junction-mediating and regulatory protein 1.00 1.81 8.35
Mm.7660 Bcl-2 binding component 3 1.00 1.80 3.70
Mm.2444 myelocytomatosis oncogene 1.32 1.00 2.67
Mm.29816 programmed cell death 6 interacting protein 1.00 1.27 2.65
Mm.7087 rabaptin, RAB GTPase binding effector protein 1 1.00 1.22 2.84
Mm.297905 DNA fragmentation factor, beta subunit 1.00 1.19 5.93
Mm.40828 sequestosome 1 1.46 1.00 3.86
 
 
Upregulated in BMP-2+ cells than ES cells but downregulated than 7day control 
EBs 
 
 
 
 
Downregulated in BMP-2+ cells than both ES cells and 7 day control EBs 
 
 The down-regulated transcripts are categorized according to the biological 
processes using DAVID functional annotation tool and is shown in annexure 10. The 
development related transcripts are listed in annexure 11. 
  54 unique transcripts were found to be upregulated in BMP-2+ cells compared to 
ES cells but down regulated in comparison to 7d control EBs. Among the 54 transcripts, 9 
transcripts are developmentally important genes as shown in the annexure 12A.  
The transcripts upregulated in BMP-2+ cells than 7 day control EBs but 
downregulated than ES cells. 
There are 119 unique transcripts that are upregulated in BMP-2+ cells compared to 
7day EBs cells but downregulated in comparison to ES cells and development related 
transcripts are shown in annexure 12B. It is interesting to note that the nanog transcript is 
upregulated in BMP-2+ cells compared to the control EBs.  
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4.5 CHARACTERIZATION OF αMHC+ CARDIOMYOCYTES  
4.5.1.Generation and analysis of the αMHC+ ES cell clone  
Embryoid Bodies, when made from the αMHC+ ES cell clone by hanging drop protocol and 
analyzed at regular intervals, showed the expression of αMHC+ transcripts as shown by 
RT-PCR in figure 50. The EGFP expressing cells were first detectable in 7-8 days old EBs 
and the EGFP fluorescence increases significantly after 7 days. The ES cells and EBs 
from this transgenic clone behaved faithfully with the wild type ES and EBs.  
 
 
 
 
 
 
 
 
 
 
Figure 50. Expression pattern of αMHC transcript during the course of differentiation. 
4.5.2.Isolation and transcriptomic profiling of αMHC+ cardiomyocytes 
The EBs were generated by hanging drop protocol. On day 7, the first contracting 
clusters started to appear. On the next day (day 8), the EBs were treated with or without 
puromycin at a concentration of 4µg/ml for the subsequent 7 days (Figure 51A). On day 
15, the EBs untreated and puromycin treated were harvested by trypsinisation and 
analyzed with FACS to determine the purity of the cardiomyocytes in the puromycin 
treated cultures along with the control EBs. As shown in figure 51B, the puromycin treated 
cultures contained an enriched population of cardiomyocytes up to 91.15% compared to 
16.72% of the control EBs. Thus an enrichment of the pure cardiomyocytes by 5.5 fold 
compared the control EBs was obtained by this approach. RNA was isolated from these 
cardiomyocytes for the transcriptomic profiling by Affymetrix. 
The αMHC+ cardiomyocytes thus derived from the ES cells were analyzed by 
immunohistochemistry. They showed a multi-angular (Fig. 52a and b), more rectangular 
(Figure 52c and d) and a tri-angular morphology (Figure 52e and f). Detection of cardiac α-
actinin by immunocytochemistry (Figure 52b, d and f) clearly indicated the Z-disc specific 
protein and the characteristic striations of sarcomeric structures of the cardiac cells. The 
gap junction protein Connexin43 is highly expressed in the heart and was detected by 
immunocytochemistry (Figure 52g and h). Connexin43 is distributed in the cytosol and in 
the outer membranes in the cell border regions (Figure 52g and h, middle panel).  
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Figure 51. Enrichment of αMHC+ cells isolated from the αMHC+ ES cell lineage after 
puromycin treatment. A, progressive purification of αMHC+ cardiac cell aggregates after 
treatment of the 8-days old EBs with 4µg/ml puromycin for 7 days. Puromycin containing 
medium was refreshed every second day. B, C, Cells from 15-days old EBs and 15-days 
old puromycin purified αMHC+ aggregates were dissociated by trypsinisation and the purity 
of the αMHC+ cells in the 15-days old EBs (C) and in the 15-days old αMHC+ aggregates 
(D) was examined by FACS analysis.   
 
Puromycin treated  15day EB 
16.72% 91.15%
15day EB without Puromycin
B 
Day 0
Control EB Puromycin treated
200 µm
200 µm 200 µm
P
ur
om
yc
in
tre
at
m
en
t
Lid
PBS
Medium
P
ur
om
yc
in
tre
at
m
en
t
C 
A 
  
Results and Discussion  92 
 
 
 
 
 
 
 
 
 
 
Figure 52. Characterization of the ES cell-derived cardiomyocytes by 
immunocytochemistry. αMHC+ cardiomyocytes were dissociated with collagenase B and 
plated on fibronectin coated cover slips.  (a, c, e) EGFP expression of single αMHC+ cells 
with different morphology. (b, d, f) Detection of α-cardiac actinin and Connexin43 (g, h) 
was performed using anti-cardiac Actinin (1:400) and anti-Connexin43 1:400. Secondary 
detection was performed with anti-mouseIgG1-AlexaFluor555 and anti-rabbit-Ig-
AlexaFluor647. Hoechst dye was used to stain nuclei. Bars in (a-f) represent 50 and bars 
in (g) 20 and (h) 7.5  µm.  
 
4.5.3 Electrophysiological characterization of the cardiomyocytes 
Functional characterization of the αMHC+ cardiac cells has been performed by 
measurements of their typical spontaneous action potentials (APs). Spontaneous APs 
were measured in single αMHC+ cardiomyocytes (n=32) as well as in 
multicellular            αMHC+ aggregates (n=24). All APs possessed characteristic 
parameters of cardiac APs. The minimal diastolic potential was -60.2±1.1 mV, membrane 
potentials normally showed a diastolic depolarization leading to a spontaneous AP 
frequency of 125.9±8.0 /min. The maximal upstroke velocity was 22.9±2.2 V/s, pointing to 
a contribution of voltage-activated Na+ currents, which was confirmed by voltage-clamp 
measurements (data not shown). APD90, APD50 and APD20 (AP duration from maximum to 
90%, 50% and 20% repolarization) were 96.4±4.2 ms, 71.1±3.9 ms and 41.3±2.6 ms. APs 
had a variety of morphologies, including pacemaker-, atrial- and ventricular-like APs 
(Figure 53). In most cases, however, morphological properties did not match any type of 
specific differentiation. These unspecified APs mostly possessed a plateau phase, but had 
a much shorter APD90 than ventricular APs, which are characterized by a long APD90 of 
about 200 ms 112.  
To characterize the hormonal regulation of αMHC cardiomyocytes, carbachol (Cch, 
an agonist of m-cholinoceptors), and isoproterenol (ISO, an agonist of β1-adrenoceptors), 
were applied (Figure 53B and C). 1 µM Cch decreased the AP frequency significantly to 
44.8±7.5 % of the control values  (n=20; the frequency under control conditions was 
a c e g
b d f h
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determined for each recording and set to 100; Figure. 53D). 1 µM ISO evoked a significant 
increase of the frequency to 238.5±23.7 % of the control values (n=19; Fig. 2E). 
Intracellular recordings of spontaneous APs revealed typical cardiac AP parameters and 
morphologies confirming the cardiac differentiation and functionality of puromycin-selected 
αMHC+ cells. The muscarinic and adrenergic regulation of the AP frequency, which is 
known for ES cell-derived cardiomyocytes 113 as well as for native murine cardiomyocytes 
at early developmental stages 114, further supports a physiological cardiac differentiation of 
αMHC cells. As described previously 115,116, APs at the intermediate developmental stage 
showed diastolic depolarizations and diverse shapes. APs with a distinct plateau phase 
were frequent but considered to be unspecific rather than ventricular-like in the majority of 
cases, since the APD90 was much shorter than reported for early stage murine ventricular 
cardiomyocytes as well as for murine ES cell-derived ventricular-like cardiomyocytes 117. 
Since most APs had unspecific morphological properties, a general classification into 
pacemaker-like, atrial-like and ventricular-like APs could not be made, which accords well 
with previous findings from intermediate stage ES cell-derived cardiomyocytes 118,119. Only 
few APs possessed typical morphological features of the respective differentiation types. 
 
It has been reported recently that, in ES cell-derived cardiomyocytes expressing 
GFP under control of the αMHC promoter, green fluorescence is restricted to pacemaker- 
and atrial-like cells 120. Since we found puromycin-purified αMHC+ cardiomyocytes with a 
ventricular-like AP morphology in few cases, our data suggest that αMHC expression is 
not completely absent in ES cell-derived ventricular-like cardiomyocytes. This apparent 
discrepancy might arise from the complex stage-dependent expression pattern described 
for αMHC in murine embryoid bodies 121 and murine embryonic ventricles 122, as a different 
developmental stage of ES cell-derived cardiomyocytes was investigated in the present 
study (15-day old cardiomyocytes) as compared to the study by Kolossov et al. (9-day to 
11-day old cardiomyocytes) 123. 
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Figure 53. Electrophysiological characterisation of αMHC+ cells. A, Characteristic cardiac 
APs of puromycin purified αMHC cells. Most APs had a typical cardiac AP morphology but 
could not be further specified. Only few APs showed typical features of pacemaker-like 
atrial-like or ventricular-like APs. The minimal diastolic potential was –60.2±1.1 mV. The 
maximal upstroke velocity was 22.9±2.2 V/s. APD90, APD50 and APD20 were 96.4±4.2 ms, 
71.1±3.9 ms and 41.3±2.6 ms. B, C, Representative recordings showing the effect of Cch 
(1 µM) (B) and ISO (1 µM) (B) on the spontaneous AP frequency. C, D, Statistical analysis 
of the effects of Cch (1 µM) and ISO (1 µM), respectively, on the spontaneous AP 
frequency. Cch caused a decrease while ISO increased the spontaneous AP frequency.  
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4.5.4.Validation of Affymetrix data by quantitative real time PCR 
The affymetrix data obtained from the ES cells, 15 days old puromycin treated and 
untreated αMHC EBs were verified by quantitative real time PCR analysis of the 
pluripotent and germ layer specific genes –Nanog, T- Brachyury, BMP-2, Neurofilament H, 
Sox 17 and a- myosin heavy chain. As seen in the figure 54, the Real time PCR data 
correlated very well with the affymetrix data. Additionally, the cardiomyocyte specific 
markers were analyzed in these samples by semi-quantitative PCR (Figure 55). 
 
 
 
Figure 54. Validation of the Affymetrix data by Quantitative real-time PCR analysis of 5 
representative genes. The  fold  change was calculated  by  using the  formula, fold-
change =  2-(
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 gene1 - C Ct gene2). t Ct  of the gene in the sample in which it is expressed lowest 
is taken as Ct gene2 to calculate the fold change using the above formula. The resulting 
fold change is expressed as percentage of the maximum (=100%).Values are expressed 
as mean ± SD.  
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Figure 55. RT-PCR analysis of cardiomyocyte-specific markers and an endodermal 
marker (AFP). B, Relative mean fluorescence signal for the expression level of the genes 
obtained from the Affymetrix data.   
 
 
 
 
 
 
 
 
 
 
 
 
GAPDH
AFP
Nkx2.5
MLC-2v
Mef2c
α-MHC
Myocardin
Troponin T
A B
Relative  mean fluorescence signal values as obtained from the
Affymetrix microarrays
Gene α-MHC ES cells 15 days old EBs α-MHC + cells
Troponin T 9 4142 12873
Myocardin 12 142 1359
α-MHC 36 3814 15372
Mef2c 23 834 1889
Nkx2-5 49 101 787
MLC-2v 47 3642 16050
AFP 12 5120 14
Neurofilament -M 12 17 12
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4.5.5.Transcripomic analysis of  αMHC+ cardiomyocytes 
   
To rule out the differentially expressed transcripts are specific to cardiomyocytes 
and are not due to the puromycin application, under the same experimental conditions as 
for the derivation of cardiomyocytes, on day 8 the EBs were either treated with puromycin 
or untreated for the subsequent 7 days. On day 15, the RNA samples were prepared from 
the β actin ES cells, 15 day old puromycin treated β actin EBs and untreated control βactin 
EBs. The samples were affymetrix profiled in the same way as for the αMHC samples.  
 
 
 
As the first step, the differentially expressed genes due to puromycin treatment 
were analyzed. There were 235 unique transcripts with student t-test value of p<0.01 
among the transcripts differentially expressed among puromycin treated β actin EBs and 
untreated control βactin EBs and these transcripts were excluded from the analysis of the 
αMHC transcriptome.  
Overall, there are 7700 unique transcripts differentially expressed in αMHC+ 
cardiomyocytes (2 fold up or 2 fold down with an ANOVA p value cut off of 0.01) compared 
to either the αMHC ES cells or 6day old control EBs. Among these transcripts, 1315 
transcripts with ANOVA p value <0.01 are participating in pathways as shown in the 
annexure 13 and this comprises 17.08% of the 7700 unique transcripts differentially 
expressed in αMHC+ cardiomyocytes. It is not surprise to see a significant number of 
transcripts differentially expressed that are participating in oxidative phosphorylation. This 
process is essential for the cardiomyocytes to derive the energy for their contraction. 
Strikingly 128 transcripts participate in MAPK signaling pathway, 68 transcripts in Wnt 
Signaling and 52 transcripts in TGFβ signaling pathways as shown in the figures 56,58- 
62.  Among the 7700 transcripts differentially expressed in αMHC+ cardiomyocytes in 
comparison to αMHC ES cells and 15 day αMHC control EBs, 873 genes are implicated in 
embryonic development as shown in Figure 57. 
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Figure 56.   List of the transcripts that are differentially expressed in cardiomyocytes and 
are involved in pathways in comparison to ES cells, 15day old EBs or both. The count 
represents the relative ratio of the transcripts belonging to the particular pathway to the 
total transcripts differentially expressed in cardiomyocytes.  
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Figure.57 Schematic outline of the biological processes overepresented by the 
differentially expressed transcripts in cardiomyocytes in comparison to ES cells and 15day 
old EBs.   
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Figure 58. Hierarchical clustering of the transcripts differentially expressed in αMHC+ cells 
that participate in MAPK signaling pathway. 
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Figure 58 (continued). Hierarchical clustering of the transcripts differentially expressed in αMHC+ 
cells that participate in MAPK signaling pathway (continued).  
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Figure 59.Hierarchical clustering of the transcripts differentially expressed in αMHC+ cells 
that participate in Wnt signaling pathway  
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Figure 60.Hierarchical clustering of the transcripts differentially expressed in αMHC+ cells 
that participate in oxidative phosphorylation. 
Up regulated
No change
Down regulated
Legend
  
Results and Discussion   103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Hierarchical clustering of the transcripts differentially expressed in αMHC+ cells 
that participate in cell cycle. 
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Figure 62. Hierarchical clustering of the transcripts differentially expressed in αMHC+ cells 
that participate in TGFβ signaling.  
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Classification of differentially expressed transcripts in αMHC+ cardiomyocytes in 
To analyze the transcriptome of αMHC+ cardiomyocytes, the comparison of αMHC+ 
iomyocytes than both ES ells and 15 day control 
 
i. Uniquely upregulated in αMHC+ cardiomyocytes (Not differentially expressed 
 
ii. diomyocytes (Differentially expressed 
among ES cells and 15-days old EBs) 
 
2. Transcripts downregulated in αMHC+ cardiomyocytes than both ES ells and 15 day control 
 
ii. es (Differentially expressed 
 
3. Transcripts up ES cells but downregulated than 
 
4. lated in αMHC+ cardiomyocytes than 15 day control EBs but 
Analysis of upregulated transcripts in αMHC+ cardiomyocytes in comparison to both ES 
 scripts upregulated in αMHC+ cardiomyocytes than both ES cells and 
 day
comparison to ES cells and 15day control EBs.  
 
 
cardiomyocytes with ES cells and 15 day control EBs were made in the same way as analyzed for 
T Brachyury+ and BMP-2+cells transcriptomes.  
 
1. Transcripts upregulated in αMHC+ card
EBs 
among ES cells and 15-days old EBs)  
Not Uniquely expressed in αMHC+ car
EBs 
i. Uniquely downregulated in αMHC+ cardiomyocytes (Not differentially 
expressed among ES cells and 15-days old EBs) 
Not Uniquely expressed in αMHC+ cardiomyocyt
among ES cells and 15-days old EBs) 
regulated in αMHC+ cardiomyocytes than 
15 day control EBs 
Transcripts upregu
downregulated than ES cells 
 
cells and 15-day-old EBs  
 
 There are 1319 tran
15  control EBs. Among them, there are 927 transcripts, which do not show any differential 
expression among ES cells and 15day old control EBs. The other 392 transcripts even though are 
upregulated than both ES cells and 15 day old EBs, they in turn show differential expression 
among ES cells and EBs. The distribution of the transcripts according to Gene Ontology “Biological 
Process” by David Bioinformatics resource analysis is presented in the figure 63.  The 927 
transcripts upregulated uniquely in αMHC+ cardiomyocytes but not among ES cells and EBs are 
the bonafide transcriptomic signatures of αMHC+ cardiomyocytes.  As seen from the figure 63B, 
the transcripts of cardiomyocyte transcriptome are involved in the cardiac specific physiological 
processes like ATP synthesis and oxidative phosphorylation. There are 81 αMHC+ cardiomyocytes 
specific transcripts involved in development according DAVID analysis and are enlisted in table 8. 
Among the transcripts upregulated in αMHC+ cardiomyocytes which in turn show differential 
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expression among ES cells and EBs, the 18 transcripts involved in developmental processes are 
listed in the annexure 14. 8 transcripts are involved in MAPK signaling pathway and 10 transcripts 
in calcium signaling pathway (annexure 15). 
A  
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Table 8a. Dev s. 
The fold change is expressed relative to the lowest value of expression that is normalized to be 1. 
15day 
C+
elopment related transcripts specifically expressed in αMHC+ cardiomyocyte
NCBI ID Gene Name ES cells 
control 
EBs α−MH
NM_008664 myomesin 2 1.00 41.891.33
NM_011915 Wnt inhibitory factor 1  931.00 1. 17.60
XM_136682 
PREDICTED: v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 [Mus musculus] 1.00 1.13 14.89
NM_021447 tripartite motif-containing 54 1.18 1.00 14.40
NM_010332 endothelin receptor type A 1.00 1.88 11.11
NM_008904 
peroxisome proliferative activated receptor, gamma, 
coactivator 1 alpha 1.00 1.59 9.95
NM_145602 N-myc downstream regulated gene 4 1.00 1.83 9.95
NM_031260 Moloney leukemia virus 10-like 1 1.00 1.28 9.85
NM_019684 serine/threonine kinase 23 1.00 1.39 9.60
NM_007419 adrenergic receptor, beta 1 1.00 1.76 8.73
NM_011486 signal transducer and activator of transcription 3 1.00 1.95 6.96
NM_008092 Transcription factor GATA-4 1.00 1.80 6.73
NM_145136 myocardin 1.00 1.19 6.26
NM_010564 inhibin alpha 1.00 1.90 6.04
XM_487682 neuralized-like 2 (Drosophila) 1.811.00 5.90
NM_007956 estrogen receptor 1 (alpha) 1.00 1.09 5.79
NM_025282 Myocyte enhancer factor 2C 1.00 1.32 5.74
NM_021881 Quaking (Qk), mRNA 1.13 1.00 5.65
NM_009895 cytokine inducible SH2-containing protein 1.00 1.87 5.58
NM_007826 DACH protein (Dach) 1.00 1.45 5.22
NM_015763 lipin 1 1.00 1.54 5.08
NM_013883 sex comb on midleg homolog 1 1.00 1.76 5.08
NM_024226 reticulon 4 1.14 1.00 5.00
NM_011540 titin-cap 1.00 1.13 4.91
NM_054085 alpha-kinase 3 1.98 1.00 4.68
NM_024441 heat shock protein 2 1.00 1.06 4.62
NM_031158 ankyrin 1, erythroid 1.09 1.00 4.61
NM_009670 ankyrin 3, epithelial 1.07 1.00 4.58
NM_008434 
KCNQ1b mRNA for Q1-type potassium channel spliced 
variant 1.77 1.00 4.49
NM_020496 T-box 20 1.00 1.22 4.47
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Table 8b. Development related transcripts specifically expressed in αMHC+ cardiomyocytes 
NCBI ID Gene Name 
ES 
cells 
15day 
α−MHC+
(continued). The fold change is expressed relative to the lowest value of expression that is 
normalized to 1. 
 
control 
EBs 
NM CDC42 effector protein (Rho GTPase binding) 3 5_026514 1.00 1.6 4.16
NM_007555 bone morphogenetic protein 5 1.00 1.58 4.05
NM_001003817 
 viral oncogene homolog 2, 
1.00 1.95 3.94
v-erb-b2 erythroblastic leukemia
neuro/glioblastoma derived oncogene homolog (avian) 
NM_001013580 
Par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), 
transcript variant 3, mRNA 1.11 1.00 3.74
NM_008937 prospero-related homeobox 1 1.00 1.08 3.67
--- antisense Igf2r RNA 1.00 1.54 3.44
XM_204015 MKIAA0458 protein 1.03 1.00 3.40
--- B6-derived CD11 +ve dendritic cells cDNA 1.00 1.11 3.40
NM_178740 SLIT and NTRK-like family, member 4 1.00 1.48 3.35
NM_172739 Premature mRNA for mKIAA1722 protein 1.41 1.00 3.34
NM_010789 Myeloid ecotropic viral integration site 1, mRNA  1.00 1.62 3.34
NM_145584 spondin 1, (f-spondin) extracellular matrix protein 1.00 1.17 3.33
NM_021527 McKusick-Kaufman syndrome protein 1.00 1.63 3.31
NM_009953 corticotropin releasing hormone receptor 2 1.05 1.00 3.29
NM_019411 Protein phosphatase 2a, catalytic subunit, alpha isoform, mRNA  1.17 1.00 3.28
NM_020295 limb region 1 1.06 1.00 3.22
NM_016798 PDZ and LIM domain 3 (Pdlim3), mRNA 1.00 1.09 3.20
NM_022433 
sirtuin 3 (silent mating type information regulation 2, homolog) 3 
(S. cerevisiae) 1.22 1.00 3.14
NM_175473 Fras1 protein 1.00 1.53 3.14
NM_010875 neural cell adhesion molecule 1 1.00 1.09 3.09
NM_026163 Plakophilin 2 (Pkp2), mRNA 1.00 1.08 2.99
NM_010017 dystroglycan 1 1.00 1.43 2.94
NM_009367 Transforming growth factor, beta 2, mRNA  1.00 1.11 2.94
NM_009274 serine/arginine-rich protein specific kinase 2 1.22 1.00 2.88
NM_139001 chondroitin sulfate proteoglycan 4 1.00 1.40 2.85
NM_007935 enhancer of polycomb homolog 1 (Drosophila) 1.00 1.09 2.84
NM_009762 SET and MYND domain containing 1 1.18 1.00 2.78
NM_009824 
core-binding factor, runt domain, alpha subunit 2, translocated to, 
3 homolog (human) 1.00 1.27 2.78
NM_008398 integrin alpha 7 1.03 1.00 2.72
NM_007462 Adenomatosis polyposis coli (Apc), mRNA 1.00 1.19 2.71
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Table 8c. Deve ly expressed in αMH rd ocyt
NCBI ID Gene Name 
ES 
cells 
15day 
control
α−MHC+
lopment related transcripts specifical C+ ca iomy es 
(continued). The fold change is expressed relative to the lowest value of expression that is 
normalized to be 1. 
 
 
EBs 
XM_619767 Similar to hypothetical protein FLJ39502 1.00 1.00 2.61
NM_172868 paralemmin 2 1.01 1.00 2.60
NM_008844 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma 1.00 1.23 2.60
NM_008854 protein kinase, cAMP dependent, catalytic, alpha 1.00 1.29 2.58
NM_022305 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 
(B4galt1), mRNA 1.00 1.21 2.48
NM_008601 microphthalmia-associated transcription factor 1.22 1.00 2.46
NM_027326 
Myeloid/lymphoid or mixed lineage-leukemia translocation to 3 
homolog (Drosophila) (Mllt3), transcript variant 1, mRNA 1.00 1.10 2.46
NM_183428 erythrocyte protein band 4.1 1.00 1.07 2.46
NM_172416 osteopetrosis associated transmembrane protein 1 1.13 1.00 2.42
NM_173182 MKIAA4164 protein 1.13 1.00 2.38
NM_007428 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1.09 1.00 2.32
NM_146104 anterior pharynx defective 1a homolog (C. elegans) 1.00 1.13 2.28
NM_023505 glutaredoxin 2 (thioltransferase) 1.00 1.08 2.27
XM_125745 integrin beta 1 binding protein 3 1.00 1.06 2.24
NM_024200 mitofusin 1 1.01 1.00 2.22
NM_019408 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, 
p49/p100 1.00 1.00 2.07
--- Transcribed locus 1.00 1.01 2.04
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Downregulated Transcripts in αMHC+ cardiomyocytes than both ES cells and 6day control 
There are 1444 unique transcripts downregulated in αMHC+ cardiomyocytes than both ES 
EBs 
 
 
 
cells and 15 day control EBs. Of them, there are 939 transcripts uniquely downregulated in αMHC+ 
cardiomyocytes cells which do not show any differential expression among ES cells and 15 day 
EBs. Those transcripts categorized according to the biological process they mediate are shown in 
figure 65.  Apart from that, 494 transcripts are downregulated than both ES cells and 6d EBs but in 
turn show differential expression among ES cells. The developmental related transcripts are listed 
in annexure 16. 
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Figure 65. The major biological processes overrepresented by the transcripts downregulated than 
both ES cells and 15day EBs (green bar) and unique αMHC+ cardiomyocytes specific 
transcriptome downregulated in comparison to ES cells and 15-day cardiomyocytes (in red bar).   
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Transcripts upregulated in αMHC cardiomyocytes than ES cells but downregulated than 
nscripts were found to be upregulated in αMHC cardiomyocytes compared to 
S cel
he transcripts upregulated in αMHC cardiomyocytes than 15 day control EBs but 
cripts that are upregulated in αMHC+ cells compared to 15-day 
EBs ce
.6 FUNCTIONAL EVALUATION OF NOVEL TRANSCRIPTS  
.6.1 Experimental approach 
  Three novel candidate genes whose functions have not yet been annotated but highly 
The T Brachyury ES cell clone were transfected with siRNAs targeted to each of these 
vel t
 
15 day control EBs 
 
243 unique tra 
E ls but down regulated in comparison to 15day control EBs. Among the 243 transcripts, 56 
transcripts are developmentally important genes as shown in the annexure 17. 
 
T
downregulated than ES cells. 
 
There are 22 unique trans
lls but downregulated in comparison to ES cells (annexure 18).  
 
4
 
4
 
enriched in BMP-2+ cell lineages were chosen after assessing the pattern of transcript expression 
in differentiating EBs.  Since the differentiating EBs can not be transfected efficiently with siRNA 
with non-viral delivery methods due to their multicellular 3 dimensional aggregations, the 
transcripts that are expressed even in the undifferentiated pluripotent state were specifically 
chosen. These transcripts were functionally evaluated by a systematic “loss of or gain of function“ 
studies using siRNA knockdown approaches and episomal overexpression systems.  
 
 
no ranscripts. At 48 hours post transfection, the transfected ES cells were used for making 
“hanging drop” EBs and followed up. RNA were isolated at 24 hours post transfection, and just 
before making hanging drop EBs (48 hours post transfection) and then at regular intervals at days 
3, 5 and 7, the time points at which T Brachyury, BMP-2 and αMHC peak their transcripts 
expression respectively (Figure 66) and on day 9. The RNA isolated were analyzed for magnitude 
of expression by the germ layer representative and other genes, Nefh (ectodermal marker), T 
brachyury (mesodermal marker), BMP-2 (mesodermal marker), Sox17 (endodermal marker), 
Nanog (pluripotent ES cells marker) and αMHC (cardiomyocyte marker, actual gene name is 
Myh6).  siRNA transfected ES cells were monitored for any morphological changes associated with 
any differentiated cell types. On day 4, T Brachyury driven EGFP was quantified by FACS analysis 
as an index of mesodermal cells formed within the siRNA transfected EBs.   
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Figure 66 Overview of the experimental approach to functionally evaluate the novel transcripts 
using ES cells with siRNA knock down (“loss of function”) and “gain of function” approaches.  
 (for NCBI details, please see annexure 19) . 
It conta
 
4.6.2 The candidate genes- overview and results 
 
1. MGC117846 (Similar to zinc finger protein 665) 
 
This transcript is a putative transcription factor
ins the single conserved domain each of krueppel associated box and SFP1 (Putative 
transcriptional repressor regulating G2/M transition) and multiple conserved domains of Zn-finger 
as shown in figure 67. During the early embryonic development, this transcript expression is 
developmentally regulated as seen in figure 70.  In the ES cell/EBs system, this transcript is 
expressed at highest level in the undifferentiated ES cells and as its expression start to decline, the 
BMP-2 transcript start to be expressed (Figure 68). The fold changes in comparison to ES cells 
and the respective control EBs as obtained from the transcriptomic profiling of T Brachyury and 
BMP-2 lineages cells are shown in the figure 69.  So, being a transcription factor expressed in pre-
implantation stage and mid-gestation embryos and its downregulation precedes BMP-2 transcript 
expression, it may be likely that this transcript may have an influence on BMP-2 expression since 
this transcript is highly expressed in ES cell-derived BMP-2+ lineage cells. Hence this candidate 
was chosen for the functional evaluation to check whether this transcript has any inhibitory effect 
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on BMP-2 expression. The nucleotide and protein sequence information are shown in the 
annexure.  
 
  
     
 
 
 
 
 
 
 
 
 
 
KRAB  = krueppel associated box; 
COG5048 = FOG: Zn-finger [General function prediction only]. 
SFP1  =Putative transcriptional repressor regulating G2/M transition 
 
Figure 67   Conservation domains contained in the MGC117846. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68 Expression of MGC117846 transcript during the course of differentiation. 
 
igure 69. Fold change of the 
cells in comparison to ES cells and the control same day EBs as obtained from transcriptomic 
profiling.  
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Breakdown by Developmental Stage
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Figure 70. A, Developmental stage specific expression of MGC117846 
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siRNA knockdown: 
Knockdown by siRNA targeted against MGC117846 did not cause any significant effect as 
hown in the figure 71.  There were no morphological differences observed or growth rate.  
 
ig RNA mediated knock
ost siRNA transfection. (B-F) Quantitative PCR analysis 
iRNA transfected samples targeted against MGC117846 
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1700108L22Rik 
 
This is RNA binding protein that is developmentally regulated in early embryonic stages as 
shown in figure 74. The NCB
plantation embryos. The function of this gene has not yet been reported even 
ough 
 
 
 
Conserved LA domain contained in the 1700108L22Rik. B., Expression of 
700108L22Rik transcript during the course of differentiation. 
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I details for this gene are  presented in annexure 20.  This transcript is 
enriched in pre-im
th it is guessed from the LA domain contained in this gene that this codes for a protein which 
binds to RNA. Generally La protein plays a role in the transcription of RNA polymerase III. It is 
most probably a transcription termination factor. Binds to the 3' termini of virtually all-nascent 
polymerase III transcripts. It is associated with precursor forms of RNA polymerase III transcripts 
including tRNA and 4.5S, 5S, 7S, and 7-2 RNAs (By similarity). Since this transcript is temporally 
and spatially regulated during development and also upregulated in the T brachyury and BMP-2 
cell lineages, this gene was chosen assuming that the rest of the protein apart from the La domain 
may be playing any role especially modulating the BMP-2 transcription as shown in the Figure   It 
is interesting to note pattern of this transcript in comparison to BMP-2 transcripts that the 
downregulation of this transcript is coupled with the up regulation of BMP-2 transcript.  
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Figure 74. A., Developmental stage specific expression of 1700108L22Rik  
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unfertilized ovum 0 0 / 20660 
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siRNA knockdown of 1700108L22Rik 
Knockdown by siRNA targeted against 1700108L22Rik did cause a down regulation of 
BMP-2  
al differences observed. The down regulation of the BMP-2 
0470D encoding the 1700108L22Rik was purchased 
om RZPD, Germany and the 1700108L22Rik cDNA was subcloned into the pPyCAGIP over 
as transfected into T Brachyury ES cell clone and 
enera
 
transcripts on day 3. Apart from that, it did not cause any significant effect as shown in the
figure 75. There were no morphologic
transcript by the knockdown of the 1700108L22Rik shows a positive interaction between these 2 
transcripts. But in comparison to the time kinetics in differentiating EBs, there is reciprocal 
interaction may be inferred. This needs to be addressed further since there are several modes of 
auto-regulatory mechanisms existing. But there were no effects when over-expressed.  So, this 
has to be addressed this contrary situation.  
 
 
Episomal overexpression of 1700108L22Rik 
 
Full Length cDNA Clone IRAVp968A
fr
expression plasmid. The resulting plasmid w
g ted the overexpression clone. Hanging drop EBs made from the EBs were analyzed in 
terms of the lineage specific transcript levels including BMP-2. There was no significant effect was 
observed as shown in figure 76. 
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igure 75. A., RT-PCR analysis of siRNA mediated knoc
ours post siRNA transfection. (B-F) Quantitative PCR ana
e siRNA transfected samples targeted against 1700108L
ontrol samples that were not treated with siRNA or Lipofect
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Gm397 
It is a novel transcript predicted by electronical models as shown in annexure 21.  It is a 
ryo and 
nd 78). This gene was selected under the 
ssumption that it might be involved in the maintenance of ES cell pluripotency. It is still a 
ypothetical protein, even then the transcripts are expressed and its mRNA sequence information 
 known.  The protein has one leucine rich domain and shows zinc ion binding sites and 
cally annotated to be a transcription factor. But in the development context, the function of 
this ge
Figure 77. A., Developmental 
very interesting gene since its expression is uniquely restricted to pre-implantation emb
luripotent undifferentiated ES cells (Figure 77 Ap
a
h
is
electroni
ne is still unknown even though they are enriched in the ES cells. This transcript is highly 
enriched in T Brachyury and BMP-2 lineage cells, unlike Pou5f1 (Oct4), the pluripotent associated 
marker.  
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oocyte 0 0 / 20033 
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 Conserved domains contained in the 1700108L22Rik B., 
stage specific expression of 1700108L22Rik   transcript. C., Legend for B.  
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B., Fold change 
f the Gm397 transcript in pure T Brachyury and BMP2 mesodermal cells in comparison to ES cells 
nd the control same day EBs as obtained from transcriptomic profiling. 
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Figure.78 A.
o
, Expression of Gm397 transcript during the course of differentiation. 
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siRNA knockdown: 
Knockdown by siRNA targeted against Gm397 did not cause any significant effect as shown 
 the figure 79. There were no morphological differences observed. 
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Overexpression 
d generated the overexpression 
clone. Hanging drop EBs made from the Gm397 overexpressing ES cell clones were analyzed in 
e specific transcript levels including BMP-2. There was no significant effect was 
 
 
 
 
igure 80. 
m397 ove ssing differentiati
Full Length cDNA Clone IRAKp961F07111Q encoding the Gm397 was purchased from RZPD, 
German and the Gm397 cDNA was subcloned into the pPyCAGIP over expression plasmid. The 
resulting plasmid was transfected into T Brachyury ES cell clone an
terms of the lineag
observed as shown in Figure  80. 
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Conclusion and Outlook  
 
The transcriptomic analyses of the mesodermal cells and cardiomyocytes have defined 
unique cellular and genetics identities of the respective lineages towards understanding the 
inducible fate of mesodermal patterning and predicting to some extent how the prospective 
mesodermal cells integrate the various signals they receive and how they resolve this information 
netic behaviors and cell-fate decisions. They in turn significantly 
ontribute in building lineage specific transcriptomic atlas, which will be of immense application for 
the dev
sodermal cells, BMP-2 cells represent the late 
stage mesodermal population that can autonomously give rise to cardiomyocytes and are already 
lineage
to regulate their morphoge
c
elopmental biologists and also for promoting the protocols for the derivation of selective 
lineages for the future cell replacement therapy.  
 
 The isolated T Brachyury+ and BMP-2+ cells are able to prime themselves to become 
cardiomyocytes. While the ES cell-derived T Brachyury lineage also gives rise to endodermal 
lineages, the BMP-2+ lineages are completely devoid of any endodermal derivatives. In addition, 
early BMP-2+ lineages exhibit neural crest stem cell properties. Thus, while T Brachyury cells 
represent lineage non-committed early stage me
 committed. Comparison of both the lineages points out that they exhibit certain plasticity at 
the early stage. Even the T Brachyury+ cells can be maintained in culture for longer time with 
optimal amount of Leukemia inhibitor factors (LIF) and simultaneous puromycin selection. The EBs 
made from these cultures gave rise to contracting cardiomyocytes, even though the process of 
cardiomyogenesis was delayed. This represents a model to study patterning of mesodermal cells 
into cardiomyocytes in a selective approach without starting from ES cells in which case, the 
interplay of the ectodermal derivatives in mesodermal patterning would make the investigation very 
complex. In addition, the transcriptomic analysis of T Brachyury cells characterizes the cellular and 
genetics identity of the mesodermal cells, which have not yet been reported till date. This would 
significantly complement the better understanding of the mesodermal patterning.  In vitro ES 
derived BMP-2+ cell population contains neural crest stem cells and their derivatives-smooth 
muscle cells, melanocytes, cardiomyocytes and vascular and hematopoietic progenitors. 
Enrichment of the neural crest cells and their lineages by BMP-2 promoter driven selection marker 
paves the way for ES cell-derived neural crest stem cell biology. These cells are the attractive 
candidates for the future cell replacement therapy due their plasticity into any tissue depending 
upon the local environment existing within the injected tissue. This study enlists the cells 
expressing BMP-2 and gives an initial clue how these BMP-2 secreting cells play an important role 
during the development. The characterization of ES cell-derived cardiomyocytes proves that they 
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behave more or less similar to native in vivo cardiomyocytes in terms of the transcripts involved in 
physiological processes and other development processes.  
 
The future approach will be to further analyze the transcripts to elucidate the underlying 
mechanisms using several approaches like finding the preferred transcription binding sites by most 
of the transcription factors to get a clue about the molecular details about the mesodermal 
patterning. The novel transcripts whose functions have not yet been annotated but enriched in 
these lineages have to be functionally decoded to fill up the missing links in the developmental 
proces
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s by loss of function and gain of function studies using ES cells and also in vivo zebra fish 
models.   In addition, the T Brachyury+ cells can be used as starting culture for directing into 
cardiomyocytes to decipher the molecular mechanisms of cardiomyocytes more closely in an 
efficient way.  
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Annexure-1  
Pathways differentially regulated in T Brach ry+ cells in comparison to T Brachyury ES 
cells and T Brachyury control EBs.  
Category Term Count % PValue 
 
yu
 
KEGG_PATHWAY MMU04010: MAPK SIGNALING PATHWAY 95 1.69% 0.03802829
KEGG_PATHWAY MMU04510: FOCAL ADHESION 82 1.46% 0.00410464
KEGG_PATHWAY MMU04360: AXON GUIDANCE 56 1.00% 0.00211058
KEGG_PATHWAY MMU04310: WNT SIGNALING PAT AY 54 0.96% 0.05802459HW
KEGG_PATHWAY MMU04110: CELL CYCLE 45 0.80% 0.00725305
KEGG_PATHWAY MMU04350: TGF-BETA SIGNALING PATHWAY 41 0.73% 8.38E-04
KEGG_PATHWAY MMU04512: ECM-RECEPTOR INT RACTION 40 0.71% 0.00293432E
KEGG_PATHWAY MMU04540: GAP JUNCTION 37 0.66% 0.03179355
KEGG_PATHWAY MMU00310: LYSINE DEGRADATION 27 0.48% 0.03009477
KEGG_PATHWAY MMU00051: FRUCTOSE AND MANNOSE METABOLISM 24 0.43% 0.02629444
KEGG_PATHWAY MMU00500: STARCH AND SUCROSE METABOLISM 24 0.43% 0.07417547
KEGG_PATHWAY 
MMU00280: VALINE, LEUCINE AND ISOLEUCINE 
DEGRADATION 22 0.39% 0.07152007
KEGG_PATHWAY 
MMU00632: BENZOATE DEGRADATION VIA COA 
LIGATION 21 0.37% 0.03611389
KEGG_PATHWAY MMU00620: PYRUVATE MET 0.36% 0.01976104ABOLISM 20 
KEGG_PATHWAY MMU00052: GALACTOSE 18 0.32% 0.01122606 METABOLISM 
KEGG_PATHWAY MMU00640: PROPANOATE METABOLISM 17 0.30% 0.04698314
KEGG_PATHWAY MMU00251: GLUTAMATE METABOLISM 17 0.30% 0.01374867
KEGG_PATHWAY 
MMU00040: PENTOSE AND GLUCURONATE 
INTERCONVERSIONS 13 0.23% 0.00141937
KEGG_PATHWAY 
MMU00220: UREA CYCLE AND METABOLISM OF AMINO 
GROUPS 13 0.23% 0.08003552
KEGG_PATHWAY MMU00910: NITROGEN METABOLISM 13 0.23% 0.01400915
KEGG_PATHWAY MMU00903: LIMONENE AND PINENE DEGRADATION 13 0.23% 0.08003552
KEGG_PATHWAY MMU00100: BIOSYNTHESIS OF S ROIDS 11 0.20% 0.00712206TE
KEGG_PATHWAY MMU05060: PRION DISEASE 8 0.14% 0.02168277
BIOCARTA 
m_arfPathway:Tumor Suppressor Arf Inhibits Ribosomal 
Biogenesis 9 0.16% 0.005623
BIOCARTA m_badPathway:Regulation of BAD phosphorylation 9 0.16% 0.093991
BIOCARTA m_telPathway:Telomeres 11 0.20% 0.050115
BIOCARTA m_plcePathway:Phospholipase C-epsilon pathway 5 0.09% 0.077789
BIOCARTA m_p53Pathway:p53 Signaling Path y 11 0.20% 0.009843wa
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Annexure-2  
 
t , transcription and signaling.  
 
 
 
 
 
 
 
 
 
Table.7 Proportion of the transcripts Upregulated in AMHC than ES cells but  
 
Heat map of the transcripts upregulated specifically in T Brachyury+ cell population that are 
not included in GOs of developmen
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Annexure-3 
Development related transcripts that are upregulated in T Brachyury+ cells than ES 
 
NCBI ID Gene Name ES cells
6day 
Control 
EBs 
T 
Brachyury+
cells 
 
cells and 6d control EBs  but show differential expression among ES cells and 6 day 
EBs. The fold change is expressed relative to the lowest value of expression that is 
normalized to 1. 
NM_013562 
interferon-related developmental regulator 
1 2.60 1.00 7.28
NM_009964 crystallin, alpha B 1.00 5.74 13.16
NM_009255 
serine (or cysteine) peptidase inhibitor, 
clade E, member 2 1.00 5.90 14.33
NM_013749 
tumor necrosis factor receptor 
superfamily, member 12a 1.00 2.07 11.37
NM_011674 UDP galactosyltransferase 8A 4.22 1.00 9.39
NM_011580 thrombospondin 1 1.00 14.95 30.90
NM_008343 insulin-like growth factor binding protein 3 1.00 3.36 9.74
NM_009573 zinc finger protein of the cerebellum 1 1.00 4.78 11.86
NM_011526 transgelin 1.00 6.55 14.00
NM_010029 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
4 18.81 1.00 92.42
NM_010118 early growth response 2 1.00 2.80 7.38
NM_013657 
sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3C 1.00 2.03 24.21
NM_176930 RIKEN cDNA C130076O07 gene 1.00 4.47 10.74
NM_139298 wingless-type MMTV integration site 9A 1.00 2.96 15.99
NM_010516 cysteine rich protein 61 1.00 2.48 5.31
NM_008655 
growth arrest and DNA-damage-inducible 
45 beta 1.00 2.44 11.38
NM_011817 
growth arrest and DNA-damage-inducible 
45 gamma 1.00 7.53 26.97
NM_011536 T-box 4 1.00 2.03 4.67
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Ann
NCBI ID Gene Name ES cells
ntrol 
ry+
exure-4 
Transcripts that are downregulated specifically in T-brachyury population and play a 
role in development. The fold change is expressed relative to the lowest value of 
expression that is normalized to be 1. 
 
 
6d Co
EBs T Brachyu
NM_009468 dihydropyrimidinase-like .91 4.17 1.003 2
NM_013685 transcription factor 4 3.65 3.43 1.00
NM glycogen synthase 3, brain 90 71 00_008195 2. 4. 1.
NM 6 kinase, polypeptide 2 71 57 00_011299 ribosomal protein S 2. 3. 1.
NM_013865 2.26 2.58 1.00N-myc downstream regulated gene 3 
NM asion and metastasis 1 00_009384 T-cell lymphoma inv 3.57 2.07 1.
NM_007548 NF domain 11.85 7.18 1.00PR domain containing 1, with Z
NM rotein 2 42 90 00_007792 cysteine and glycine-rich p 3. 5. 1.
NM 24 04 00_007936 Eph receptor A4 2. 2. 1.
NM e 3, endothelial cell 90 85 00_008713 nitric oxide synthas 2. 2. 1.
NM bone morphogenetic protein 4 86 89 00_007554 4. 3. 1.
NM uence 39 10 00_033524 
sprouty protein with EVH-1 domain 1, 
related seq 2. 2. 1.
NM_010875 4.13 5.60 1.00neural cell adhesion molecule 1 
NM ocollagen, type XVIII, alpha 1 67 37 00_009929 pr 2. 3. 1.
NM ntiation regulator 33 2.11 00_133719 meteorin, glial cell differe 2. 1.
NM_019413 3.43 3.40 1.00roundabout homolog 1 (Drosophila) 
NM_011652 2.33 2.33 1.00titin 
NM 1 36 67 00_008957 patched homolog 4. 8. 1.
NM 12 20 00_016809 RNA binding motif protein 3 2. 2. 1.
NM
 
29 68 00_008914 
protein phosphatase 3, catalytic subunit,
beta isoform 2. 2. 1.
NM_198127 abl-interactor 2 2.14 3.56 1.00
NM odd Oz/ten-m homolog 4 (Drosophila) 89 59 00_011858 2. 2. 1.
--- --- 2.51 2.81 1.00
NM loop tail associated protein 05 78 00_033509 2. 2. 1.
NM_010233 fibronectin 1 06 68 004. 5. 1.
NM_001033299 zinc finger protein 217 2.53 2.36 1.00
NM_146194 
Phosphatidylinositol binding clathrin 
assembly protein 2.01 2.64 1.00
NM_013864 N-myc downstream regulated gene 2 5.84 5.54 1.00
NM_019588 phospholipase C, epsilon 1 6.53 7.01 1.00
NM_178688 actin-binding LIM protein 1 2.25 3.48 1.00
NM_008342 insulin-like growth factor binding protein 2 2.60 3.09 1.00
NM_030732 transducin (beta)-like 1X-linked receptor 1 3.94 2.80 1.00
NM_020259 Hedgehog-interacting protein 4.21 3.30 1.00
NM_009706 
Rho GTPase activating protein 5 (Arhgap5), 
mRNA 2.29 2.33 1.00
NM_010164 eyes absent 1 homolog (Drosophila) 9.12 5.64 1.00
NM_010162 Exostoses (multiple) 1, mRNA 2.46 2.02 1.00 
XM_486096 deleted in liver cancer 1 3.16 2.09 1.00
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Annexure-5 
NCBI ID Gene Name ES cells
6d Control 
Ebs 
T 
Brachyury+
Transcription factors that are downregulated specifically in T-brachyury population. 
The fold change is expressed relative to the lowest value of expression that is normalized 
to 1. 
NM_009122 special AT-rich sequence binding protein 1 2.90 1.002.47 
NM_013685 transcription factor 4 3.65 3.43 1.00
NM_007548 PR domain containing 1, with ZNF domain 11.85 7.18 1.00
NM_133210 S 2.11ERTA domain containing 3 2.22 1.00
NM_011249 r 5.2etinoblastoma-like 1 (p107) 0 4.98 1.00
NM_011605 t 2.24hymopoietin 2.68 1.00
NM_021559 z 2inc finger protein 191 .23 2.28 1.00
NM_019574 z 2.22inc finger protein 278 2.23 1.00
NM_027642 P 2.67HD finger protein 6 3.00 1.00
non-POU-domain-containing, octamer binding 
p 2.3 1.00NM_023144 rotein 0 2.03 
NM_001015099 R 8C04 gene 5.3IKEN cDNA 603040 8 5.88 1.00
NM_146066 G 3.31 to S phase transition 1 3 2.32 1.00
NM_053202 F 2.9orkhead box P1 (Foxp1), mRNA 8 2.01 1.00
NM_028399 c 5.8yclin T2 3 3.11 1.00
XM_125901 
cullin associated and neddylation disassociated 
1 3.2 1 2.02 1.00
NM_011308 n 2.3uclear receptor co-repressor 1 2 2.29 1.00
NM_177358 R 2.72 1.00IKEN cDNA A630033E08 gene 3.07 
NM_001024910 s 2.5 1.00eptin 10 6 3.84 
NM_001013391 c  6 2.3leavage and polyadenylation specific factor 6 2.83 1.00
NM_177359 RIKEN cDNA 6030490I01 gene 3.19 3.66 1.00
High mobility group box transcription factor 1 
NM_153198 (Hbp1) 2.14 2.33 1.00
NM_172586 Zinc finger protein 322a, mRNA 2.20 2.88 1.00
NM_138755 PHD finger protein 21A (Phf21a), mRNA 3.80 3.69 1.00
NM_138679 
A
( 2.1
sh1(absent, small,or homeotic)-like 
Drosophila)(Ash1l) 6 2.15 1.00
NM_013843 z 2.4 1.00inc finger protein 53 9 3.03 
NM_011546 Z 2.2inc finger homeobox 1a (Zfhx1a), mRNA 2 2.72 1.00
NM_172153 Mlr1 mRNA for transcription factor MLR1 2.51 2.56 1.00
T
( 2.12
SC22-related inducible leucine zipper 1b 
Tilz1b) NM_009366 2.00 1.00
NM_023868 r 2.0yanodine receptor 2, cardiac 3 2.79 1.00
NM_030887 J 3.1un dimerization protein 2 5 2.50 1.00
NM_030732 transducin (beta)-like 1X-linked receptor 1 3.94 2.80 1.00
NM_139141 inc finger protein 192 (Zfp192), mRNA 2.68 5.27 1.00Z
NM_010164 eyes absent 1 homolog (Drosophila) 9.12 5.64 1.00
NM_152895 
jumonji, AT rich interactive domain 1B (Rbp2 
like) 2.64 2.56 1.00
 
  
Annexures  143 
Annexure-6 
A. GTPase regulators that are downregulated in T-brachyury population and also 
differentially expressed among ES cells and 6day control EBs. The fold change is 
expressed relative to the lowest value of expression that is normalized to 1. 
 
 
6d Control 
EB
T 
BracNCBI ID Gene Name 
ES 
cells s hyury+
N
omain and SH3 binding 
5  1.00M_023884 
Ral GEF with PH d
motif 2 2.0 2.14
NM_009384 and metastasis 1 7  T-cell lymphoma invasion 3.5 2.07 1.00
X  4  M_129913 dedicator of cytokinesis 10 2.3 4.07 1.00
N 64
t and differentiation enhancing 
7  M_0010043  
developmen
factor 2 2.1 2.37 1.00
X ociated 13 2  M_147847 spermatogenesis ass 2.5 4.49 1.00
N
ration-associated 1 like 
6  M_172579 
signal-induced prolife
1 4.3 3.84 1.00
N 3  M_019588 phospholipase C, epsilon 1 6.5 7.01 1.00
X nase 3  M_130797 TRAF2 and NCK interacting ki 2.1 3.27 1.00
N
rotein 5 (Arhgap5), 
9  M_009706 
Rho GTPase activating p
mRNA 2.2 2.33 1.00
X 6  M_486096 deleted in liver cancer 1 3.1 2.09 1.00
 
 
pm that are downregulated in T-brachy
 an d in ES cells a dcontrol  The 
ative to the lowest value of expression is normal o be 1
NCBI ID 
 
cells 
6d Control 
Ebs Brachyury+
 
B. Develo ent related transcripts  ury 
population d also differentially expresse nd 6  EBs. fold 
change is expressed rel  that ized t . 
 
Gene Name 
ES T 
N laminin, alpha 1 .45 8 M_008480 11 5.1 1
N endothelial-specific receptor tyrosine kinase .18 6 M_013690 4 25.1 1
N interferon induced transmembrane protein 1 .59 8 M_026820 7 2.9 1
NM_177546 isoform 
phosphate cytidylyltransferase 1, choline, beta 
9.82 2.27 1
-
PREDICTED: M
yp .54 3 -- h
us musculus similar to 
othetical protein FLJ39502  10 2.1 1
N secreted frizzled-related sequence protein 1 .72 5 M_013834 6 2.9 1
N car .29 7 M_019922 tilage associated protein 4 2.0 1
N gly .54 8 M_016697 pican 3 3 46.1 1
X .93 8 M_136212 GLI-Kruppel family member GLI2 4 2.1 1
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evelopment related transcripts that are upregulated in  T Brachyury+ than ES cells 
but downregulated than EBs . The fold change is expressed tive st value 
of n that is normalized
 
S 
lls 
6d
Cont
EB
T 
rach
 
Annexure-7 
D
 rela  to the lowe
 expressio  to 1. 
 
NCBI ID Gene Name 
E
ce
 
rol 
s B yury+
NM_153319 angiomotin 1.00 279.17 25.10
XM_129060 serologically defined colon cancer antigen 33 00 48 11. .90 0.54
NM_007553 00 85bone morphogenetic protein 2 1. .99 7.98
NM_008259 1.00 43.79 6.39forkhead box A1 
NM_011514 
suppressor of variegation 3-9 homolog 1 
00 18 6.05(Drosophila) 1. .57 
NM_001013833 e I 00 12 protein kinase, cGMP-dependent, typ 1. .63 5.80
NM_008239 1.00 13.89 5.80Forkhead box Q1 (Foxq1), mRNA 
NM_011098 paired-like homeodomain transcription factor 2 1.00 57.25 5.25
NM_010514 insulin-like growth factor 2 1.00 234.66 4.21
NM_010882 necdin 1.00 27.67 3.89
NM_007441 aristaless 3 1.00 7.80 3.77
NM_018826 Iroquois related homeobox 5 (Drosophila) 1.00 8.55 3.73
NM_010449 homeo box A1 1.00 7.41 3.51
NM_009851 CD44 antigen 1.00 43.29 3.51
NM_010109 ephrin A5 00 501.  8.94 3.
NM_009367 transforming growth factor, beta 2 1.00 59.11 3.42
NM_178804 slit homolog 2 (Drosophila) 1.00 32.94 3.41
NM_007471 amyloid beta (A4) precursor protein 1.00 13 3.4.74 0
NM_00758 1.00 8.93 3.325 annexin A2 
NM_013904 hairy/enhancer-of-split related with YRPW motif 2 0 14 3.21.0 .82 6
NM_01359 30.30 3.158 kit ligand 1.00 
NM_010258 GATA binding protein 6 1.00 26 3.1.13 4
NM_008495 lectin, galactose binding, soluble 1 0 7 2.91.0 .15 6
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Annexure-7 (continued) 
malized to be 1. 
G
ES 
ce
6d
o
E
T
Br
 
 
Development related transcripts that are upregulated in  T Brachyury+ than ES cells 
but downregulated than EBs  (continued). The fold change is expressed relative to the 
lowest value of expression that is nor
 
NCBI ID ene Name 
ll
s 
C
 
ntrol 
Bs 
 
achyury+
NM_010423 h er-of-split related with YRPW motif 1 1. 1airy/enhanc 00 7.37 2.91
NM_008737 n 1. 264.22 europilin 1 00 2.65
NM_020510 f 1. 18rizzled homolog 2 (Drosophila) 00 .61 2.54
NM_008321 inhibitor of DNA binding 3 1. 11.50 00 2.54
NM_008413 J 1.00 5.06 anus kinase 2 2.46
NM_021457 frizzled homolog 1 (Drosophila) 1.00 11.20 2.44
NM_029770 unc-5 homolog B (C. elegans) 1.00 12.28 2.36
NM_007664 cadherin 2 1.00 17.86 2.35
NM_008592 forkhead box C1 1.00 5.05 2.28
NM_011594 tissue inhibitor of metalloproteinase 2 1.00 10.88 2.25
NM_008937 prospero-related homeobox 1 1. 4.400 8 2.21
NM_015753 zinc finger homeobox 1b 1.00 7.32 2.20
NM_016769 MAD homolog 3 (Drosophila) 1.00 4.75 2.14
NM_009021 retinoic acid induced 1 1.00 5.58 2.12
NM_011864 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.00 5.03 2.09
NM_010612 kinase insert domain prot 1.00 36.35 ein receptor 2.09
NM_011415 snail homolog 2 (Drosophila) 1.00 18.78 2.09
NM_008091 GATA binding protein 3 1.00 5.11 2.04
NM_145506 erythrocyte protein band 4.1-like 5 1.00 5.44 2.03
NM_017464 
neural precursor cell expressed, developmentally 
d 1. 16own-regulated gene 9 00 .42 2.02
NM_009876 cyclin-dependent kinase inhibitor 1C (P57) 1. 1500 .54 2.01
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Annexure-8 
 
Development related transcripts   T-brachyury population 
than the ES cells but upregula EBs. The fold change is 
NCBI ID Gene Name ES cells EBs 
T 
Brachyury+
that are downregulated in
ted than 6day control 
expressed relative to the lowest value of expression that is normalized to 1. 
 
6d Control 
NM_007430 nuclear receptor subfamily 0, group B, member 1 16 1.00 90.02240.
XM_132755 Nanog homeobox 1. 49.75112.17 00
NM_01944 ytosine-5-)-methyltra e 1 .34 37.648 DNA (c nsferase 3-lik 42  1.00
NM_01 om 33 1.003633 POU d ain, class 5, transcription factor 1 87. 29.06
NM_01 ast r 4 48 1.000202 fibrobl growth facto 175.  25.68
NM_13 tran 62.18 1.003197 mcf.2 sforming sequence 12.30
NM_01 carc tor 26 1.001562 terato inoma-derived growth fac 54. 10.71
NM_17 -bl 12 1.00 9.832496 cordon eu 21.
NM_00 nge 38 1.00 6.649575 zinc fi r protein of the cerebellum 3 15.
NM_172303 1.00 6.25PHD finger protein 17 13.35 
NM_17
latent transforming growth factor beta binding 
 4 59 1.00 5.675641 protein 14.
NM_01 d m thy gene 1 74 1.00 5.219926 X-linke yotubular myopa 10.
NM_13 om 31 1.00 4.478944 POU d ain, class 4, transcription factor 2 64.
NM_00 ncti n beta 3 88 1.00 4.478126 gap ju on membrane channel protei 16.
NM_02 rian 95 1.00 4.343794 ets va t gene 5 8.
NM_01 lial 77 1.00 4.330128 epithe membrane protein 1 10.
NM_033077 DNA segment, Chr 1, Pasteur Institute 1 1.00 4.2911.53 
NM_019984 transglutaminase 1, K polypeptide 26.74 1.00 3.65
NM_008381 inhibin beta-B 32.21 1.00 3.18
NM_01 latio 93 1.00 2.990262 gastru n brain homeobox 2 12.
NM_01  inh  66 1.00 2.681593 tissue ibitor of metalloproteinase 1 8.
NM_00 ripti 43 1.00 2.589328 transc on factor 15 8.
NM_01 ad 7.42 1.00 2.540425 forkhe box D3 
NM_020581 angiopoie 6.25 1.00 2.53tin-like 4 
NM_028199 1.00 2.38plexin domain containing 1 5.90 
NM_14 ulle 45 1.00 2.364547 anti-M rian hormone type 2 receptor 5.
NM_011518 spleen tyrosine kinase 4.73 1.00 2.31
NM_007905 polyhomeotic-like 1 (Drosophila) 4.76 1.00 2.29
NM_030886 Ankyrin repeat domain 17, mRNA 6.47 1.00 2.23
NM_133195 bruno-like 4, RNA binding protein (Drosophila) 6.56 1.00 2.22
NM_008234 helicase, lymphoid specific 5.97 1.00 2.19
NM_011898 sprouty homolog 4 (Drosophila) 14.23 1.00 2.10
NM_008601 microphthalmia-associated transcription factor 19.18 1.00 2.04
NM_007868 dystrophin, muscular dystrophy 6.16 1.00 2.01
  
Annexures  147 
Annexure-9 
sed relative to 
e lowest value of expression that is normalized to be 1. 
 
ES cells
 Control
Ebs brachyury
 
Transcription factors that are downregulated in T-Brachyury+ population than the ES 
cells but upregulated than 6day control EBs. The fold change is expres
th
NCBI ID Gene Name 
6d  T-
+
NM_001017525 BTB (POZ) domain containing 11 6.61 1.00 3.21
NM_009482 
undifferentiated embryonic cell 
transcription factor 1 12.05 1.00 5.92
NM_023258 PYD and CARD domain containing 12.32 1.00 3.94
NM_00
subfamily 0, group B, 
240.16 1.00 .027430 member 1 
nuclear receptor 
90
NM_013633 1 
POU domain, class 5, transcription factor 
87.33 1.00 29.06
NM_02  6.25 1.00 3755 transcription factor CP2-like 1 2.44
NM_010827 musculin 24.23 1.00 4.07
NM_01 12.93 1.00 2.990262 gastrulation brain homeobox 2 
NM_030676 member 2 
nuclear receptor subfamily 5, group A, 
19.41 1.00 6.72
NM_008578 myocyte enhancer factor 2B 4.96 1.00 2.27
NM_010425 forkhead box D3 7.42 1.00 2.54
NM_011542 transcription elongation factor A (SII), 3 13.36 1.00 2.71
NM_019448 
DNA (cytosine-5-)-me
like 
thyltransferase 3-
142.34 1.00 .6437
NM_023794 ets variant gene 5 8.95 1.00 4.34
NM_178935 CXORF15 14.19 1.00 6.77
NM_01 tor, beta 68.86 1.00 .751934 estrogen related recep 24
NM_138944 
transcr
2 
POU domain, class 4, iption factor 
64.31 1.00 4.47
XM_139740 gene model 313, (NCBI) 6.59 1.00 3.07
NM_023184 Kruppel-like factor 15 5.71 1.00 2.35
NM_011487 transcription 4 
signal transducer and activator of 
12.64 1.00 2.42
NM_008452 Kruppel-like factor 2 (lung) 40.84 1.00 .6311
NM_009328 transcription factor 15 8.43 1.00 2.58
NM_008601 factor 
microphthalmia-associated transcription 
19.18 1.00 2.04
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Annexu
 
The biological processed represented by the transcripts downregulated in BMP-2+ 
C Count % PValue 
re-10 
cells in comparison to both ES cells and 7 day control EBs.  
 
tegory Term a
GOTERM_BP_ALL double-strand break repair via homologous recombination 0  0.0424032 1. 5%
GOTERM_BP_ALL double-strand break repair 2 1.05% 0.090936
GOTERM_BP_AL 2 0.066983L negative regulation of neuron differentiation 1.05% 
GOTERM_BP_ALL 9 % 1.86E-05 DNA replication  4.71
GOTERM_BP_ALL 11 % 1.62E-06 DNA repair  5.76
GOTERM_BP_ALL 4  DNA recombination 2.09% 0.008177
GOTERM_BP_ALL 3 % 0. chromosome segregation  1.57 040413
GOTERM_BP_ALL 18 9.42% 2.42E-13 cell division 
GOTERM_BP_ALL combinational repair 2 % 0. re  1.05 042403
GOTERM_BP_ALL 2 % 0.090936 pyridine nucleotide biosynthesis  1.05
GOTERM_BP_ALL bolism 24 % 1.68E-10 DNA meta  12.57
GOTERM_BP_ALL 24 % 3.11E-09 cell cycle  12.57
GOTERM_BP_ALL 11 5.76% 1.57E-05 response to endogenous stimulus 
GOTERM_BP_ALL on repair 3 % 0.0 base-excisi  1.57 12677
GOTERM_BP_ALL 99 % 0.007573 cellular physiological process 51.83
G LL side, nucleotide and nucleic a 36 18.85% 0.045319OTERM_BP_A  nucleobase, nucleo cid metabolism 
GOTERM_BP_ALL 3 % 0.0 sterol metabolism  1.57 91987
GOTERM_BP_ALL 75 % 0. cellular metabolism  39.27 004404
GOTERM_BP_ALL sm 3 % 0.0 cholesterol metaboli  1.57 81602
GOTERM_BP_ALL 19  protein modification 9.95% 0.088599
GOTERM_BP_ALL 4  steroid biosynthesis 2.09% 0.015016
GOTERM_BP_ALL 8 % 0. cellular catabolism  4.19 091393
GOTERM_BP_ALL 9 % 0.010783 regulation of progression through cell cycle 4.71
GOTERM_BP_ALL e 11 % 1.43E-07 M phase of mitotic cell cycl  5.76
GOTERM_BP_ALL 4 6.42E-04 cytokinesis 2.09% 
GOTERM_BP_ALL 13 % 5.59E-08 M phase  6.81
GOTERM_BP_ALL 20 % 0.07165 biopolymer modification  10.47
GOTERM_BP_ALL 52 % 7.08E-04 macromolecule metabolism  27.23
GOTERM_BP_ALL 3  biopolymer methylation 1.57% 0.069186
GOTERM_BP_ALL 44 2.51E-06 biopolymer metabolism 23.04% 
GOTERM_BP_ALL 78 % 0.0 metabolism  40.84 08402
GOTERM_BP_AL  mitotic cell cycle 12 6.28% 6.46E-07L
GOTERM_BP_AL  response to DNA damage stimulus 11 5.76% 8.67E-06L
GOTERM_BP_AL  regulation of cell cycle 9 4.71% 0.010958L
GOTERM_BP_AL  mitosis 11 5.76% 1.33E-07L
GOTERM_BP_AL  primary metabolism 69 36.13% 0.020493L
GOTERM_BP_ALL DNA-dependent DNA replication 4 2.09% 0.007714
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Annexure-11 
The development related transcripts downregulated in BMP-2  cells  comparison to 
both ES cells and 7day control EBs. The fold change is expressed relative to the lowest 
alue of expression that is normalized to 1. 
+
e ES cells 
Control 
v
 
 
Unigene ID 
7d 
Ebs BMP-2+Gene Nam
Mm.90003 gap junction membrane channel protein beta 3 5.99 2.60 1.00
Mm.4269 transcription factor 4 4.56 2.01 1.00
Mm.3488 aurora kinase B 2.14 4.88 1.00
Mm.175661 interferon induced transmembrane protein 1 13.78 5.07 1.00
Mm.4974 neural cell adhesion molecule 1 5.16 2.38 1.00
Mm.228798 patched homolog 1 2.79 6.63 1.00
Mm.250185 eyes absent 1 homolog (Drosophila) 3.00 6.93 1.00
Mm.281691 secreted frizzled-related sequence protein 1 11.14 4.68 1.00
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Annexure-12 
at is normalized to 1. 
Unigene ID 
 Gene Name ES cells 
7d 
Control BMP-
2+ 
A) Development related transcripts that are upregulated in BMP-2 cells more than the 
ES cells but downregulated than 7 day control EBs . The fold change is expressed 
relative to the lowest value of expression th
 
EBs 
M inhibitor of DNA binding 3  m.110 1.00 34.11 10.14
Mm.181959 1 9.47 2early growth response 1 .00 .37
Mm.257437 1 11 3cadherin 2 .00 .93 .35
Mm.197 homeo box A1 1 4 2.00 .39 .19
Mm.246513 FBJ osteosarcoma oncogene 16 51.00 .95 .49
Mm.233903 1 62.79 7neuronatin .00 .14
Mm.246804 paired-like homeodomain transcription factor 2 1 17 7.00 .55 .78
Mm.193925 guanine nucleotide binding protein, alpha 13 1 5 2.00 .03 .26
Mm.38378 Fras1 related extracellular matrix protein 2 10 21.00 .08 .27
 
 
B) Development related transcripts that are upregulated more than the 7 day control 
EBs in BMP-2+ cells but downregulated than the ES cells. The fold change is expressed 
relative to the lowest value of expression that is normalized to 1. 
Unigene ID Gene Name ES cells 
7d 
Control 
Ebs 
BMP-
2+ 
Mm.15105 ositol polyphosphate-5-phosphatase D 17.65 1.00 3.51in
Mm.286536 amin binding LIM protein 1 10.82 1.00 2.15fil
Mm.280641 leted in azoospermia-like 20.08 1.00 9.34de
Mm.2581 ph receptor A2 5.73 1.00 2.79E
Mm.13433 DNA (cytosine-5-)-methyltransferase 3-like 59.10 1.00 14.01
Mm.3092 inhibin beta-B 39.70 1.00 2.34
Mm.6047 Nanog homeobox 27.15 1.00 2.68
Mm.272251 
tent transforming growth factor beta binding 
otein 4 9.73 1.00 3.40
la
pr
--- active X specific transcripts 16.58 1.00 3.00in
Mm.108054 NA segment, Chr 1, Pasteur Institute 1 13.35 1.00 2.42D
Mm.288474 creted phosphoprotein 1 25.58 1.00 5.59se
Mm.3881 transcription factor 15 5.26 1.00 2.56
Mm.5090 teratocarcinoma-derived growth factor 60.58 1.00 9.00
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Annex
Category Term Count PValue 
ure-13 
 
Biological processes overrepresented by differentially regulated transcripts in αMHC+ 
cells  in comparison to αMHC ES cells and 15day old αMHC control EBs.  
 
% 
KEGG_PATHWAY MMU04010:MAPK SIGNALING PATHWAY % 06128 1.66 0.0078
KEGG_PATHWAY MMU04510:FO  10 2% CAL ADHESION 9 1.4 4.53E-04
KEGG_PATHWAY MMU00230:PURINE METABOLISM 76  40.99% 0.00431
KEGG_PATHWAY MMU04110:CELL CYCLE 70 0.91% 1.33E-07
KEGG_PATHWAY MMU04360:AXON GUIDANCE 68  0.006319 0.88%
KEGG_PATHW NT SIGNALING PATHWAY 68  0.089166AY MMU04310:W 0.88%
KEGG_PATHWAY MMU00190:OXIDATIVE PHOSPHORYLATION 65  0.0015860.84%
KEGG_PATHWAY MIGRATION 
MMU04670:LEUKOCYTE TRANSENDOTHELIAL 
60 0.78% 0.045594
KEGG_PATHWAY MMU04530:TIGHT JUNCTION 57  0.0978270.74%
KEGG_PATHWAY MMU04350:TGF-BETA SIGNALING PATHWAY 52  2.27E-040.68%
KEGG_PATHWAY MMU00240:PYRIMIDINE METABOLISM 51 0.66% 0.002039
KEGG_PATHWAY MMU04512:ECM-RECEPTOR INTERACTION 48 0.62% 0.007577
KEGG_PATHWAY MMU04540:GAP JUNCTION 46 0.60% 0.043825
KEGG_PATHWAY 
MMU04070:PHOSPHATIDYLINOSITOL SIGNALING 
SYSTEM 44 0.57% 0.048484
KEGG_PATHWAY MMU04520:ADHERENS JUNCTION 41 0.53% 0.017819
KEGG_PATHWAY MMU04730:LONG-TERM DEPRESSION 40 % 0.52 0.038833
KEGG_PATHWAY MMU04662:B C  SIGNALING PATHW  06ELL RECEPTOR AY 35 0.45% 0.0625
KEGG_PATHWA BOLISM 33  0.01421Y MMU00500:STARCH AND SUCROSE META 0.43%
KEGG_PATHWA
 NICOTINAMIDE 
33  0.007227Y 
MMU00760:NICOTINATE AND
METABOLISM 0.43%
KEGG_PATHWA
RADATION VIA COA 
28  0.008187Y LIGATION 
MMU00632:BENZOATE DEG
0.36%
KEGG_PATHWA 27  6Y 
MMU00260:GLYCINE, SERINE AND THREONINE 
METABOLISM 0.35% 0.05918
KEGG_PATHWAY MMU00620:PYRUVATE METABOLISM 24  0.0278540.31%
KEGG_PATHWA O-VENTRAL AXIS FORMATION 19  0.032942Y MMU04320:DORS 0.25%
KEGG_PATHWA
 AMINO 
18  0.013778Y 
MMU00220:UREA CYCLE AND METABOLISM OF
GROUPS 0.23%
KEGG_PATHWA  SYNTHETASES 18  0.022143Y MMU00970:AMINOACYL-TRNA 0.23%
KEGG_PATHWA
 
14 0.18% 0.005913Y 
MMU00040:PENTOSE AND GLUCURONATE
INTERCONVERSIONS 
KEGG_PATHWA ISEASE 14  0.056557Y MMU05010:ALZHEIMER'S D 0.18%
KEGG_PATHWA BON POOL BY FOLATE 12  0.035696Y MMU00670:ONE CAR 0.16%
KEGG_PATHWA S 12  0.019641Y MMU00100:BIOSYNTHESIS OF STEROID 0.16%
KEGG_PATHWAY MMU00900:TERPENOID BIOSYNTHESIS 5 0.06% 0.088275
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Annexure-14 
sion among 
S cells and control EBs. The fold change is expressed relative to the lowest value of 
Development related transctirpts upregulated in αMHC+ cardiomyocytes  compared to both 
ES cells and 15day old control EBs and which in turn  show diffrential expres
E
expression that is normalized to be 1. 
Refseq Genes  MHC+ES cells 15d control EBs α
N p 1.00M_009468 dihydro yrimidinase-like 3 2.60 5.68
NM_009964 1.00 12.43 crystallin, alpha B 58.96
NM_019564 1.00 11.80 HtrA serine peptidase 1 44.56
NM_024223 1.00cysteine rich protein 2 3.23 16.86
NM_015814 1.00dickkopf homolog 3 (Xenopus laevis) 9.99 45.07
N  h 1.00M_010856 myosin, eavy polypeptide 6, cardiac muscle, alpha 2.15 81.41
N d 1.00M_026131 PDZ an  LIM domain 7 2.67 7.09
N m 1.00M_009365 transfor ing growth factor beta 1 induced transcript 1 3.67 9.34
N e 1.00M_020493 serum r sponse factor 2.18 5.91
N  l 1.00M_010801 myeloid eukemia factor 1 8.68 61.38
N n 1.00 9M_007664 cadheri  2 8.44 329.84
NM_007561 bone morphogenic protein receptor, type II 1.00 4.51 9.24
NM_025282 e enhancer fact 1.00 31.69 myocyt or 2C 75.13
NM_007555 1.00bone morphogenetic protein 5 2.04 5.65
N e 4.78M_009814 calsequ strin 2 1.00 13.09
N  1.00 1M_009406 troponin I, cardiac 2.88 110.42
N  1.00M_009324 T-box 2 7.69 22.95
N oM_010255 guanidin acetate methyltransferase 1.00 2.02 4.81
NM_007911 ephrin 3 00B  1. 2.99 6.30
NM_010197 fibroblast 1.00 2.12 7.11 growth factor 1 
N m r, beta 2 1.00 2M_009367 transfor ing growth facto 1.25 48.11
NM_019972 sortilin 1 1.00 2.42 8.30
NM_008441 1.00kinesin family member 1B 2.25 5.68
N  1.00M_011537 T-box 5 2.31 17.52
N di 1.00 1M_145136 myocar n 2.15 116.41
N  a 1.00M_008481 laminin, lpha 2 5.24 29.44
NM_011486 signal tra 2.02 4.87nsducer and activator of transcription 3 1.00
N 1.00M_010043 desmin 2.59 9.79
XM_110852 amyotrophic lateral sclerosis 2 (juvenile) chromosome 1.00 2.09 5.18
N 1.00 2M_028004 titin 0.06 148.28
NM_010118 1.00 15.50 early growth response 2 43.66
NM_175606 homeobox only domain 1.00 6.87 45.81
NM_026163 plakophilin 1.002 2.01 7.85
NM_029273 1.00SLIT and NTRK-like family, member 5 3.05 23.01
N e 1.00M_009116 paired r lated homeobox 2 3.05 9.54
NM_024124 histone deacetylase 9 1.00 5.79 31.55
NM_009861 cell division cycle 42 homolog (S. cerevisiae) 1.00 2.05 6.37
XM_484197 PREDICTED: integrin beta 8 1.00 10.60 73.78
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Annexure-14 (continued) 
Development related transctirpts upregulated in αMHC+ cardiomyocytes  compared to both 
ES cells and 15day old control EBs and which in turn show differential expression among 
ES cells and control EBs. The fold change is expressed relative to the lowest value of 
expression that is normalized to 1. 
Refseq Genes ES cells 15d control α MHC+
NM 018781 early growth response 3 1 00 6 49 23 64
NM 175013 phosphoglucomutase 5 1 00 5 14 16 78
NM 008937 prospero-related homeobox 1 1 00 2 07 7 54
NM 008664 myomesin 2 1 00 2 13 40 73
NM 010788 methyl CpG binding protein 2 1 00 3 69 7 49
NM 021320 Netrin 4 (Ntn4) mRNA 1 00 2 25 24 35
NM 010789 Myeloid ecotropic viral integration site 1 mRNA 1 00 6 66 15 86
NM 145519 FERM RhoGEF and pleckstrin domain protein 1 00 2 35 5 01
NM 009762 SET and MYND domain containing 1 1 00 3 65 63 17
NM 010141 Eph receptor A7 mRNA (cDNA clone 1 00 2 67 7 34
NM 008854 Protein kinase cAMP dependent catalytic 1 00 2 11 5 33
NM 019684 serine/threonine kinase 23 1 00 7 98 89 16
NM 013613 nuclear receptor subfamily 4 group A member 1 00 2 61 12 09
NM 133201 mitofusin 2 1 00 2 17 8 06
NM 013864 N-myc downstream regulated gene 2 1 00 2 72 7 08
NM 080728 myosin heavy polypeptide 6 cardiac muscle 1 00 4 20 88 11
NM 016798 PDZ and LIM domain 3 1 00 3 44 7 55
NM 008700 NK2 transcription factor related locus 5 1 00 2 05 15 95
NM 020332 progressive ankylosis 1 00 3 35 7 42
NM 013593 myoglobin 1 00 7 49 164 09
NM 145584 spondin 1 (f-spondin) extracellular matrix 1 00 22 59 100 57
NM 010518 insulin-like growth factor binding protein 5 1 00 113 32 283 56
XM 485171 myosin light polypeptide 9 regulatory 1 00 32 50 292 93
NM 020496; T-box 20 1 00 26 76 99 84
NM 011817 growth arrest and DNA-damage-inducible 45 1 00 18 14 50 32
NM 008601 microphthalmia-associated transcription factor 2 24 1 00 6 13
NM 011935 estrogen-related receptor gamma 1 00 2 90 8 39
NM 021566 junctophilin 2 1 00 2 59 14 01
NM 008904 peroxisome proliferative activated receptor 1 00 3 04 33 29
NM 172862 Fras1 related extracellular matrix protein 2 1 00 11 24 36 72
NM 008737 neuropilin 1 1 00 2 26 13 03
NM 013808 cysteine and glycine-rich protein 3 1 00 9 40 42 77
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Annexure-15 
The transcripts involved in MAPK signalling that are upregulated in αMHC+ 
es 
E
c
control 
EBs H
cardiomyocytes compared to both ES cells and 15day old control EBs and which in 
turn show diffrential expression among ES cella and control EBs. The fold change is 
expressed relative to the lowest value of expression that is normalized to 1. 
 
Refseq Gen
S 
ells
15d 
α M C+
NM_009393 troponin C, cardiac/slow skeletal 79.1639 161 1  561. 86
NM_023129 p an 1.68295 3hospholamb 1 1  147. 904
NM_011406 
s calcium 
e .729582 1
olute carrier family 8 (sodium/
xchanger), member 1 1 5  83.5 378
NM_023868 r .845286 7yanodine receptor 2, cardiac 1 4  71.7 675
NM_175441 R .465861 78IKEN cDNA D830007F02 gene 1 4  53.4 37
NM_009722 
ATPase, Ca++ transporting, cardiac muscle, slow 
t 7.55059 96witch 2 1  21.2 64
NM_021415 
calcium channel, voltage-dependent, T type, 
a .802638 6lpha 1H subunit 1 5  17.2 068
NM_009781 
c  
alpha 1C subunit 2.16628 01
alcium channel, voltage-dependent, L type, 
1  16.4 57
NM_028981 
calcium channel, voltage-dependent, L type, 
a 2.8751 6lpha 1D subunit 1  8.58 728
NM_008854 
Protein kinase, cAMP dependent, catalytic, 
a
I .109265 5
lpha, mRNA (cDNA clone MGC:6169 
MAGE:3497908) 1 2  5.32 959
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Annexure-16 
Development related transctirpts downregulated in αMHC  cardiomyocytes  compared to 
both ES cells and 15day old control EBs and which in turn show diffrential expression 
among ES cella and control EBs. The fold change is expressed relative to the lowest value 
of expression that is normalized to 1. 
+
Refseq Genes ES cells 15d control α MHC+
NM 019768 mortality factor 4 like 2 2 3827 2 399584 1
NM 019641 stathmin 1 3 665087 2 471618 1
N 96M 0118 sprouty homolog 1 4 695359 7 37134 1
NM 011418 SWI/SNF related matrix 3 678515 2 537717 1
NM 011379 signal-induced proliferation 2 567472 3 708008 1
NM 011370 cytoplasmic FMR1 3 910966 3 667405 1
NM 010798 macrophage migration 2 028321 2 090147 1
NM 020006 CDC42 effector protein (Rho 2 308123 3 62208 1
NM 007971 enhancer of zeste homolog 2 5 537979 3 649182 1
NM 019676 phospholipase C delta 1 2 000191 2 975177 1
NM 011801 craniofacial development 2 291356 2 132353 1
NM 020581 angiopoietin-like 4 3 244748 2 817706 1
NM 008709 v-myc myelocytomatosis 7 085321 5 742079 1
NM 007892 E2F transcription factor 5 2 075681 2 942454 1
NM 011524 transforming acidic coiled- 13 6565 8 250881 1
NM 027324 sideroflexin 1 5 945818 4 819637 1
NM 133762 leucine zipper protein 5 12 29549 8 990721 1
NM 009929 procollagen type XVIII 4 134619 5 437193 1
NM 009616 a disintegrin and 2 317457 3 697396 1
NM 031877 WASP family 1 3 031342 2 529039 1
NM 008714 Notch gene homolog 1 2 668646 3 994116 1
NM 013690 endothelial-specific receptor 3 957614 7 05991 1
NM 019971 platelet-derived growth 3 171103 3 837322 1
NM 009506 vascular endothelia growthl 3 247194 3 516279 1
NM 010067 DNA methyltransferase 2 2 662462 2 787407 1
NM 181327 myosin heavy polypeptide 9 2 020944 2 373787 1
NM 033608 immunoglobulin superfamily 3 08558 4 373959 1
NM 011035 p21 (CDKN1A)-activated 3 385995 2 963145 1
NM 013471 annexin A4 3 348172 5 559627 1
NM 010590 ajuba 7 858155 4 474931 1
NM 011898 sprouty homolog 4 2 969037 2 137937 1
NM 008713 nitric oxide synthase 3 3 88712 2 938937 1
NM 011917 5'-3' exoribonuclease 2 4 326286 2 268112 1
NM 007554 bone morphogenetic protein 6 715097 3 609592 1
NM 010066 DNA methyltransferase 7 919341 4 175482 1
NM 033524 sprouty protein with EVH-1 2 974918 3 244007 1
NM 021409 par-6 (partitioning defective 2 090105 3 959838 1
NM 009361 transcription factor Dp 1 2 333865 2 6165 1
NM 008245 hematopoietically expressed 3 668262 4 426747 1
NM 008031 fragile X mental retardation 2 730245 2 358289 1
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Annexure-16 (continued) 
Refseq Genes ES cells 
15d control 
EBs α MHC+
NM_02369
 T-cells, cytoplasmic, 
ineurin-dependent 4 2953 5 19 calc
nuclear factor of activated
2.02 2.99532  
N anscription 2  1M_013685 tr factor 4 .250863 2.778532
N urora kinase  1M_011496 a  B 12.10002 10.32018
 N aculoviral IA   1M_009689 b P repeat-containing 5 15.20271 8.3278
N ukocyte sp  1M_010734 le ecific transcript 1 4.257557 2.664464
N rthodenticle  1M_144841 o  homolog 2 (Drosophila) 22.24234 11.34875
N omesoderm is)  1M_010136 e in homolog (Xenopus laev 2.686802 2.165604
N ell division c  1M_009863 c ycle 7 (S. cerevisiae) 10.40622 8.770731
N permatid pe  1M_009261 s rinuclear RNA binding protein 3.879285 2.596944
NM_178598 transgelin 2  14.323942 5.032029
NM_010233 fibronectin 1  13.40462 3.832651
XM_127565 filamin, beta  12.455687 2.397417
NM_008995 peroxisome b  1iogenesis factor 5 2.709981 2.447557
N itogen activ n  1M_011952 m ated protein ki ase 3 2.292793 2.6013
X entromere a  1M_129658 c utoantigen F 7.776469 5.802609
NM_008255 
-hydroxy-3-  
reductase  1
3 methylglutaryl-Coenzyme A
3.750631 3.472402
N undabout h ila)  1M_019413 ro omolog 1 (Drosoph 5.078589 3.458883
NM_033320 glucuronyl C  15-epimerase 4.0164 2.771649
N ynein 2 ligh  1M_172256 d t intermediate chain 2.605158 2.456556
N atched hom  1M_008957 p olog 1 7.428647 6.097137
N uc7 homolo  1M_025881 L g (S. cerevisiae)-like 2.012057 2.410539
N psilon-tubul  1M_028006 e in 1 8.215935 6.593246
N ucleophosm  1M_008722 n in 1 3.533406 2.709068
N polipoprotei  1M_009696 a n E 14.30636 12.07333
N rythrocyte p  1M_013511 e rotein band 4.1-like 2 3.407721 4.066809
N
rotein phosp alytic subunit, beta 
oform  1M_008914 is
p hatase 3, cat
2.505594 2.6818
NM_008662 myosin VI 3.800492  15.806802
N
-Ki-ras2 Kirs ogene 
omolog  1M_021284 h
v ten rat sarcoma viral onc
3.434407 2.719002
N ryl hydrocar r 2  1M_007488 a bon receptor nuclear translocato 2.013441 3.209756
N dd Oz/ten-m  1M_011858 o  homolog 4 (Drosophila) 2.212676 2.341704
N
-erb-b2 eryt ene 
omolog 3 (a  1M_010153 h
v hroblastic leukemia viral oncog
vian) 4.986544 2.673098
NM_010939 neuropilin 2  12.331395 3.52589
N GF-like dom  1M_178444 E ain 7 2.144922 3.349859
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Annexure-16 (continued) 
Refseq Genes ES cells 
15d control 
EBs α MHC+
NM_010422 hexosaminidase B 8.088736 4.208275 1
NM_010774 
Methyl-CpG binding domain protein 4, mRNA 
GC:36060 IMAGE:5356016) 2.012679 (cDNA clone M 3.687663 1
NM_011916 5'-3' exoribonuclease 1 (Xrn1), mRNA 3.289551 2.281186 1
NM_010907 
nuclear factor of kappa light chain gene 
alpha enhancer in B-cells inhibitor, 2.194143 2.21978 1
NM_019424 
Hermansky-Pudlak syndrome 1 homo
(human) 
log 
2.851202 2.343379 1
NM_009376 tetratricopeptide repeat domain 10 3.291793 2.176994 1
NM_008021 forkhead box M1 2.956777 2.062402 1
NM_007795 cardiotrophin 1 2.075084 2.550527 1
NM_010929 Notch gene homolog 4 (Drosophila) 2.593436 2.678144 1
NM_011976 
sema domain, immunoglobulin domain (Ig), 
transmem
cytoplasmic domain, (s
brane domain (TM) and short 
emaphorin) 4G 2.023384 2.20944 1
NM_008057 frizzled homolog 7 (Drosophila) 7.683741 5.192648 1
NM_030732 transducin (beta)-like 1X-linked receptor 1 2.045006 2.036298 1
NM_021383 
rcd1 (required for cell differentiation) homolog 1 
3.416921 1(S. pombe) 5.690296
NM_025564 RIKEN cDNA 2010012C16 gene 3.312168 2.341818 1
NM_017405 liver-specific bHLH-Zip transcription factor 2.49742 3.485917 1
NM_020331 
general transcription factor II I repeat domain-
containing 1 2.347795 2.465841 1
NM_010472 HIV-1 Rev binding protein 5.916857 3.363449 1
NM_030147 bromodomain containing 8 2.167344 2.16721 1
NM_021099 kit oncogene 11.94732 10.62623 1
NM_145990 CDK5 regulatory subunit associated protein 2 2.899983 2.186952 1
NM_019830 
heterogeneous nuclear ribonucleoproteins 
methyltransferase-like 2 (S. cerevisiae) 3.635778 2.852337 1
NM_008021; 
NM_018858; 
XM_132869 
forkhead box M1; phosphatidy
binding protein;
lethanolamine 
 RIKEN cDNA 4933413G19 
gene 7.520145 3.884855 1
NM_008342 insulin-like growth factor binding protein 2 23.85178 14.84272 1
NM_011623 topoisomerase (DNA) II alpha 19.12018 11.34437 1
NM_011759 zinc finger protein 41 3.585899 3.539256 1
NM_175930 
Rap gu
5 
anine nucleotide exchange factor (GEF) 
2.501675 3.914852 1
NM_008449 kinesin family member 5C 4.011012 3.035083 1
NM_020259 Hedgehog-interacting protein 3.825948 3.437845 1
XM_109868 tensin 3 7.237513 3.782385 1
NM_022987 Opr 10.61627 6.16661 1
NM_010164 3.689654 4.226483 1eyes absent 1 homolog (Drosophila) 
NM_153138 
Wiskott-Aldrich syndrome protein interacting 
protein 3.001951 5.039865 1
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Annexure-17 
ts that are upregulated  in αDevelopmental related transcrip  MHC + cells more than the ES 
cells but downregulated than 15day EBs.  The fold change is expressed relative to the 
lowest value of expression that is normalized to 1.  
ES 
 
15d 
α MHC+
 
Refseq Genes cells
control 
EBs 
NM_013598 kit ligand 1.00 21.97 7.97
NM_008973  2.63pleiotrophin 1.00 15.14
NM_010825 
gration s
related gene 1  5.53
myeloid ecotropic viral inte ite-
1.00 16.59
NM_019521  6  3.24growth arrest specific 1.00 12.18
NM_001012477 chemokine (C-X-C motif) ligand 12 6.751.00 35.60 
NM_009876 .00  11.56
cyclin-dependent kinase inhibitor 1C 
(P57) 1 28.29
NM_008520 
ctor beta 
 3.51
latent transforming growth fa
binding protein 3 1.00 7.45
NM_010151 
ubfamily 2, grou
 9.42
nuclear receptor s p F, 
member 1 1.00 37.98
NM_008259 1.00 26.40 2.33forkhead box A1 
NM_011658 twist gene homolog 1 (Drosophila) 1.00 12.75 3.81
NM_026162 plexin domain containing 2 1.00 6.72 2.85
NM_007585 1.00 8.89 2.15annexin A2 
NM_008813 
tonucleotide 
ase/phosphodiestera
.00  2.27
ec
pyrophosphat se 
1 1 4.97
NM_008495 in, galactose binding, soluble 1  2.45lect  1.00 9.82
NM_010111  3.41ephrin B2 1.00 9.84
NM_001008702; 
NM_023118 sophila)  5.28disabled homolog 2 (Dro 1.00 45.13
NM_011580 1.00 112.16 3.71thrombospondin 1 
NM_010496 inhibitor of DNA binding 2  3.691.00 7.86
NM_015753  17.61zinc finger homeobox 1b 1.00 43.18
NM_009821 cription factor 1  2.32runt related trans 1.00 10.32
NM_130448 erin 18  3.87protocadh 1.00 26.56
NM_009573 zinc finger protein of the cerebellum  2.83 1 1.00 41.27
NM_015784 oblast specific factor  31.78periostin, oste  1.00 130.64
NM_010517 
h factor binding 
protein 4 2.63
insulin-like growt
1.00 60.34 
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Refseq Genes 
ES 
cells 
control 
EBs α MHC+
Annexure-17(continued) 
15d 
NM_009851 CD44 antigen 1.00 93 5.7722.
NM_0084 minin B1 subunit 1 1.00 7 82 la 5.8 2.70
NM_178804 slit homolog 2 (Drosophila) 0 1.0 21.73 2.37
NM_011098 paired-like homeodomain transcription factor 2 0 1.0 13.71 4.77
NM_144783 Wilms tumo 1.00 7.34 2.04r homolog 
NM_009371 transforming growth factor, beta receptor II 0 1.0 19.97 2.15
NM_011544 transcription 0  factor 12 1.0 4.54 2.06
NM_013657 
se
do
ma doma sic 
main, sec 0 
in, immunoglobulin domain (Ig), short ba
reted, (semaphorin) 3C 1.0 26.93 11.16
--- Transcribed 0  locus 1.0 10.90 5.00
NM_008687 nuclear factor I/B 1.00 4.47 2.15
NM_009524 wingless-re 0 lated MMTV integration site 5A 1.0 19.80 5.26
NM_017464 
neural precursor cell expressed, developmentally down-
regulated g 1.00 15.73 ene 9 2.40
NM_021457 frizzled homolog 1 (Drosophila) 1.00 29.16 6.83
NM_007904 endothelin r 0 eceptor type B 1.0 40.31 2.48
NM_010512 Insulin-like 0 growth factor 1 1.0 36.10 2.24
NM_009154 
sema domain, seven thrombospondin repeats (type 1 and 
type 1-like), ne domain (TM) and short 
cytoplasmic domain, (semaphorin) 5A 
 transmembra
1.00 13.29 5.21
NM_007963 ecotropic vi 1.00 14.66 2.09ral integration site 1 
NM_011415 snail homolog 2 (Drosophila) 0 2.861.0 15.10 
NM_010514 insulin-like 0 2 113.88growth factor 2 1.0 64.94 
NM_010417;  hephaestin 0 1.0 14.34 2.52
NM_019932 chemokine (C-X-C motif) ligand 4 1.00 33.96 8.95
NM_007483 ras homolog 1.00  gene family, member B 15.30 4.90
NM_010612 kinase inse ptor 0 rt domain protein rece 1.0 14.87 2.05
NM_009472 unc-5 homo 0 log C (C. elegans) 1.0 12.73 2.40
NM_021459 ISL1 transc ain (islet 1) 0 ription factor, LIM/homeodom 1.0 7.34 2.33
NM_016697 glypican 3 0 1.0 11.59 2.46
NM_011756 zinc finger p 0 rotein 36 1.0 13.73 5.44
NM_175260 myosin, heavy polypeptide 10, non-muscle 1.00 4.19 2.03
NM_153319 angiomotin 0 1.0 64.44 12.68
NM_011243 retinoic acid 0  receptor, beta 1.0 29.81 4.00
NM_016707 B-cell CLL/l 1.00 ymphoma 11A (zinc finger protein) 4.03 2.00
NM_007441 aristaless 3 1.00 7.28 3.50
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Annexure-18 
Developmental related transcripts that are upregulated in α MHC + more than the 15d 
control EBs but downregulated than the ES cells.The fold change is expressed relative 
to the lowest value of expression that is normalized to 1. 
 
nes ES cells 
15
on
E  MHRefseq Ge
d 
trol c
Bs α C+
NM_009447 6 1 2tubulin, alpha 4 .15 .00 .98
NM_019812 
ating type information 
regulation 2, homolog) 1 (S. cerevisiae) 6 1 2
sirtuin 1 ((silent m
.24 .00 .27
NM_031386 ene 14 14 1.00 2testis expressed g .05 .05
XM_485238 6 1hypothetical LOC433593 .36 .00 2.82
NM_023844 ion molecule 2 12 1 2junction adhes .96 .00 .13
XM_488684 RIKEN cDNA D630045M09 gene 12 1 3.83 .00 .73
NR_001463 8 1.00 2inactive X specific transcripts .07 .18
NM_025768 905 IMAGE:3500563) 7 1 3
GH regulated TBC protein 1, mRNA (cDNA 
clone MGC:27 .73 .00 .44
--- 
DNA segment, Chr 14, ERATO Doi 725, 
4 1.00 2expressed .64 .12
--- hypothetical protein 9630027E11 8 1.00 2.94 .15
XM_130232 6 1.00 2
PREDICTED: nebulin [Mus musculus], mRNA 
sequence .58 .36
NM_016754 
orylatable, fast 
skeletal muscle 15 1 2
myosin light chain, phosph
.54 .00 .36
NM_009477  1 5 1.00 uridine phosphorylase .45 2.41
NM_030697 ankyrin repeat domain 47 5 1 2.01 .00 .41
NM_146100 
iate filament 
protein, alpha 5 1 2
internexin neuronal intermed
.06 .00 .33
NM_022409 23 1.00 2zinc finger protein 296 .45 .44
--- RIKEN cDNA 2310043M15 gene 7 1 3.82 .00 .33
NM_00100391 4 1 28 Ubiquitin specific peptidase 7 (Usp7), mRNA .19 .00 .00
--- RIKEN cDNA A230083H22 gene 6.85 1.00 2.36
--- 
16 days embryo head cDNA, RIKEN 
enriched library, clone:C130032P17 
full-length 
unclassifiable, full insert sequence 10.15 1.00 product: 2.34
--- 
DNA segment, Chr 13, ERATO Doi 787, 
7 1.00 2expressed .19 .37
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